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ACTIVE SURVEILLANCE AND INCIDENCE RATE OF DENGUE INFECTION IN 
A COHORT OF HIGH RISK POPULATION IN MARACAY, VENEZUELA 
 
Carlos Espino, MD., Ph.D. candidate 
 
ABSTRACT 
 
 In the absence of an effective vaccine, vector control and surveillance of dengue fever 
(DF) and dengue hemorrhagic fever (DHF) are the most important strategies currently 
used to reduce the impact of these diseases in affected population. The objectives of this 
study were to estimate the incidence of symptomatic and asymptomatic dengue cases, the 
prevalence of antidengue antibodies, and to evaluate the laboratory and clinical aspects 
related to an active surveillance of dengue cases. In this study, active surveillance was 
incorporated as a part of the study design. At total of 3,255 people from four high risk 
neighborhoods were followed in a two years prospective study whereby the participants’ 
houses were visited three times a week. During these visits, dengue cases were 
characterized by identifying patients with fever as well as other symptoms that were 
compatible with dengue disease. In addition, a biannual blood sample was taken for each 
study participants, to establish the prevalence and six month incidence of dengue 
infection.  
 We found a crude incidence density (ID) of 3.24 by 100,000 person/days (p/d) which 
changed from 5.69 by 100,000 p/d for the first year of the study to 1.45 by 100.000 p/d  
in the second year. In both years, the months from July through September had the 
                                                     viii 
 
highest ID of 8.81 by 100,000 p/d.  Children displayed higher ID when compared to 
adults, RR: 3.92 (2.38 – 6.48).  
The Plaque Reduction Neutralization Test was used to assay for the presence of 
antidengue antibody in 2,125 study participants (65.3% of total). The prevalence of anti 
dengue antibodies was found to be 86.6% (1,840 positives). The prevalence of anti 
DENV-1 was 74%, while 65.2 % of the participants had anti- DENV-1 and anti- DENV-
2 simultaneously. The cumulative incidence of anti IgG dengue antibody in the negative 
participants (283 at the start of the study) was 30% in the first 6 months period, 29.6% in 
the second 6 months, and 23.8 in the third one.       
 The difference between the numbers of participants detected in the active surveillance, 
(270 confirmed and non confirmed dengue cases) with the numbers of people who 
showed sero-conversion to anti-IgG dengue antibody within a relatively short period of 
time suggested that there was a high number of asymptomatic dengue infections present 
in the population.  Transmissibility of the virus, the surveillance of dengue, and vaccine 
implementation in the near future would all be affected by the large number of 
asymptomatic people in hyperendemic countries.  
 .   
 
  
Keywords: Prevalence, asymptomatic, sero-conversion, antibodies, epidemic. 
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CHAPTER ONE: THE STUDY PROBLEM 
 
Introduction to the Problem 
  
 In the last forty years in the Americas, Dengue Fever (DF) and Dengue Hemorrhagic 
Fever (DHF) respectively have been considered a re-emergence and an emergence 
disease (OPS, 2000), (OPS, 2006). In the absence of an effective vaccine, mosquito 
control and surveillance of dengue disease have been the strategies used worldwide to 
prevent this infection. However, 40 years later, the combination of these strategies has 
not been totally effective in reducing the number of DF and DHF cases. Dengue virus 
(DENV) is spread in all Central and South American countries; all four DENV 
serotypes (DENV-1, DENV-2, DENV-3 and DENV-4) are circulating, and the number 
of cases reported each year is increasing. A deficient vector control and the type of 
ineffective public health surveillance currently being used in Central and South 
American countries could partly explain the unsuccessful prevention and control of 
dengue (OPS, 1994), (Call et al 2006), (Ooil et al 2006). Usually surveillance is based 
only on the passive detection of symptomatic cases and thus does not provide 
information about the actual number of people infected, and the true proportion of the 
population at risk to get a secondary infection (which is a risk factor of DHF). Passive 
surveillance system cannot detect epidemics at a pace rapid enough to provide ample 
time for appropriate preventive actions. Furthermore, this type of passive surveillance 
system cannot provide an updated analysis related to the dynamic of the dengue disease. 
For example, the introduction of a new serotype or genotype could change the expected 
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clinical presentation and epidemiological indicators in the population.  Additionally, 
this type of information would be essential in the new era of dengue vaccine and 
necessary to understand the dynamic of the viral infection.  Passive surveillance that 
provides only general information such as the number of symptomatic cases reported is 
not adequate; alternative options such as active, vector, sentinel and interepidemic 
surveillance will have to be globally implemented. (Gubler, 2002), (WHO,1997), 
(WHO,1999).     
Incidence and Prevalence as measures of Dengue Infection. 
In order to achieve a good system of disease surveillance, the epidemiology system 
requires specific indicators to be able to calculate and determine the frequency of the 
disease. Usually the selected measurement (and/or indicators) depends on the type of 
disease. That is how the measure of the dengue infection can be made, which is either to 
directly determine the occurrence of their new symptomatic cases (disease incidence) in 
a risk population within a given period, or indirectly, to calculate the prevalence of 
presence of anti-dengue antibodies in healthy people previously infected in a 
determined population. Estimating the infection incidence could be determined by 
computing symptomatic and asymptomatic cases of dengue. The disease incidence is 
the measure to establish what would be the magnitude of dengue epidemics; what 
would be the impact of the problem in terms of public health, and which should be the 
best way to proceed to reduce their consequences. The prevalence of antibodies permits 
us to know the magnitude of the transmission in a given period, how the virus is 
circulating, which age groups are more affected. Furthermore, having two or more 
prospective measures of antibody prevalence, we can also estimate the incidence of the 
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infection. Through all of these possibilities, early prediction of new epidemics is 
reasonably the main goal of many public health programs. (Runge-Ranzinger et al, 
2008), (Gordis & Saunders, 2000).  
The simultaneous analysis of these two measures of disease and infection permits us 
to understand the dynamic of the dengue virus, determine the proportion of 
symptomatic and asymptomatic cases, and establish the risk and the factors associated 
with the disease. 
Historically in dengue disease, Cumulative Incidence (CI) and serological prevalence 
of anti dengue antibodies have been the most frequent indicators used to determine the 
frequency of clinical dengue disease and dengue infection respectively. Since dengue is 
an acute disease, the incidence is the best way to determine its frequency. Since 
immunological conversion is a prevalent condition, sero prevalence of anti dengue 
antibodies is the best way to determine previous infection of DENV, both usually 
reported in surveillance dengue information and through epidemiological dengue 
researches (WHO-DENGUENET, 2009).     
Considering incidence exclusively, Cumulative Incidence is a good indicator of risk 
and the only incidence indicator that can be used to compare temporal and geographical 
impact of dengue epidemics. However, its value is not enough to determine factors 
associated with the disease. Incidence Density (ID), defined as the number of cases over 
the sum of length of time at risk for each participant in a prospective study, is the best 
indicator to establish association between factors and disease. Besides, ID is more 
precise to estimate the rate of disease occurrence. Due to the fact that ID requires a 
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close follow up on the studied population, relatively few studies of dengue have been 
reported with this indicator. (Kleimbaum et al, 1982). 
In spite of the fact that Venezuela has had the highest incidence of DF and DHF from 
1989 to 2005 in the Americas, this country has not studied prospectively exposed 
population. There are no reports available to date of dengue researches that use 
Incidence Density and also, the studies of sero prevalence of antibodies have been 
limited to school children and transversal evaluations (WHO-DENGUENET 2009), 
(Guzman, 1999). 
Surveillance of Dengue 
Public Health Surveillance has been defined by Thacker as: “The ongoing systematic 
collection, analysis, and interpretation of outcome-specific data for use in the planning, 
implementation, and evaluation of public health practice”. In this definition, the goal is 
clear, the steps are logical; however, the procedures of each one of those parts in the 
definition can differ among countries, particularly between developing and developed 
countries, and can even differ within the same country when comparing data from 
different decades. In general, developed countries have better surveillance systems, with 
better laboratories for diagnosis, better integration between health service dependences, 
and better quality of the data. Gubler, analyzing dengue data generated prospectively, 
has been specific about these differences   (Gluber, 2002), ( Teutsch and Churchill, 
1994).   
The choice of which types of surveillance system to use will depend on the 
characteristics of the disease, the magnitude of the problem caused by the disease in a 
specific country (or global region), and the resource and technology of each affected 
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country. In this respect, when analyzing all Latin American countries and Venezuela in 
particular, the areas most affected by dengue in the Americas could be considered 
developing countries, according to the World Bank classification.. Cuba and Puerto 
Rico have demonstrated superior efficacy to control and prevent dengue epidemics. In 
the case of Puerto Rico, this country has tried to develop a surveillance system during 
inter epidemic periods by implementing a system of the early detection of circulating 
viruses, before the epidemic has been recognized (Rigau-Perez, 2005), (Gubler, 2002). 
(Guzman, 2005). Venezuela has supported its surveillance system with the passive 
reporting of cases; when the number of cases reported is higher than the number of 
cases expected; the system can declare epidemic and activate the specific measure of 
control.  This is the regular application of surveillance in many Latin American 
countries, and certainly that is better than nothing, because it has reduced the fatality 
from DHF in the last 25 years in the region. (Feldman, 2004). 
Clinical symptoms and laboratory diagnosis of Dengue 
Diagnosis based on clinical symptoms and laboratory diagnosis of dengue play two 
important roles that may be different somewhat. On the one hand, early recognition of 
dengue based on the clinical symptoms and early laboratory confirmation could make 
the difference between the life and the death of the patient; both of these contribute 
towards individual significance of surveillance. On the other hand, clinical symptoms 
and diagnosis are also indispensable to detect the presence of the disease and thus could 
help to predict and avoid an epidemic. If an epidemic is recognized early, control 
measures can be implemented immediately; this represents the public importance and is 
the point that is related to the public health surveillance system. (WHO, 1997) 
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Statement of the problem 
Latin America and many other developing countries do not have a good surveillance 
system to detect cases of dengue that are less evident and less symptomatic, whereby 
infection of dengue does not yet produce epidemic but may very well be on its way to 
generating one. 
Specific aspects that could be obtained in these cases include the number of 
asymptomatic cases, clinical variations and changes in the criteria for clinical and 
laboratory diagnosis of dengue. Additional information that can be acquired include 
differences between what regular passive surveillance system is detecting and what 
active surveillance system could detect, which and how other risk factors could affect 
incidence of dengue and its consideration in an active surveillance system. 
Purpose of the Study 
 The purpose of this study was to establish those epidemiological characteristics, 
diagnostic and clinical aspects of dengue disease that could be related with the 
surveillance of dengue, and use these to understand how surveillance can be used as one 
strategy to prevent the effect of the disease caused by dengue infection. The goal of this 
study is to compare and contrast the findings with the traditional or regular dengue 
surveillance system. Epidemiological aspects are those indicators which usually are not 
considered in the passive surveillance systems but are affecting the dynamic of the 
disease in the populations. In this study, epidemiological aspects included are frequency 
of dengue, silent or asymptomatically infected people, and the proportion of people at 
risk to acquire DHF. Clinical and laboratory diagnostic aspects are those criteria which 
can improve the identification of the dengue cases. We considered and collected during 
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the course of this study this information, the day of the physical exam was performed and 
the blood sample taken, as well as the specific time and type of diagnostic test used and 
the clinical symptoms presented. A surveillance system of dengue should have the 
capacity to collect and analyze this kind of information in order to prevent disease 
effects.   
Aims of the Study 
1. To estimate the incidence density of dengue disease in the population, by detecting 
the number of symptomatic cases during active surveillance, and sorting out and 
analyzing data by age groups, location and seasonal year period.  
1.1 To estimate the incidence of dengue disease in four neighborhoods. 
1.2  To estimate the incidence of dengue disease in children from 5 to 14 years old, 
and adults from 15 to 94 years old. 
1.3 To establish the Incidence density and compare the Relative Risk of dengue 
disease between children and adults.  
2.  To estimate the prevalence of antibody against dengue in the population using anti-
dengue IgM MAC ELISA and anti-dengue IgG by Plaque Reduction Neutralization 
Test (PRNT) using biannual sero-prevalence surveys. 
2.1 To estimate the prevalence of antibody against dengue according to specific 
serotype and age group. 
3. To estimate the proportion of dengue infection through the biannual seroprevalence 
surveys, by detecting asymptomatic and symptomatic dengue cases during each interval 
of blood sample collection.  
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3.1 To estimate the proportion of dengue infection in people with primary and 
secondary dengue infection. 
3.2 To estimate the proportion of specific dengue serotypes in people tested negative 
in the first sero-prevalence sample of dengue antibody (Sample number1). 
4. To identify and compare procedure in laboratory test used in the active surveillance, 
by considering viremic and immunological indicators at specific time points, which are 
categorized based on the number of days after onset of the symptoms, age group, 
neighborhoods and serotype from the active surveillance. 
4.1 To describe the frequency of blood samples that were taken according to the days 
after onset of the symptoms. 
4.2 To estimate the proportion of specific dengue serotype by age group of patients, 
and looking for possible association between these parameters. 
4.3 To estimate the proportion of specific dengue serotype by four neighborhoods, 
looking for possible association between these parameters.   
4.4 To estimate the number of cases detected by specific type of diagnostic test, and 
the day of sample taken after the onset of the symptoms. 
4.5 To compare the results of confirmed dengue cases determined by Active 
Surveillance with the same samples tested using PRNT, and establishing the 
proportion of congruency between temporal and specific dengue serotype.  
4.6 To compare the results of IgM MAC ELISA test in confirmed dengue cases by 
Active Surveillance with the same samples tested by PRNT, looking for the 
proportion of primary and secondary infection according to IgM test results. 
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5. To identify clinical symptoms according to disease confirmation and age group in 
those people who were detected in the active surveillance. 
5.1 To describe the most frequent symptoms present in all people detected to be 
dengue positive by the active surveillance as designed in the study. 
5.2 To compare the most frequent symptoms between confirmed and non- confirmed 
dengue cases as detected by the active surveillance. 
5.3 To identify those symptoms and hematologic indicators associated with 
confirmed and non confirmed cases by the active surveillance. 
5.4 To identify hematologic indicators of dengue and anti-dengue IgM antibody in 
consecutives samples during acute phase of dengue disease in people detected by the 
active surveillance.  
6. To identify the differences between the regular system of passive surveillance of 
dengue disease in the national and local department of health and the data obtained in 
this study, assuming this study represents a system of active surveillance.  
 6.1 To determine diagnostic classification according WHO in the study data. 
6.2 To describe the cumulative incidence of dengue in 2007 related with the seasonal 
rainy months.  
6.3 To describe the cumulative incidence of dengue in 2007 related with the passive 
national and local surveillance of dengue. 
 
Significance of the Study 
  In dengue, surveillance is a recognized preventive measure to control the disease. 
However, few studies have been conducted to determine which specific aspects of the 
  
10 
dengue disease can be used to improve that surveillance system. This is particularly true 
in developing countries where the disease is hyperendemic, and where many control 
activities have had little impact in controlling the increasing numbers of epidemics. The 
goal of this study is to identify some of the aspects within an active surveillance design 
that can be applied in a real community, and which include children as well as adults as 
the study subjects.  Apart from our study, we could not find any prospective study 
focusing on the communities that conducted weekly door to door visits and which take in 
consideration a broad range of age, when we reviewed more than 75 articles searched 
through PubMed that reported prospective studies of dengue. Most of these studies were 
conducted either in schools or workplaces, or using community health services. Besides, 
these studies were usually focalized in a specific age group, which are either children or 
adults, but not both. 
  With dengue vaccines continually being developed in different phases of study but still 
elusive, the precise knowledge of virus transmission and early detection of cases is 
becoming extremely necessary in the effort to work towards prevention of dengue 
diseases.   
  This study will contribute towards increasing the knowledge pertaining to dengue. 
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CHAPTER TWO: BACKGROUND AND LITERATURE REVIEW 
Dengue Disease: General Characteristics. 
Worldwide, dengue is the most important viral disease transmitted by mosquitoes and 
other arthropods, with an estimation of around 100 million cases and 20,000 deaths 
annually (Stephenson, 2005). Dengue affects tropical areas of Asia, Africa, Oceania and 
the Americas. The causal agent is the Dengue Virus (DENV), which belongs to the 
Flavivirus genus, and is transmitted mainly among humans by the species of 
mosquitoes Aedes egypti and Aedes albopictus (Fields 2001), (Kuno 1997).
 
For more 
than 200 years, this infection has been recognized causing important epidemics in the 
Americas, Africa and Asia. However, Dengue Fever (DF) or also known as classical 
dengue was not considered a fatal disease until the 1950’s when it appeared in South 
East Asia as a new, severe and fatal variant of dengue disease known as Dengue 
Hemorrhagic Fever (DHF). Even though a few hemorrhagic cases of dengue had been 
described before 1950, these cases had never occurred as an epidemic. Therefore since 
that time, DHF is considered an Emergence disease (WHO, 1997), (Isturiz et al, 2000), 
(Gubler 1995), (Pinheiro 1997). 
 
Clinical presentation of dengue is described as an asymptomatic infection until severe 
and fatal Hemorrhagic and shock syndrome, passing by mild like viral syndrome and 
non fatal Dengue Fever. (WHO, 1997). 
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Without an effective vaccine and antiviral treatment for dengue, control of the vector 
and surveillance are the only two most important public health strategies to prevent and 
control this disease and its consequences. (Stephenson, 2005), (WHO, 1999). 
Supported by established theories, dengue disease could be considered as one of only 
a few viral human diseases where previous infection by heterologus dengue serotypes 
increases the risk to a developing a new, severe and sometimes fatal dengue virus 
infection. (Rico-Hesse et al, 1997), (Gubler, 2002).  
Dengue Virus. 
Dengue virus is a positive sense single strand RNA virus, belonging to the family 
flaviviridae. This family has three genera: Hepacivirus, Pestivirus and Flavivirus. 
DENV is a flavivirus which belongs to a genus with more than 70 viruses, including 
two phylogenetic groups: the mosquito borne with West Nile Virus (WNV), Saint Luis 
Virus (SLE), Yellow Fever Virus (YFV), Murray Valley encephalitis virus, Kunjin 
virus and Japanese Encephalitis Virus (JEV) and the tick borne with Powassan virus, 
central European encephalitis virus and Far Eastern encephalitis virus. (Fields, 2001), 
(Mukhopadhyay et al. 2005). 
The dengue virion consists of an envelope and nucleocapsid, and is spherical with a 
diameter of 40-60 nm.  The RNA complete sequence is around 10,700 nucleotides long. 
(ICTV, 2009). The genome encodes three structural proteins (capsid, pre-membrane and 
envelope) and seven non structural proteins (NS1–NS2A–NS2B-NS3-NS4A– NS4B-
NS5). Due to polarity and exposition, the majority of the primers to identify and 
differentiate DENV to other flavivirus target the Envelope and NS1 regions. Primer 
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regions usually are related with the pathogenesis and cross reactive immunity of the 
viruses (Kuhn et al, 2002). 
Dengue virus is subdivided into antigenic types according to serological criteria and 
four serotypes have been recognized: Dengue virus 1 (DENV-1), Dengue virus 2 
(DENV-2), Dengue Virus 3 (DENV-3), and Dengue Virus 4 (DENV-4). Each serotype 
produces lifetime immunity against homologous dengue viruses, and temporary and 
partial immunity against heterologous dengue viruses. (WHO, 1997), (Fields, 2001), 
(Kuno, 1997). 
Depending on the area of the world, the cross reactivity among the flaviviruses plays 
a key role in specific antibody identification and surveillance system. This cross-
reactivity among flavivirus species can be causative of false positive in serological test 
results. In Asia, Japanese encephalitis and West Nile infections are the main cause of 
cross reactive immunological response in dengue laboratory surveillance. Yellow fever 
has the same importance in Central and South America, while West Nile and Saint Luis 
Encephalitis viruses are more prevalent in North America (Mukhopadhyay et al 2005), 
(Koraka et al 2002). In addition, cross reactivity can be generated by vaccination of 
YFV live attenuated and JE inactivated virus. (Scharwtz et al 2000), (Vasquez et al, 
2003).  
Based on the nucleotides substitution rates estimation of Dengue virus, mean 
substitution rates are in a range from 4.55 x 10
-4 
(DENV-1) to 9.01 x 10
-4 
(DENV-3) 
substitutions per site, per year; therefore, the origin of DENV could be relatively recent, 
at around approximately 1,000 years ago.(Twiddy et al., 2003).  
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Anti DENV antibodies have been found in non human primates in West Africa and 
Asia (Malaysian), supporting sylvatic transmission cycle idea for Dengue viruses. 
Indirectly, this provides evidence that dengue originated from monkeys and sylvatic 
mosquito vectors. At some point in time, the virus passes to the humans; this probably 
occurred approximately 200 or 300 years ago (Holmes, 2003), though othershave 
related the origin of dengue disease  with former cases reported from China and French 
West Indies (Gubler,1998). Supposedly, the disease was effectively spread to the 
Americas when the virus and its mosquito vector ( Aedes species) were transported in 
slave trading or other commercial trips from Africa either during the XVIII century or 
before.  Even when two cycles (sylvatic and non-sylvatic) of the DENV transmission 
are recognized, clinically and epidemiologically, dengue transmission is considered a 
human to human infection disease. Therefore, in contrast to other vector-borne diseases 
and especially arthropod viral diseases, dengue does not have other hosts or reservoirs 
to facilitate or anticipate the action of public health surveillance. DENV can grow in 
monkeys and mice but these animal species do not exhibit symptoms of the disease as 
seen in humans (Holmes et al , 2003), (Pang, 2003), (CDC-DHHS, 1993).    
Disease Transmission and Vector. 
Dengue infection is transmitted from human to human through the bite of female 
mosquitoes. During the viremic phase, infected humans are capable of transmitting the 
virus to the mosquitoes taking in a blood meal. This viremic phase in human blood lasts 
approximately 5 days and takes place after one incubation period of 6-8 days; this is 
known as the “intrinsic period”. After mosquito bites an infected human while taking a 
blood meal, the viruses propagate inside the vector during the “extrinsic incubation” 
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period, which usually lasts 7 to 8 days. Finally the infected mosquito re-feeds and 
transmits the virus to a second susceptible human (WHO, 1997), (McBride et al, 2000).  
The virus human cycle is limited at 3 -5 days due to a cytopathic humans cells effect; 
this cytophatic effect does not occur in mosquito where the viruses can be propagated 
and accumulated in the salivary gland throughout the lifetime of the mosquito. (Fields, 
2001). After a mosquito gets infected, it is capable of, and is effectives in transmitting 
the Dengue virus to the next human host and cause dengue infection.   In addition, 
experimental studies have demonstrated that mosquito to mosquito transmission by 
vertical transovarial infection is possible. One study demonstrated the capabilities of 
seven mosquito generations passing the virus. This could be a way to keep the virus in a 
place without the direct infection of humans (Joshi et al, 2002).  Besides, Mourya found 
DENV in aedes aegypti eggs and the vertical transmission rate was higher in those eggs 
with more time to hatch. (Mourya et al, 2001). 
Aedes aegypti and Aedes albopictus are the two most important mosquitoes capable 
of transmitting the Dengue viruses and infecting humans. Both mosquito species are 
present in the Americas and Asia where dengue is a public health problem. However, 
Aedes aegypti has demonstrated more efficiency for dengue viral transmission. This 
advantage is related to the capacity of A. aegypti to live within the human communities, 
sharing resting areas and using the stored human consumption water as a feeding 
habitat. All the life stages of this mosquito can be developed within the human habitat; 
this behavior is different when compared to A. albopictus which is a more aggressive 
vector which sustains feeding habitats farther away from human houses. Consequently, 
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A. aegypti has been considered to be the principal vector, and A. albopictus the 
secondary vector in the transmission of dengue (Kuno 1997), (Nagao et al, 2003).  
In the absence of an effective vaccine against dengue, control of the mosquito vectors 
which is based o elimination of larvae and breeding ground sites more than the adult 
mosquitoes control, is the key to prevention of the disease and the epidemics. However, 
in many developing countries, the current vector control emphasis is in emergency 
response rather than prevention of epidemics. This is illustrated by the emphasis on 
adult mosquito elimination, which corresponds to an emergency response approach, 
versus larvae elimination which unfortunately is not perceived as a great control 
measure since the impact is not immediate.(Gubler, 1998).  The best examples to 
illustrate the point above are represented by these countries where the focus of 
prevention has been the mosquito control; United State in the last century, Cuba after 
1981, and Singapore in the last 25 years (Wilder-Smith et al, 2004), (Halstead, 2000).  
Of course, mosquito control by use of chemicals such as insecticide is not the only 
method for an effective vector control. Other approaches that could  also be very 
important include ways such to improve the housing conditions, education of people at 
risk, and improvement of water system supply in the community so as to reach a 
definitive prevention of this disease (Heukelbach et al, 2001), (Gubler, 2002).   
In addition to the control of vector to prevent disease, mosquitoes can also play a 
significant role in conducting the dengue disease surveillance. The measures of the 
larvae or mosquito density are indicators to identify areas of greater risk.  Breteau index 
has been classically been one of the most used method to estimate relative densities of 
mosquito. Breteau index is defined as the number of positive containers (Aedes aegypti 
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larvae that can be visually detected) per 100 houses inspected. House Index is another 
indicator that can be used to estimate the mosquito density; it is defined as the 
percentage of households infested with larvae or pupas in a specific urban or rural area. 
Another aspect of the dengue vector surveillance that poses a challenge is the fact that 
dengue does not have other hosts that can be used to detect or predict, during the early 
stages that the virus is circulating in the community. In other words, beyond knowing 
the density of the mosquitoes in terms of determining the entomological risk, and 
identification of dengue viruses and their specific serotypes in these mosquitoes; these 
would be the only invaluable measures that can provide information about circulating 
dengue viruses during the interepidemic periods. In the United State the mosquitoes 
surveillance for both purposes. However in developing countries, the mosquitoes’ 
surveillance when it does take place is used only to determine the density of the 
mosquito (CDC- DHHS, 1993). 
Transmissibility 
The transmission dynamic in dengue disease is the result of many variables. This is 
due to a combination of actions by four independent serotypes, and the different ways 
the disease is presented into the variety of environmental conditions. The four serotypes 
have the capacity to circulate simultaneously in hyperendemic areas where secondary or 
tertiary infections can be potentiated by previous heterologous serotypes and non 
neutralizing antibodies. The majority of infections are unapparent or asymptomatic even 
though some clinical cases can be severe. Information from the literature does not 
describe if the asymptomatic cases have the same transmission capacity than patients 
presenting with dengue symptoms. This concern is expressed in this quote “Another 
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problem rarely addressed in BRR determination is the impact of asymptomatic 
infections” (BRR: Basic Reproductive Rate). (Kuno, 1997).     
 Basis Reproductive Rate (Ro/BRR) also known as Basis Reproductive Number, is 
the average number of new infections produced for each case of current infection. This 
indicator helps to determine how a disease infection can spread throughout the 
population. When Ro is higher than 1, the infection is able to spread in the population, 
and if Ro is less than 1, epidemiologically the infection will die out. In addition, BRR 
has public health importance as it can be used to establish the proportion of population 
that needs to be vaccinated to reach herd immunity. The higher the BRR, the higher the 
proportion of people that needs to be vaccinated.  According to Kuno, the range of 
dengue BRR would be from 1.33 to 2.00, though recent studies show that the numbers 
can be greater. BRR is in direct relation with the number of contact per unit of time, 
transmission probability per contact and duration of infectiousness. (Kuno, 1997), 
(Massad, 2003). 
 Special situations can occur with DENV transmission; DHF cases could increase 
when vector prevention control partially reduces the mosquito density.  In his study, 
Thamalato concluded that the negative relationship between DHF incidence and dengue 
transmission intensity implies that in regions of intense transmission, insufficient 
reduction of vector abundance may increase long-term DHF incidence. (Thamalato et 
al., 2008).  Singapore provides another example of a situation of dengue transmission 
that is difficult to understand. This country has been successful in reducing the 
mosquito density; however, simultaneously they have had an increase of dengue fever 
cases in the last years. (Egger et al, 2008). In other viruses the infection transmissibility 
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could be explained easier but not so for dengue as it is almost like four diseases that is 
closely linked by a confused immunological system.   
Herd Immunity 
Herd immunity is the resistance of a group or community to attack by an infectious 
disease due to the fact that a large proportion of the population is immune against the 
disease. This term is usually associated to vaccination effect; however, having the 
disease is a way to acquire “natural” immunity and theoretically acquire herd immunity.  
Herd immunity threshold is the maximum level of immunity beyond which 
transmission is eliminated (Kuno, 1997). There is not only a meaning to this concept, 
John and Samuel proposed one interesting differentiation: herd immunity as “the 
proportion of subjects with immunity in a given population” and “herd effect” defined 
as “the reduction of infection in the unimmunized segment as a result of immunizing a 
proportion of the population”. (John & Samuel, 2000). 
 In any case, herd immunity is closely related to the Basic Reproductive Rate. Massad 
in Brazil showed 64 cities with dengue epidemic; all these cities had BRR greater than 1 
with a range from of 2.74 to 11.57. The maximum value in Brazil is similar to the BRR 
of Measles infection viral disease which required between 83% and 94 % of vaccine 
coverage.  Ferguson in Thailand obtained BRR to four serotypes using different 
methods; the range of values was from 1.39 to 7.73 but they did not find differences 
among serotypes. (Massad, 2003), (Ferguson, 1999).  
 When we check the different mathematic models proposed in studies to estimate the 
Basic Reproductive Rates, these are based on the number of cases that started the 
epidemics, known probabilities of human to mosquitoes contact, and the number of 
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susceptible at a certain time. However, probable effect of asymptomatically infected 
people in the transmission is not clearly represented in these mathematical models. 
(Koopman and Longini, 1999), (Kuno, 1997).  
Epidemiology and Surveillance of Dengue 
Worldwide Distribution 
Historically, there are at least three different sources providing report about the first 
dengue case; chronologically, a report from China provided the first description of a 
disease compatible with dengue in 610 A.C. (Gubler, 1998). The second report probably 
registered the source of dengue outbreak was in West French Indies in 1635 (Izturiz et 
al, 2000), (Gubler, 1998). Finally, and usually the most cited first dengue report was 
about dengue in Philadelphia in the summer of 1779 (Gubler, 1995), (Holmes, 2003).  
There is disagreement about the the origin of the dengue virus, reported to be either 
from Africa or Asia. This is due to non-human primates that were detected with DENV 
in the sylvatic cycles in both continents; and is not clear which was the direction of the 
expansion.  (Holmes, 2003). 
 There were at least 4 Dengue-like illness epidemics in the Americas that happened in 
the XVIII century occurred (Pinheiro et al, 1997). Asia had similar evidence of non-
fatal disease with epidemics of 10-40 years intervals (Gubler, 1995).  The negative 
effect of the World War Two in the South East Asia environment was probably the 
event which separated the benign dengue disease from the severe and sometime fatal 
dengue. Hyperendemicity and expanded DENV epidemics in the region were the 
prelude to the first confirmed epidemics worldwide of Dengue Hemorrhagic Fever, 
which later became established as an emerging global disease. The exact event that 
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started all of this was thought to have occurred in Manila Philippines in 1953–1954, 
(Gubler, 1998). However, according to Halstead, non confirmed DHF epidemics had 
already previously appeared in Australia in 1897 and in Greece (western hemisphere) in 
1928, (Halstead, 1980).  After the 1953 epidemic of Manila, the DHF spread throughout 
all of Asia, beginning by the south east countries and extending to the rest of Asia.    
  The first report of an epidemic of Dengue Hemorrhagic Fever (DHF) in the Americas 
occurred in Cuba in 1981, whereby 158 people died and 10,300 DHF cases were 
registered. The second large epidemic took place in Venezuela in 1989 with 2,665 DHF 
cases, extending to 1990 with 3,325 DHF cases, whereby 18 and 52 people died 
respectively, in those two years of outbreak. According to WHO-DENGUENET, since 
1960 to 1980, Cuba and Venezuela were the two countries with the most number of 
dengue fever reported to WHO; in Cuba the highest number of DF cases occurred in 
1977 (477,440 cases) and in 1978 (75,692). Venezuela had three peaks of DF cases; 
18,306 in 1964, 7,750 in 1966 and 100,000 in 1978.  (WHO-DENGUENET, 2009). 
However, after the epidemics described above, Cuba and Venezuela followed different 
paths reporting different epidemiological histories. Cuba did not have cases reported 
again after the earlier epidemics until 1997, when Cubans suffered a second epidemic 
which characteristically affected only adults. On the contrary, after 1989, Venezuela 
became the Latin American and Caribbean country with the greatest number of DHF 
cases, whereby many people died from dengue disease. Other countries also have had 
higher incidence of dengue but none has had worst indicators in terms of magnitude 
(Kouri et al, 1998).
 
According to the Antibody Dependent Enhancement theory, DHF 
could be directly correlated to hyperendemicity. This could explain the high number of 
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DHF cases in Venezuela, specifically in Maracay which is the capital of the Aragua 
State, where geographical studies has demonstrated the simultaneous circulation of all 
dengue serotypes.(Rico-Hesse et al, 1997), (Barrera et al, 2000).  
Incidence of Dengue 
Incidence means new events or cases happening within a period of time. In 
epidemiology these new events are referred either in relation to the population at risk, or 
in relation to the population-time at risk. As a result, incidence of a disease could be 
measured by two ways.  One way is determining the Cumulative Incidence (CI) which is 
estimated by calculating the proportion of people who developed the disease in a fixed 
and disease-free population at the beginning of the follow-up period. Frequently, the CI is 
the indicator used either by the regular system of surveillance, or by the public health 
programs inserted in a national or international communicable disease network. CI is 
obtained considering new cases detected in annual periods of time. Theoretically, 
Cumulative Incidence can measure the risk and predict risk in an individual level. The 
other way to obtain incidence is by determining the Incidence Density (ID) which is 
defined as the instantaneously change of disease status per unit of time. The ID 
determination requires the amount of population-time (PT) added by each person in the 
study. PT can be expressed interchangeably in years, months, days and hours. ID can 
estimate rate referred to a population thus it does not have direct interpretation on the 
individual level. (Kleinbaum, Kupper and Morgenstern, 1982)  (Rothman, 1986). The 
Incidence Density is mostly used by Researchers who are looking for association among 
factors and the frequency of the disease.    
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Through DENGUENET, World Heath Organization has the most complete historical 
database about the amount of dengue cases represented by the three more affected 
regions in the world: Pan American Health Organization (PAHO) in the Americas, South 
East Asia Region, and Western Pacific Region in Asia. (WHO-DENGUENET, 2009)   
According to data of PAHO in the period from 2000 to 2005, the highest Cumulative 
Incidence of dengue (by 100,000 population) in the Americas has consecutively been in 
French Guiana (1,001), Costa Rica (343), Honduras (254), Barbados (221), Brazil (195), 
San Vincent (158), Suriname (154), Venezuela (143), Puerto Rico (92), Colombia (82), 
Paraguay (81), Ecuador (72) and El Salvador (68).  Considering the period time from 
1980 to 2005 and dividing into two sub periods: one from 1980 to 1996 and the other 
from 1997 to 2005, it is important to indicate that Brazil and Costa Rica have had more 
than 80 % of their cases after 1996, compared with Venezuela, Colombia and Honduras, 
which reported having similar number of cases in both the 1980 to 1996 period as well as 
in 1996 to 2005 period. (WHO-DENGUENET, 2009).  
In the South East Region of Asia and in the same period from 2000 to 2005, the 
highest CI of dengue were in Maldives, Thailand, Sri Lanka and Indonesia with 113, 109, 
37 and 26 dengue cases by 100,000 population.  In Western Pacific Region, Palua, 
French Polynesia, Cook Island, Northern Mariana Island and American Samoa had more 
than 1,000 cases by 100,000 populations. Malaysia had CI of 82.8 while Singapore had 
368, but only in 2005 (WHO-DENGUENET, 2009). 
In dengue disease, one of the first prospective studies was performed by Burke et al. in 
Thailand in 1980.  They followed 1,757 students between the ages of 4 to 16 years old, 
and obtained two blood samples within an interval period of six months. Febrile students 
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were always tested in acute and convalescent stages. 103 (5.6%) were infected in the 7 
month study period and 90 out of these were asymptomatic children. Seven students were 
hospitalized with DHF and all of them had previous antibodies against dengue. (Burke et. 
al.1988). A second follow up three year study was performed in Thailand in 2002; this 
time 2,214 school children made up the cohort. The overall incidence was 5.8 %, and out 
of them 3.1 % was in Asymptomatic dengue virus infection and 2.7% in symptomatic 
dengue. The incidence of dengue was gradually declining in the three year study from 7.9 
% in 1998 to 6.5 % in 1999 and down to 2% in 2000. They found similar incidence 
between symptomatic and Asymptomatic infection, contrary to the conclusion in other 
studies.(Endy et al. 2002).  Other incidence study was performed in adults in Bandung, 
Indonesia. Incidence Density was calculated; contrary to Endy et al conclusion, they 
found 56 per 1,000 person-day dengue infection in asymptomatic people versus 18 per 
1,000 person-days in symptomatic cases. Even in areas without symptomatic cases, they 
found incidence density of 8 per 1,000 person-days in asymptomatic people.  (Porter et al 
2005).   Other prospective study was performed in Indonesia in 1995, reporting an 
incidence of 29.2 % in the year of follow up.  All febrile cases in this study were 
secondary infection (Graham, 1999). In Vietnam where a study on 977 school children 
was conducted, an annual incidence of 11.7 % of dengue primary infection was estimated 
by binary regression of the sero-prevalence by age. In a second part of the study two 
years later, the sero negative school population (831 children) was newly tested with 30.6 
% of sero-converted, and then the true annual incidence of primary dengue was 17.5%. 
(Thai et al, 2005), (Thai et al, 2007).     
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In the western hemisphere less numbers of prospective studies have been reported. 
However, incidence of dengue has been published from different region of epidemics. 
The Puerto Rican 1994-1995 epidemic presented an incidence of 7.01 per 1,000 people 
increasing from 2.55 per 1,000 people annual average incidence in the last 4 years from 
1991 to 1994 (Rigau-Perez et al, 2001).  Teixeira in a prospective study in Salvador, 
Brazil reported an incidence of 70.6 % of dengue infection but it was significantly higher 
in those people previously tested positive with one serotype (83.0% ) than those people 
previously tested negative (60.8%), (Teixeira et al, 2002).  Balmaseda et al in Nicaragua 
in a two year follow up study found 12% of dengue incidence the first year, decreasing to 
6 % in the second year (Balmaseda et al 2006). In Brazil, where the incidence of endemic 
disease included dengue, it was studied in the Amazon region. The average incidence of 
dengue from 2001 to 2005 was 185 per 100,000 populations, which is very similar to that 
registered by DENGUENET in all of Brazil (195 per 100,000 population) in a similar 
period from 2000 to 2005 (Penna et al 2009). 
Sero-prevalence of Dengue. 
Most of the epidemiological studies in dengue have been performed to determine 
which proportion of the population has been previously infected by the dengue virus, 
which age group is more affected and which dengue virus serotypes are present in the 
population. Single transversal sero-prevalence surveys and prospective sero-prevalence 
studies have been designed to reach those goals.  In Indonesia in 1995, 1,837 children 
from 4 to 9 years old were studied. Dengue serotype antibodies prevalence was estimated 
twice during a one year interval. At the beginning of the study, 56.1 % of the children 
were positive to dengue antibodies, 12.0% were immune to DENV-1, 16.3% to DENV-2, 
  
26 
2.2% to DENV-3,  3.8% to DENV-4, and 21.8% were immune to two or more serotypes. 
The prevalence of two or more serotypes increased from 37.2 % in the 4 year old children 
to 69.7 % in 9 year old children. At the end of the study, 26.8 % of the sero-negative 
children seroconverted; the children with primary infection in the cohort study (Graham 
et al 1999). Similar study was performed in Vietnam but with an age group of children 
from the ages of 7 to 14 year olds. The dengue serotype antibodies prevalence increased 
from 53 % for the 7 year old children to 88 % in the 13 year old children.  (Thai et al, 
2005). In Singapore, a cross sectional seroprevalence study was conducted to estimate the 
proportion of adult people (18 to 45 year old) with anti dengue antibodies 133 of 298 
(45%) enrolled participants were tested positive. The prevalence increased with the age 
group from 17 % in the group of 18 to 25 year old, to 44% and 74% in the groups of 25 
to 35 year old and 36 to 45 year old, respectively.  Singapore is one of the few Asia 
countries which have been able to reduce the incidence of dengue cases. (Wilder-Smith et 
al, 2004).   
 The study of Teixeira in Brazil presented a seroprevalence of 68.7%. The lower value 
was 39.0% among 0 to 4 year old children and the greater value was 76.4 % among 30 to 
39 year old adults. Also, this study showed variation from 16.2% to 97.6 % among 30 
areas in Salvador, Brazil. (Teixeira et al 2001).  In Dominican Republic, 98 % of the 
1,008 adults recruited in blood bank and 56 % of the children less 10 year old visiting a 
Hospital in Santo Domingo were tested positive to IgG anti-dengue. Among children, the 
prevalence of antibodies increased by age (Yamashiro et al 2004).  A seroprevalence of 
dengue in children less than 11 years old found a prevalence of 19.9% of dengue 
antibodies. They compared children living in coastal area with children living in inland 
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area. The prevalence in coastal area was 36.9 % significantly higher than inland area 
which was 2.9% (Iturrino-Monge et al, 2006). The prospective study made by Balsameda 
et. al in Nicaragua presented one of the greatest prevalence of dengue antibodies in 
children (4 to 16 year old) of the Americas. The overall prevalence was 91%, increasing 
from 75% at age 4 to 100% at age 16. (Balmaseda et al, 2006).  Some areas in the 
Americas show low prevalence of dengue antibodies; one study in Tabasco Mexico was 
performed by enrolling university students between the ages of 18 to 39 year old. The 
prevalence of dengue antibodies was 9.1 %. Interestingly, the prevalence of anti DENV-1 
antibody was 20% and 100% and 68% of antibody against anti DENV-2 and DENV-4 
respectively. (Sanchez et al, 2008). In Maracay, Venezuela, a prospective study was 
performed on 710 schoolchildren from 5 to 13 year old. The Prevalence of anti dengue 
antibody was 51 %.; 30.1 % were tested with immune response to one serotype, and 
20.9% to two or more serotypes. The highest dengue type antibody prevalence was 
DENV-2 with 14.2% followed by DENV-1 with 13.4%. 25.6% of the children 
seroconverted among all previously sero-negative children, and 26% of the children 
seroconverted in children with secondary infection. (Comach et al. 2009).      
Surveillance of Dengue 
Public Health surveillance is defined, according to Thacker and Berkelman as: “Public 
Health Surveillance is the ongoing systematic collection, analysis, and interpretation of 
outcome-specific data for use in the planning, implementation, and evaluation of public 
health practice.” (Thacker & Berkelman, 1988). However, this concept has undergone 
several changes through the time, until the middle of the last century the emphasis was on 
the contacts of sick people with a communicable disease. Now surveillance is addressing 
  
28 
to the risk factors and other health-related events like accidents, injuries, chemical 
exposure, and infection disease vectors. New features have also improved the concept, 
classifying the surveillance into the categories of passive and active. In a Passive 
Surveillance System, the disease case (or other health-related events) notification is 
dependent on information retrieved from inferior levels of public (or private) health 
institutions.  In an Active Surveillance System, the central department of health contacts 
regularly the health services to ask about (or look directly for) disease cases or other 
health-related events. In accordance with Teutsch, surveillance data can be used in the 
following ways (among others): 
“To estimate the magnitude of a health problem 
To understand the natural history of the disease 
To detect outbreaks or epidemics 
To document the distribution and spread of a health event 
To monitor changes in infection agents.” (Teutsch & Churchill 1994) (CDC, 2001).  
CDC in 2001 presented the Updated Guidelines for Evaluating Public Health 
Surveillance Systems with the purpose to ensure that public health problems are 
monitored efficiently. Also the CDC considers evaluation of traditional surveillance 
attributes including: simplicity, flexibility acceptability, sensitivity, predictive positive 
value, representativeness, timeliness and stability. However; depending on the highest 
priorities in the health, related event could change the importance of each attribute. Other 
interesting aspect in this document is the concept of Preventability defined as: ”From the 
perspective of surveillance, preventability reflects the potential for effective public health 
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intervention at any of these levels” (Primary, Secondary and Tertiary levels). (CDC 
2001).     
In dengue infection these theoretical concepts have been adapted to the disease 
characteristics. PAHO in its scientific publication No.548 links Active Surveillance with 
laboratory-based surveillance, in the effort to understand the low sensitivity of clinical 
dengue parameters in non epidemic periods. This document also defines different levels 
of surveillance depending on epidemiological situations: countries where no dengue cases 
have been detected but where the vectors are present, countries where dengue is endemic, 
and countries where dengue is epidemic. Viral laboratory support is most important 
where dengue is endemic and less important where there are no dengue cases (PAHO, 
1994).   
In health services, the final goal of any kind of surveillance is prevention. Depending 
on which level of the natural history of disease the health service wants to emphasize, it 
will represented by the type of surveillance action employed.   For example, if a country 
wants to totally prevent disease and eradicate cases, then that country has to focus on 
eliminating those risk factors which facilitates the disease as the first level of prevention. 
In dengue disease, this control could be achieved with the surveillance of density vectors, 
feeding vectors, water supply service and, human household conditions.  This kind of 
surveillance or risk surveillance is exceptionally implemented in developing countries. 
These actions are regularly implemented in a developed country; even though dengue 
would not be the exclusive focus of the intervention effort. 
In dengue endemic areas, other levels of surveillance would need to be set in place in 
preparation to detect any early increase circulation of the dengue virus, through increase 
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in virus activity either within vectors or through detection of the first human cases during 
an interepidemic period. The goal would be to predict the incensement of the human 
cases to avoid epidemics. Active Surveillance would be the best way to reach this goal. In 
this case, early control measure will be applied and the epidemic would be avoided. 
Developed countries would not need this kind of surveillance but developing countries 
do, but only a few can maintain this system because it requires an advanced viral 
laboratory. (Gluber, 2002).  
Also, in dengue endemic areas situated within a country that lacks organization and 
equipment to actively look for either early disease cases in interepidemic period or 
positive vectors to virus infection, the system has to wait passively for the dengue cases 
to be registered and analyzed. This approach is known as a Passive Surveillance system, 
whereby it would be too difficult to predict and avoid epidemics from happening. As a 
result, the goal has to shift towards to reducing impact of the epidemic as a secondary and 
tertiary level of prevention, reducing the Fatality Rate, preparing the health services and 
hospitals, eradicate the vector, and training health workers and population to handle the 
epidemic situation.    This is the usual the approach adopted in many developing 
countries facing the threat of dengue. (Gluber 2002). 
Laboratory and Diagnosis. 
The clinical manifestations of dengue are represented by symptoms that are specific 
to dengue make the diagnosis of this disease difficult. Additionally, in periods of no 
dengue epidemic, the sensitivity of the symptom identification is much lower. As a 
result, laboratory confirmed tests become necessary procedures and tools to diagnose 
dengue. Another important aspect of dengue laboratory is the high frequency of 
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asymptomatically infected cases, which are commonly detected by sero-prevalence 
surveys. Asymptomatic infections impact the knowledge of the virus transmissibility 
and new serotypes introduction. In surveillance, laboratory support is one of the 
cornerstones of the system; efficacy in the dengue diagnosis is closely related to the 
dynamic between the dengue viremia and the immune response in primary and 
secondary infections. Viremia is present in the blood patient at the moment of the onset 
of symptoms (usually fever) and could be present for more than three or five days 
which would be during the time the virus is detected. The end of the viremia usually 
marks the beginning of the immune response. The duration of the immunoglobulin in 
blood will depend on their type: IgM antibody will be in blood for 80 to 90 days and 
IgG antibody for life. (WHO, 1997).   
Therefore, there are two basic procedures to establish laboratory dengue diagnosis:  
the detection of the virus and the detection of the antibody.  
Viral Isolation. 
Viral Isolation is the most sensitive way to detect DENV. Three techniques can be 
used: 1. Mosquitoes (pool of 15 to 20) are inoculated either with serum, or plasma, or 
pleural fluid or other sterile body fluid. Days after, virus infection is confirmed by 
immunofluorescence. This is the most sensitive isolation technique. 2. Inoculation of 
mammalian or insect cell cultures (usually C6/36) is other common used for viral 
isolation. The presence of the viruses is confirmed by cytoptathic effect or plaque 
formation assay. RNA detection and immunofluorescence also can confirm the infection. 
3. Intracranial inoculation of sucking mice is the third way to isolate dengue virus; either 
encephalitis signs or antigen in brain tissue are evidence of infection. The higher 
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limitation of the Viral Isolation is that this method ise time consuming, and also there is 
high cost associated with use of of the cell culture method. (WHO 1997). 
Polymerase Chain Reaction and Dengue Virus. 
A relatively new molecular technique, Polymerase Chain Reaction (PCR) was 
developed to amplify DNA fragments. Later, a variant of that technique has also 
permitted amplification of RNA through a cDNA intermediate; this advanced technique 
has had direct consequences in the diagnosis of RNA viruses. Reverse Transcriptase–
Polymerase Chain Reaction (RT-PCR) test has reduced the time of diagnosis of dengue 
disease, while keeping a good level of sensitivity for the purpose of detection. RT-PCR 
method requires for reaction to start with the reverse transcription from RNA to a 
complementary DNA (cDNA), using the enzyme reverse transcriptase. The PCR step that 
follows reverse-transcription has three parts all performed in a thermal cycling instrument 
(which would be the same as performing traditional PCR with DNA as the starting 
material): 1. Denaturation of the DNA, increasing the temperature to melt the double 
stranded DNA into single strands , 2. Annealing the target DNA with specific primers by 
decreasing to an optimal the temperature and finally, 3. Elongation is the extension of the 
DNA from the primers, increasing the temperature according to specific DNA 
polymerase. This step should be repeated between 20 to 40 times to get the ideal 
amplification of the DNA fragment. In dengue, RT-PCR was initially used with a nested 
two step protocol   (Lanciotti et al 1992). Later, an improved version of the test was 
designed which reduced reaction time, using a single tube multiplex RT-PCR (Harris et al 
1998). In both cases, all four Dengue viruses can be detected. (McPherson et al, 1999), 
Raengsakulrach et al. in 2002 compared four RT-PCR procedures in Thailand where all 
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serotypes of dengue are circulating and need to be detected and distinguished from one 
another. The method developed by Henchal et al. amplifies the 482 nucleotide sequence 
in the NS1 region of the dengue virus genome. The method of Morita et al, utilized four 
pairs of type-specific primers to detect simultaneously the dengue serotypes.  And the 
methods of Lanciotti et al. and Yenchitsomanus et al. employed universal dengue primers 
followed by a type-specific nested PCR.  The sensitivity, considering serologically 
confirmed cases, was 54, 52, 60, 79 % respectively with the indicated methods 
(Raengsakulrach et al, 2002).  
A new advance in PCR and RT-PCR was the introduction of the real time analysis 
detecting amplified products during the process of the DNA amplification, using 
fluorescent based reporter chemistries. Comparative advantages comparing real time to 
conventional PCR and RT-PCR are; Real Time RT-PCR is less time consuming, is more 
sensitive and the viremia can be estimated quantitatively. Oliveira in Brazil compared 
RT-PCR with Real Time RT-PCR, finding better sensitivity in Real Time RT-PCR. They 
concluded that a good way to detect and diagnose dengue is by combining Real Time 
RT-PCR during the first days after onset of the symptoms with serological detection of 
anti IgM dengue antibody in later days of acute phase. (Oliveira et al, 2005). These are 
important advances in Public health surveillance system whereby laboratory diagnosis of 
dengue can be made from patient samples from any day during acute disease. To 
establish the viremia is important in studies to relate blood levels of viruses and 
pathogenesis through the different cells and cells products in infected people. 
In 2004, Lemmer et al. showed a study of external quality assurance (EQA) of 13 
laboratories which apply RT-PCR and Real Time RT-PCR in dengue diagnosis: only two 
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laboratories received the maximum score of quality, and only four detected low dilution 
of RNA dengue in samples. In their recommendation, the authors said that eight of 
thirteen laboratories should improve the sensitivity and specificity of the test (Lemmer et 
al, 2004). Oliveira et al compared five RT-PCR kits (two Two-Step kits and three One-
Step kits) and found clear advantage using One-Step kits to detect low dilution of viruses.  
The problem of short duration of virus presence in the blood of patients would be 
resolved with the use of non-structural dengue antigens, because of the long persistence 
of these antigens in the blood (Schilling, 2004). 
Serological Test. 
The use of immunological test is based in the immunological response after being 
exposed to an external agent such as virus. For the purpose of laboratory diagnosis, 
humoral response detecting antibody would be the most important criteria to consider in 
diagnosing dengue infection. Immunoglobulin G (IgG) and immunoglobulin M (IgM), 
each one or in combination, are usually the key factors to be detected in the diagnosis 
either of past dengue infection (IgG) or acute primary and secondary infection (IgM and 
IgG). A definitive diagnosis of acute infection requires a pair of samples, which need to 
be collected during the acute and convalescence phase. In addition, a secondary infection 
can be demonstrated if the ratio IgM/IgG is less than 1.5. In dengue, this would be 
possible because each type of immunoglobulin levels can rise for two or four weeks after 
infection, depending on the kind of infection. If a patient had a primary contact with the 
virus, the IgM will be expected to present with higher levels in blood; while in a 
secondary infection the IgG in blood will be higher (WHO, 1997).  
  
35 
Haemagglutination Inhibition Assay (HI), Complement Fixation (CF), Neutralization 
Test (NT), Indirect IgG Enzyme Linked Immunosorbent Assay (ELISA) and IgM 
Monoclonal Antibody Capture Enzyme Linked Immunosorbent Assay (MAC-ELISA) are 
some of the tests used in serological dengue diagnosis.  (WHO, 1997). 
For many years HI was the most used test in the routine dengue diagnosis, due to its 
high sensitivity and relatively low cost.  Characteristically however, this test does not 
distinguish between immunoglobulin isotypes. As a result, for HI, absence or low level of 
antibodies in the acute phase with increased level in convalescence phase is considered to 
be the indicator of primary infection in dengue disease. In addition to this shortcoming, 
HI is not a serotype specific test for dengue (Teles et al 2005).  
NT is the test with highest specificity in dengue infection and contrary to HI, is 
capable of discriminating the virus serotype in primary dengue infection; though, this 
would be  difficult to determine in secondary and tertiary infections (Morens et al, 1985).  
NT has an advantage related to its specificity and it is usually necessary in studies of 
sero-prevalence and prospective design. However, this test is laborious, expensive, and 
time consuming in those clinical scenerios where quick results are needed. 
Since 1987, IgM capture ELISA (MAC-ELISA) test has been recommended by WHO 
to be used in the diagnosis of acute dengue disease. Having a slightly higher sensitivity 
than HI, MAC ELISA is also more specific with less cross reactivity to other flaviviruses. 
This test becomes positive five or six days after the onset of the symptoms. The day of 
conversion when the antibody could be detected is extended to more days after the onset 
of symptoms in secondary dengue infection, whereby also a smaller proportion of 
patients appear to be negative. (Gubler et al 1998).        
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Indirect IgG ELISA test is a sensitive test to determine the chronic prevalence of anti 
dengue antibodies but is less specific and with higher cross reactivity to other 
flaviviruses. 
Guzman et al. showed the report for external control proficiency test of dengue 
serological diagnosis in the Region of the America in the period 1996-2001. Twenty 
seven laboratories received 54 serum panels. The result showed that 95.6 % of the 
antibody IgM tests were concordant with the result from the reference center.  In 
conclusion, they summarized that the majority of the participating laboratories showed 
excellent performance for diagnostic capabilities (Guzman, 2003).  Donoso et al. in 2002 
evaluated laboratories in Europe, in a program of External Quality Assurance, with 
combination of different panels of IgG and IgM antibodies (+ and +, - and +, - and – 
,etc.). They found correct results in 88% of the IgG-positive samples and for 100% of the 
IgG-negative samples, 91 % of the IgM-positive samples and 97% of the IgM-negative 
samples. (Donoso 2004).  One of the problems of serological tests is the differentiation 
among flaviviruses which is very important in countries where many of these flaviviruses 
are co-circulating simultaneously with dengue virus. (Koraka et al, 2002), (Cuzzobbo et 
al, 2000), (Scharwtz et al, 2000). As a result, some studies compare ELISA techniques 
(Palmer et al, 1999) that could distinguish these different flaviviruses. Cuzzobbo et al. 
compared PanBio Dengue Duo Igm and IgG Capture ELISA and Venture Technologies 
Dengue IgM and IgG Dot Blot. One of his most important conclusions was that in 
countries with high prevalence of co-circulating flavivirus, PanBio ELISA performed 
better because this test was able to avoid false positive results. (Cuzzobbo, et al, 2000). 
On the other hand, those countries with low prevalence like the USA DotBlot ELISA 
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would be a good choice as dengues test kit, because it can detect any case of dengue, thus 
avoiding false negatives. Another innovation with PanBio duo ELISA is to 
simultaneously measure IgG and IgM in the same test. According to Sang et al, the 
sensitivity, 99%; specificity, 96% of this technique
 
was superior to the use of IgM alone 
or IgG alone, 88 % of sensitivity and 96 % of specificity, and 85% of sensitivity and 96% 
of specificity, respectively. (Sang et al, 1998). Oliveira found more sensitivity in MAC-
ELISA compare to PCR when this test is performed in the 5 and 6 days after onset of the 
symptoms. In addition, Chanama et al. compared IgM antibodies in primary and 
secondary infection; specific IgM was detected in all the cases with primary dengue virus 
infection on disease day 9 or later. However, specific IgM cannot be detected in 28% 
(204 / 716) of the cases in secondary infections. They recommended other test for 
confirmation in all secondary infections (Chanama et al, 2004). 
One of the weaknesses of serological test is the necessity of using two samples from 
the acute and convalescence phase of infection to confirm the disease. In addition, the use 
of invasive technique which is the need to take blood samples, would be another factor 
that is considered problematic. In this sense, it is of significant interest for some studies 
to apply less or use of a non- invasive procedures for sampling such as taking saliva 
samples. These studies have found a good correlation between IgM in saliva and IgM 
serum. One of these studies
 
also included IgA in this saliva-serum comparison, but the 
result showed that these antibodies were better detected in serum. (Balmaseda et al, 
2003), (Cuzzobbo et al, 1998).  
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Clinical Manifestations. 
The clinical characteristics of Dengue disease can be different according to the kind of 
disease presentation. The dengue infection could be asymptomatic as detected through 
expressed immunological response, or symptomatic. Symptomatic patients may have 
undifferentiated fever like a viral syndrome, Dengue Fever (DF) Syndrome (with or 
without hemorrhagic manifestations) and Dengue Hemorrhagic Fever (DHF). DHF with 
shock is also known as Dengue Shock Syndrome (PAHO, 1994).  
According to WHO, a clinical case of Dengue Fever is an acute febrile illness with 
frontal headache, retroocular pain, muscle pain, joint pain, and rash; even though other 
signs and symptoms could also be presents (such as lymphadenopathy, petechiae, nausea, 
hepatomegaly, and different types of hemorrhagic). A probable case of DF is defined as 
cases with fever and two or more of the following manifestations: headache, retro-orbital 
pain, myalgias, arthralgias, rash, hemorrhagic manifestation and supportive serology (HI, 
IgG, IgM tests) or occurrence at the same location and time as other confirmed cases of 
dengue.    A confirmed case of DF is defined as cases with isolation of dengue virus for 
serum or autopsy sample; or demonstration of fourfold change in reciprocal IgG or IgM 
antibody titers in paired serum samples; or demonstration of dengue virus antigen in 
autopsy tissue, serum or cerebro-spinal fluid samples by immunohistochemestry, 
immunofluorescence or ELISA; or detection of virus genome sequence in in autopsy 
tissue, serum or cerebro-spinal fluid samples by RT-PCR.  Hemorrhagic Dengue Fever 
case has to have all the four following criteria: Fever, hemorrhagic tendencies (including 
tourniquet test), thrombocytopenia (100,000 per mm
3
 or less) and plasma leakage 
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(hematocrit >20%, signs of plasma leakage: pleural effusion, ascites and hypo-
proteinemia) (PAHO,1994), (WHO, 1997). 
Pathogenesis of Dengue Hemorrhagic Fever. 
The pathogenesis of hemorrhagic dengue fever that has been described has many 
implications in the understanding and control of this disease, as it relates to efforts to 
identify people at risk. Basically, at least two theories have been presented to explain 
the severity of DHF. (McBride et al, 2000), (Halstead et al 1977): 1. According to the 
first theory of Antibody dependent enhanced (ADE), previous antibodies of a specific 
serotype of dengue virus bind to different dengue virus serotype producing non 
neutralized antibody–virus complexes.  These complexes bind to macrophages which 
lead to activation of T cells from previous presentation to Major Histocompatibility 
Complex molecules (MHC). Cytokine production then becomes the a consequence of T 
cells activation: Interferon-γ, Tumor Necrosis Factor, IL1, IL6, IL8 (Yang et al, 2001), 
Fernandez et al 2004), (Huang et al, 2000), (Talavera et al 2004). Additionally, 
Vascular Endothelial Growth Factor (VEGF) is produced by monocytes and endothelial 
cells (Tseng et al, 2005). Among other effects, it produces changes in the wall of 
capillaries with hemorrhagic symptoms and leakage of fluid in the body cavities that 
could end in death of the patient. 2. According to the second theory, specific genotypes 
of dengue virus which are more virulent could cause of more severe symptoms of 
dengue (Rico-Hesse et al, 1997). Probably both theories are correct and complement 
each other. Epidemiological studies show the relationship between severity of 
epidemics and previous serological conditions of the population affected.  Sequence of 
infection with DENV-1 virus followed by DENV-2 has been demonstrated to correlate 
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with high rates of DHF (WHO, 1999). However, differences in the severity and number 
of DHF cases have been demonstrated when the strain of the DENV-2 virus is Asian or 
American, with the latter one being less virulent (Rico-Hesse, 1990).         
Prevention and Control. 
Worldwide, one of the challenges of the public health is the search for effective 
methods to control dengue disease. For decades, either in the Americas or Asia, WHO 
has made recommendations about the best way to prevent dengue epidemic. Throughout 
this time, the essence of the WHO’s effort is the same, though the strategies to reach 
this goal have continually changed (WHO, 1997), (PAHO, 1994), (WHO, 1999), (Parks 
et al, 2004).   Unfortunately, most of these of strategies have only generated very poor 
results (Gubler, 2005), (Calisher, 2005), (Gubler, 2002).  
There are three approaches to prevent dengue disease and dengue epidemic: 1. To 
block the virus action inside the human hosts with use of vaccine to induce specific 
immunization. 2. To halt the infectious chain reducing or eliminating the vector: 
mosquito control.  3. To detect the cases and the virus in early periods of viral activity 
by epidemiological surveillance either to reduce or prevent the impact of the epidemic 
(PAHO, 1994). 
These three activities should not work independently. However, the focus and 
intensity of each application can depend on the moment of infection, the location (world 
region or country), and the budget in health and the specific type of disease infection. 
For example: the focus of Yellow Fever prevention in South America is the vaccine and 
surveillance of human cases and monkeys, and secondarily, the mosquito control.  For 
one specific disease, the same sentinel animal could not be good in all areas of one 
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country or region (PAHO, 1994), (CDC, 1993). In addition, these three strategies can be 
(more or less, depending of each one) affected by other important factors such as 
education, family income, housing conditions and social services (water supply and 
waste disposal). For example: housing condition (without window screen) affects more 
the mosquito control than a massive vaccination campaign.   
The uncontrollable worldwide activity of dengue virus and its vector deserves a short 
analysis of each strategy of prevention.  In dengue, the vaccine is already being 
developed. However, an effective vaccine is yet far from being available for public use. 
In general terms, this challenge of an effective vaccine selection is due to the presence 
of multiple serotypes and their interactions with the heterotypic antibodies. In 
particular, it has been difficult to measure the amount of virus and its immunological 
response in different situations. Serum Neutralization, a very specific and sensible test 
to make these measurements, has presented with problems to standardize procedure 
using these four different serotypes. Many authors have always been worried about the 
risk that the dengue vaccine could be the prime vaccine for development of DHF by 
Antibody Dependent Enhancement (ADE) which makes the infection worse, instead of 
providing protection. Furthermore, a good animal model for dengue is lacking whereby 
in many cases, in the existing animal model systems showed that these animals can be 
infected but do not develop the symptoms of the disease (Stephenson, 2005), Pang, 
2003), (Calisher, 2005).  
Mosquito control has been shown to be the best strategy to prevent dengue epidemic. 
This was evident during the time when the Americas was free of dengue in the period 
(1940’s and 1950’s decades) of control and almost eradication of Aedes aegypti, as a 
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plan of yellow fever control. Re-infestation in the sixties, of Aedes aegypti permitted 
entry of new dengue virus serotypes in the Americas (PAHO, 1994). Other historical 
example was the campaign against the mosquitoes and their breeding sites carried out in 
Cuba after the huge epidemic of 1981(Guzman et al, 2005), (Kouri et al, 1998) which 
permitted for a period of 16 years without dengue to take place in that island. Singapore 
is the Asian example of the same result with the same strategy; this small but rich 
country could reduce the index of Aedes aegypti to levels apparently secure, and reduce 
almost totally the cases of dengue (Wilder-Smith et al, 2004). This strategy is based on 
the reduction of breeding sources (Essentials as storage water and Non essentials as 
tires and waste), larvae and adult mosquito control, surveillance of vector, community 
education and personal protection. These two countries which represent two opposite 
political models have been the best examples of successful mosquito control strategy. 
However, this strategy though good, has not been perfect in any of these countries. As 
an example,n 2002 Singapore had a dengue epidemic with unthinkable low density 
levels of mosquitoes, and with a high number of risk population with low level of herd 
immunity as a result of many years without epidemics. A similar situation occurred in 
Cuba in 1997 when DHF affected only adult population who had been in contact to 
dengue virus in 1981, or before. No child born after 1981 was reported with DHF in the 
1997 epidemic. This finding could explain two aspects of dengue situation in Cuba; the 
relationship between secondary infection and DHF, and the success in the control of 
Aedes aegypti for more than 15 years. (Gubler, 2002), (Kouri et al, 1998). Something 
however is true in that neither Singapore nor Cuba could avoid a new epidemic of 
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dengue. Both events indicate that the dynamic of dengue virus and its vector is complex  
and cannot be reduced to only one strategy or a single program in Public Health.    
Recognizing the little advance in the control of dengue, the last WHO's 
recommendations focused on community participation in the programs of prevention 
and mosquito control in dengue (Parks et al, 2004), (Suhaili et al, 2004). However, we 
can see how this suggestion was so general in 1995, more specific in 2002 and very 
specific in 2004 when WHO includes COMBI (Communication for Behavioral Impact) 
plan and textual analysis say: “Knowledge is not enough, Evaluation researchers have 
noted that, despite growing levels of knowledge and awareness about dengue and 
mosquitoes, many people are still not taking action.” And “Many programs continue to 
focus only on changing people’s knowledge and on raising awareness, believing that 
behavior will change.” 
The success of this strategy depends on the continuity of its implementation, either in 
the period of epidemic or during the inter-epidemic periods. In many developing 
countries, several of these activities of control are activated in the periods of epidemic, 
acting as tertiary prevention but not as primary prevention in public health, like a 
disease control focused on emergency response. Gubler stated that emphasis is on 
emergency response rather than more on prevention (Gubler, 1998).  
The third general strategy in the prevention and control of dengue is the surveillance. 
In many developing countries, surveillance is part of the epidemiology department in 
the services of public health. However, most of these countries have the passive system 
of surveillance (Gubler, 2002), (WHO, 1999. It means that the case of dengue is 
registered when the patient goes to the health service center. However, if for any reason 
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the patients with dengue fever or DHF do not go to look for medical attention, they will 
never be recognized by the system. It is clear that in passive surveillance the cases with 
diagnostic will be those with more obvious and florid disease.  Asymptomatic cases or 
mild cases could not be detected (Endy et al, 2002).  Developing countries with passive 
system of surveillance use this system to detect epidemic and activate measures of 
control and attention of patients in hospitals. For active surveillance, the goals can be 
different. The objective of active surveillance is to predict the epidemic instead to detect 
it. In active surveillance, is important to detect any case of dengue and not only the most 
florid case. In addition, the role of active surveillance is more important in inter-
epidemic periods where laboratory confirmation is essential (clinical criteria can be 
enough in epidemic stage) (Rigau-Perez, 2001), (Gubler, 2002). According to Gubler, 
few countries in the world have capacity to do an active surveillance; he summarized 
these countries in this category: Singapore in Asia and Puerto Rico and Brazil in the 
Americas, which are countries with adequate laboratory resources to sustain an active 
surveillance system. Active surveillance in Puerto Rico has permitted the prediction of 
all the epidemics since 1998 with only one wrong prediction in 2003. Gubler says that 
in Puerto Rico the rainy cyclical population of Aedes aegypti has not been historically 
affected by programs of mosquito control, as a result, this characteristic supports the 
emphasis that Puerto Rico has created and sustained the active surveillance system of 
dengue (Gubler, 2002).  In an infectious disease as dengue without other animals or host 
to detect early the circulation of the virus and consequently to activate epidemiological 
alarms, the system has to be very sensitive to detect the first human cases. Ideally, the 
virus needs to be detected two, three or four weeks before the evident ascend of the 
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epidemic. At this time the identification of the dengue case has to be very precise, and 
any gap or doubt in the case definition could affect the success of the active 
surveillance. The study of Endy et al in Thailand showed around 50 % of the cases of 
dengue could be asymptomatic and others are mild symptomatic (Endy et al, 2002). 
This is important if we see that World Health Organization promotes very specific 
criteria to define a dengue case (WHO, 1997). These criteria would leave out many 
asymptomatic and mild cases of dengue. Besides, confused procedures recommended 
by WHO avoid a better detection of cases. WHO recommends taking two blood 
samples: one in the acute phase and one in the convalescent phase, marking 10 days as 
the ideal time between the two blood samples. We have shown in un-published data 
how more than 90 % of the cases in a regular surveillance system  have access to only 
one sample, with low percentage of confirmed cases of dengue. We have also shown 
that the tendency in the last years is to reduce the days to take the blood sample after the 
onset of the symptoms, from 6 in 1998-1999 to 4.5-5 in 2000-2002. Maybe this 
tendency has been promoted for the interest in taking blood sample in the times when 
viruses can be detected. The big problem is that 4 to 5 days could be too late to detect 
RNA from the virus and too early to detect immunological response. (CDC Puerto 
Rican branch). Also, few patients would return for a second blood sample, reducing 
highly the number of case confirmation because a hypothetical second sample could 
identify elevations of antibodies from nothing in the first one (WHO, 1997).  Therefore, 
it could be reasonable to recommend taking two samples in the acute phase: the first 
sample in the first three days of fever to detect the RNA and the second one after day 
number 6 after onset of symptoms to detect the immunological response.  With this 
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condition, if RNA is detected, the case is confirmed. However, if RNA is not detected, 
two samples after day 6 looking for immune response will be necessary.   
We can summarize the limitations of a regular passive system of surveillance as such:  
1.Passive surveillance can estimate incidence of symptomatic cases of dengue but not 
incidence of infection (symptomatic, mild symptomatic and asymptomatic cases). It has 
particular importance because a first exposure to dengue virus is a significant risk factor 
to get HDF.   2. Passive surveillance waits for the cases, usually florid cases; some 
cases will never be detected if the system does not look to detect for these cases.  3. 
Passive surveillance is not concerned about the prediction of an epidemic of dengue 
with a prudent time to avoid it; the role would be to detect the cases over the epidemic 
to activate inter-sectors responsibilities: mosquito control, hospital, media and 
community.  4. Passive surveillance is not concerned about the identification of the 
prevalence to specific serotypes of dengue virus in population at risk to a new epidemic 
with new serotype or genotype.  5. Passive surveillance cannot identify changes or 
variant in the clinical presentation of the cases that could be affected for the 
introduction of new serotypes or genotypes.  
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CHAPTER THREE: METHODOLOGY 
Design 
In order to achieve our objectives, a Longitudinal Panel Study Design.  (Hybrid 
Studies) (Woodward M. 2005) was developed and implemented. A close tracking of 
people at risk for dengue was required to detect information that is usually hidden in the 
natural dynamic of the dengue disease. One strategy employed was routine visits of 
families recruited in the study, and inquiring about fever and other risk factors that could 
be related with dengue so as to determine the best way to describe unknown 
characteristics of this disease. Individuals who were recruited to participate in this study 
were from different four neighborhoods and lived in their designated family houses. The 
cohort was followed after the initial demographic questionnaires were completed, and 
determination of sero-prevalence of dengue antibodies was made. Three visits a week 
were made by nurses who asked participants about fever events experienced by 
individuals studied. If any case of fever was detected, a clinical and laboratory evaluation 
was performed by physicians. This portion was named the active surveillance in the study 
design. Besides, each six months sero-prevalence surveys of dengue antibodies were 
repeated in a procedure that was called biannual blood samples. A smaller or sub-cohort 
of people with clinic diagnosis of dengue determined according to the WHO criteria, 
were invited to participate in a special part of this study describing clinical and laboratory 
changes during the period of acute disease. This part of the study also required having 
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blood samples taken at 24, 48 and 72 hours of fever period, and 24 and 48 hours after 
fever disappears, but only in those confirmed dengue cases.    
All dengue cases were described monthly within the two years and three months 
study period. This duration of study period permitted us to compare the incidence in this 
study with the state and national incidence of dengue disease. Simultaneously, we were 
also able to compare the traditional passive model of the state and national surveillance 
with our design which, in some sense, reflected an active surveillance system to detect 
dengue disease. 
Incidence Density (ID) 
 With the purpose of obtaining the Incidence Density, we computed the number of 
days per months for each individual who participated in the study. We obtained the total 
of person-days either per months or trimester or year. The report of days began the day 
that each person is included in the study, and was completed when he or she left the 
study by any of these three possible causes: 1.When the person died. 2. When the 
person left the study before it is over, and 3. When the person left the study at the time 
the study is over. The number of person-days was also distributed by neighborhood, by 
age group, and by gender. The Incidence Density was calculated dividing the number of 
confirmed dengue cases by the total number of person-days, in general, or by specific 
groups. This number was then multiplied by 100,000, and expressed by 100,000 person-
days. 
 ID Relative Risk was calculated to age groups and gender, by dividing ID in children 
less than 15 year old by ID in adult people equal or higher than 15 year old, and 
dividing ID in females by ID in males. 
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In order to compare our data with the state and national surveillance, we had to 
calculate the Cumulative Incidence in 2007 because this is the measure used in passive 
surveillance. We divided the number of dengue cases detected in the active surveillance 
during 2007 by the total number of people who began and finished the study within the 
365 days of 2007. 
Population and selecting a sample. 
For this study, Venezuela was the reference country. In 1989 Venezuela had, after 
Cuba, the second largest epidemic of DF and DHF in the Americas. Aragua state, where 
this study was performed, was one of the most affected areas in Venezuela.  Aragua 
state is located in the central north of Venezuela, with the Maracay city as its capital. 
(Appendix A and Appendix B).  This study was conducted in four neighborhoods 
located within the city of Maracay. In Maracay, the range of temperature is between 25 
and 35 º Celsius, and for the most part, the city is situated around four hundred fifty 
meters over the sea. The mean total precipitation in Maracay is between 3.5 mm in the 
dry months to 179 mm in the rainy months. (Appendix C). The target population 
included in the regular surveillance system is represented by approximately one million 
six hundred thousand people. From this population, around thirty six percent (576,000) 
are less than fifteen years old.  In Maracay and its metropolitan area, there are about one 
million people.  Aragua state has eighteen municipalities and six of these are parts of 
Maracay’s urban and suburban areas.  Two hundred and nine local primary health 
centers are distributed in all of the state, and these are the first places utilized for dengue 
cases detection. When the dengue case is suspected, the specific characteristics of 
dengue disease according to the WHO recommendation are recorded, and then one 
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blood sample is taken for each case.  Each epidemiological municipality center collects 
the information and reports to the epidemiological department of the state health 
service, and sends the sample to the central laboratory of infections disease in the state 
(LARDIDEV).  The Laboratory performs specific tests for dengue case confirmation 
according to recommendation of the World Health Organization. The highest risk areas 
of dengue are in the urban and suburban neighborhoods of Maracay. Four 
neighborhoods (known as “Barrios” in Spanish) with the highest incidence of dengue 
cases in the last years were selected for this study. In the next step, each neighborhood 
was divided into blocks or squares of approximately 125 houses or families, and then 
one of these blocks in each neighborhood was randomly selected.  The total number of 
families ended being around 500 with a total of approximately 2,500 subjects. 
According to previous studies conducted in Maracay, we were expecting a 14 % lost of 
subjects per year.  
The sample size of 2,509 subjects was obtained by assuming a hypothetical high 
incidence of 15 %, and an estimation error of 3 % from the target population, with a 
confidence interval higher than 95 % (alpha 0.05). This calculation was made using 
EPIINFO program, to determine sample size for population survey. We established a 
number of around 500 individuals by each neighborhood except in the highest 
neighborhood called “Cana de Azucar” where we selected 1,000 individuals with 500 
participants in each two separated sections of this neighborhood. The individuals lost 
during the study were replaced by 746 people who entered into the cohort in 2007 and 
2008 (Table 1). The criteria to replace people were either someone who is a family 
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member of the study population, or neighbors living in the same blocks of the people 
studied. 
Table 1.  
People enrolled in the cohort study during 2006 and 2007 according to their 
Neighborhoods and age group. 
 
Neighborhoods 
(Barrios) 
 
Age 
Group 
 
People enrolled in 
the initial 
 Cohort in 2006 
 
People enrolled 
 in 2007 
 
 
Total 
23 de Enero <15 100 93 193 
≥15 402 98 500 
Caña de Azúcar <15 212 82 294 
≥15 794 211 1005 
Cooperativa <15 134 41 175 
≥15 367 86 453 
Piñonal <15 108 42 150 
≥15 392  93 485 
The Four 
Neighborhoods 
<15 554 258 812 
≥15 1955 488 2443 
Total  2509 746 3255 
 
Collecting data 
In the block of houses of every neighborhood, we started by visiting each family 
inviting them to participate in the study. If the family wished to be in the study, one 
informed consent had to be signed for each member after a clear explanation of the 
study was provided.  Each member of the family was free to participate independently 
of the other member’s decision.  When every family had its first visit, and the 
demographic and risk factor questionnaires were completed the first blood sample was 
taken from each member of the family. After this first visit and during the duration of 
two years and three months, the family was visited three days weekly, whereby they are 
asked about fever incidence of any family member. If any family member had fever, a 
blood sample was taken and a clinical evaluation was made. Blood Sample collection 
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was performed as follows; venipuncture was performed by an experienced phlebotomist 
followed by drawing 5 ml of whole venous blood from an antecubital vein from each 
adult, and 3 ml from each child ages 5-17.  The blood was collected in one Vacutainer® 
collection tube (red top) without anticoagulant. Sera were separated by centrifugation at 
2,500 rpm, transferred to cryo-vials and stored at -20ºC.  
This weekly activity looking for febrile cases was named the active surveillance 
component in the study.  
Persons presenting signs and symptoms consistent with dengue disease were invited to 
participate in a sub sample which was subjected to higher numbers of hematologic test. If 
the specimen was RT-PCR positive for dengue virus, additional blood samples were 
collected at 24, 48, 72 and 24-48 hours post fever defervescence, and 30 days post initial 
sample. Serology was tested in all sample and RT-PCR from 0 to 72 specimens. Ten ml 
of whole venous blood were obtained from each patient, collecting in one Vacutainer® 
collection tube (purple top) with anticoagulant.    
In the same period of the study, we were collecting the information of dengue cases 
reported in the regular surveillance system from the health department of Aragua state. 
This data will be compared with the level of the neighborhood, the municipalities and 
the state.  
Instruments of data collection. 
1. Questionnaire of the First Visit:  this instrument will include: 
1.1. Demographic Information: Age, gender, number of members by family. 
2. Serology, blood Sample taken to detect antibodies. (IgM MAC ELISA and IgG by 
PRNT). (Appendix D). 
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2.1. In the first visit: Time zero. 
2.2. Following biannual visits: Each 6 month. 
3. Card Family Visit (three times a week) in Active Surveillance component. 
3.1. Registering family members with fever. 
3.2. If somebody has fever: blood sample was taken for diagnosis of dengue and 
clinical                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
evaluation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
4. Sub-cohort card of symptomatic cases of dengue, invited to participate in this study 
component.  
4.1. Blood samples of dengue diagnosis: 0, 24, 48 and 72 hours during fever period 
and 24 and 48 hours after fever defervescence, and 30 days post initial sampling.. 
4.2. Clinical description. 
Laboratory Analysis 
  IgM MAC ELISA: Sera were tested for anti-dengue antibodies. The ELISA anti-
human IgM antibodies were coated onto 96-well microtriter plates. Aliquots of diluted 
serum were added to each of the anti-human IgM antibody coated cells, followed by 
one hour incubation. 
PRNT: Test sera were diluted two fold in the media (EMEM) from 1:5 to 1:5,120. 
200 µl media with 40 to 80 PFU of assay virus was mixed with 200 µl diluted test 
serum and then incubated at 4º C for 15 hours. In triplicate, 100 µl virus-sera mixture 
were added to 0.5 ml media containing 1.5 x 10
5 
BHK21 cells and then added to a 24 
well tissue culture plate, and incubated at 37 º with 5% CO2 for three hours. The cells 
were then overlaid with overlay media and incubated at 37 º with 5 % CO2 for 5 days. 
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Following incubation, the media were removed and the cells were stained with stain 
solution Naphthol Blue Black, sodium acetate and Glacial Acetic Acid by 30 minutes. 
Stain was removed and the plaques were counted. The results were expressed as the 
serum dilution that reduced the number of plaques by 70% compared to that of normal 
human serum at the same dilution.  
RT-PCR: Viral RNA was prepared fro 140 μl sera using QIAamp Viral RNA Mini 
Kits following the manufacture’s instructions. Nested dengue virus RT-PCR was 
performed following the protocol of Lanciotti et al.            
Processing Data 
In order to analyze and describe the result, the data was distributed by each 
neighborhood. Initially the age of the people was classified in three ways: 1. Eighteen 
age groups of 5 year intervals, from 5-9 to 90-94.  2. Three age groups; less than 15 
year old, equal or higher than 15 and less than 50 year old and, higher than 50 year old, 
and 3. Two age groups: less than 15 (called children in this study) and equal and higher 
than 15 year old (called adults in this study).  The first two age distribution was made to 
acilitate demographic comparisons. However, due to the fact that most of the studies 
have made their age distribution similar to the children - adults’ classification, most of 
the analyses were made almost exclusively with the two age groups distribution.   We 
use the femininity ratio (RT) to see the gender distribution according to the age groups 
and the four neighborhoods in the study. 
In order to describe the exact number of days of each participant and their type of 
permanency in the study, the participants were classified in five groups. Type I: people 
who never left the cohort. Type II: people who only left the Bi-annual blood sample to 
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obtain prevalence of antibodies but not left the active surveillance. Type III: People who 
left and came back to the cohort. Type IV: people who definitively left the cohort, 
active surveillance and Bi-annual sample. Type V: people who died for other causes, 
but not due to dengue. This approach was taken to see the impact of the different causes 
that made the people leave the cohort according to their frequency, age groups, gender, 
residence, and person days in each months of the study.  
The crude Incidence Density was attained in the two year period and was adjusted 
(direct method) by age (children/adults) and gender of the Maracay city population. ID 
was also calculated by each year in the study and by months and trimester of each year. 
We obtained ID by neighborhoods, age-group and gender simultaneously. 
Incidence Density Relative Risk of dengue was calculated in the two year study, 
associating age-groups (children versus adults), and gender (female versus male). 
IgM anti-dengue antibody was tested (MAC ELISA) each six months in all study 
individuals to establish its prevalence as a percentage. This percentage was obtained 
with the positive number of people to IgM, dividing by the number of people tested.  
IgG anti-dengue antibody was tested by PRNT. All prevalence were calculated by 
determining the percentages of monotypic antibody (for each four serotypes), and 
multitypic antibodies with two, tree and four antibodies simultaneously, and all 
combination of serotypes detected. The percentages of people with negative results 
were also obtained. These results were analyzed according to the year (2006-2007) and 
age-group (children/adults and each 5 year intervals). The percentages of sero-
conversion were also calculated into the three intervals of the four biannual samples: 
{between the first sample (S1) and the second sample (S2)}, {between the second 
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sample (S2) and the third sample (S3)} and {between the third sample (S3) and the 
fourth sample (S4)}.  Simple Proportion test was applied to establish the difference in 
the percentage of infection among negatives and infected people, and monotypic 
infected and multytipic infected people Simple proportion test was also applied to 
compare difference between samples in each group of negatives, monotypic and 
multytipic infected people.   
A model of  Nominal (Binary)  Logistic Regression was made to estimate the relation 
between the infection by dengue virus in a period of six month, considering the sample 
2 (S2) as a dependent variable and as independent variables or factors: previous 
infection in time cero (the first sample at the beginning of the study) and sample 1 (S1) 
at the first six months, age, sex, residence (neighborhoods), beginning of the study 
(cohort 2006 or 2007),  number of serotypes in time cero and sample 1 and interaction 
variables between age and sex, residence and age, cohort and age and cohort and sex, 
with a confidence level of 95%   The infection in sample 3 (S3) was not used as a 
dependent variable because the number of lost people was higher that last sample.  
In the patients detected by active surveillance, confirmed cases were defined as those 
patients with clinical manifestation of dengue according to WHO and positive RT-PCR; 
probable cases as those patients with clinical manifestation of dengue, positives IgM 
and negative RT-PCR. Finally, negative cases were those patients with clinical 
manifestations of dengue but negative in RT-PCR and IgM. 
The people detected by active surveillance were analyzed by case definition, 
residence, serotype, age-group, and days of diagnosis after the onset of the symptom. 
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Independence among categorical variables was tested with Chi square test with a 
confidence level of 95%.         
Percentage of specific symptoms and signs were obtained in people detected in active 
surveillance distributed by age group, and by confirmed and non confirmed cases. 
Independence among categorical variables was tested with Chi square test with a 
confidence level of 95%. To confirm the statistical results by bi-variable test and adjust 
them by age group, gender and residency, logistic regression analysis was applied with the 
symptoms and signs of the people detected in the active surveillance. 
 Additional tests were done in a sub sample of patients during the acute and 
convalescence phase of the dengue disease, including: hemoglobin, hematocrit, platelets, 
white blood cells, lymphocytes and neutrophils. Statistical differences among these 
hematologic quantitative variables were tested with Student T test and F test when was 
compared between confirmed and non confirmed cases, and Student T matched test when 
consecutive samples were made.  
Acute and convalescence sero-conversion to IgM anti-dengue antibody was evaluated in 
those patients confirmed with dengue by RT-PCR.   
To do comparable analysis of the active surveillance in this study with the passive 
surveillance in the local and national system, we redefined the terms of confirmed cases of 
dengue. In this part of the analysis people detected in active surveillance with clinical 
manifestation of dengue and positive IgM sero-converted in the convalescence phase of the 
dengue disease were considered confirmed cases. Besides, for similar reasons, cumulative 
incidence was calculated in the sample studied. The comparison between both surveillance 
systems was made in the year 2007 exclusively.    
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Ethical consideration. 
The confidentiality of all participants will be maintained throughout the study.  All forms 
with identifiers will be maintained in a limited access office at the BIOMED. In the 
reporting of the laboratory results, names were used, but the information was only provided 
to the head of the household or the attending physician. All demographic, clinical, 
epidemiological, and laboratory data on each sample were entered into a database by the 
unique identification number. The risks of infection with venipuncture sampling were 
minimized by using only trained personnel to perform the venipuncture procedures using 
sterile, single use needles, alcohol/betadine wipes and bandages. All official protocol files 
(protocol, IRB minutes, and approvals) were maintained at the NMRCD under password 
protection.  All consent forms and questionnaires will be maintained in the BIOMED, 
Maracay, with copies provided to NMRCD and stored under limited access.  
   Informed Consent Process: Wellness visits/longitudinal cohort: in selected Barrios, a 
study representative was knock on prospective participant’s doors, identified them self 
and described the study.  If the head of household was interested in participating, they 
gave a blank consent form and the representative returned in 3-5 days, allowing time for 
the household members to discuss the study, to enroll the household if the household 
members agree to participate.  The enrollment process included reading the informed 
consent document (ICD) to the potential subjects followed with the potential subjects 
reading the ICD and signing it, for children and adults. (Appendix E and Appendix F).   
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CHAPTER FOUR: RESULTS 
Demographic Description: 
A total of 3,255 people aged 5 to 94 years old were recruited to participate in 
longitudinal study. Enrolled people were followed during two years in four 
neighborhoods (Barrios) of Maracay, Venezuela. The barrios selected were: “23 de 
Enero” including 693 (21.3%) people, “Caña de Azucar” with 1299 (39.9%) people, “La 
Cooperativa” 628 (19.3%), and “Piñonal” 635 (19.5%). The goals were to detect acute 
dengue cases in an active surveillance of fever and dengue symptoms, and to identify 
antibodies anti-dengue virus with biannual blood samples. According to the age group 
dividing in children and adults, 784 people (24.1%) were children (among 5 and 15 years 
old), 1,721 (53.9%) adults equal and older than 15 and less than 50 years old, and 750 
(23.0%) were adults equal and older than 50 years old. (Table 2). 
Table 2.  
 
Demographic Features of the enrolled people, distributed by Barrios, gender and age groups < 15 
year of age, ≥ 15 < 50 and ≥ 50 years of age. 
 
Neighborhoods (Barrios) 
 
Gender 
Age Groups in Years 
<15            ≥15<50            ≥50 
 
Total 
 
23 de Enero 
Female 73 263 108 444 
Male 92 113 44 249 
Sub total 165 376 152 693 
 
Caña de Azúcar 
Female 144 459 240 843 
Male 150 222 84 456 
Sub total 294 681 324 1299 
 
La Cooperativa 
Female 94 218 100 412 
Male 81 92 43 216 
Sub total 175 310 143 628 
 
Piñonal 
 
Female 68 221 86 375 
Male 82 133 45 260 
Sub total 150 354 131 635 
Total  784 1721 750 3255 
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The number of females was higher than the number of males in the study with 2,074 
women (63.7%) and 1,181 men (36.3%). The femininity ratio (FR) was 1.76, being 
higher in older people, from 15 to 94 than young people from 5 to 15; 2.18 and 0.94 
respectively.  This tendency also can be seen in age group by 5 years from 5 to 9 to 90 to 
94. (Table 3). 
Table 3 
  
Distribution of the people studied by age group, gender and Femininity Ratio (FR). 
 
Age Groups in years Female Male Total Femininity Ratio 
(FR) 
5-9 176 206 382 0.85 
10-14 203 199 402 1.02 
15-19 197 135 332 1.46 
20-24 184 78 262 2.36 
25-29 188 92 280 2.04 
30-34 191 90 281 2.12 
35-39 150 54 204 2.78 
40-44 140 51 191 2.75 
45-49 111 60 171 1.85 
50-54 144 54 198 2.67 
55-59 136 40 176 3.40 
60-64 76 45 121 1.69 
65-69 78 30 108 2.60 
70-74 52 24 76 2.17 
75-79 23 15 38 1.53 
80-84 14 5 19 2.80 
85-89 8 1 9 8.00 
90-94 3 2 5 1.50 
Total 2074 1181 3255 1.76 
  
These femininity ratios by age groups were similar in the four barrios of Maracay, 
and comparing with the total. (Table 4). 
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Table 4  
 
Distribution of Age Group, Gender and Femininity Ratio in the Four Neighborhoods in 
the study. Maracay 2006-2008. 
 
 
Neighborhoods (Barrios) 
Age 
Group 
 
Female 
 
Male 
 
Total 
Femininity 
Ratio 
23 de Enero <15 73 92 165 0.79 
≥15 371 157 528 2.36 
Caña de Azúcar <15 144 150 294 0.96 
≥15 699 306 1005 2.28 
Cooperativa <15 94 81 175 1.16 
≥15 318 135 453 2.36 
Piñonal <15 68 82 150 0.83 
≥15 307 178 485 1.72 
The Four Neighborhoods <15 379 405 784 0.94 
≥15 1695 776 2471 2.18 
Total  2074 1181 3255 1.76 
 
The study of the cohort began in September 2006 with 2,509 people. During the first 
year of follow-up, until September 2007; 556 people were added in the cohort.  In the 
second year of the study, 190 people were added, from October 2007 to December 2008. 
The people lost in the follow-up were 471 in the first year (15.4%) and 239 (8.6%) in 
the second one. These people were lost in both groups: on the active surveillance of 
febrile cases of dengue and in the bi-annual detection of specific IgG antibody anti-
dengue. However, 178 people rejected, exclusively, to participate in the bi-annual blood 
sample to detect specific IgG antibody anti-dengue so they kept in the active surveillance 
of febrile cases of dengue, (66 people in the first year and 112 in the second one). 
  In the total period of two years 710 people (21.8%) were lost in the follow-up on active 
surveillance and 888 (27.3%) in both  the active surveillance and bi-annual IgG anti-
dengue antibody detection.  
 
  
62 
Table 5. 
 
Distribution of the people according to their type of permanency in the study. Maracay 
2006-2008. 
 
Group  
of Age 
and 
sex 
People 
 who  
never 
 left the 
Cohort 
Group 
I 
People who 
 only left 
 the Bi-annual 
blood sample 
but not the 
active 
surveillance. 
Group II 
People who 
Left and came 
back to the 
Cohort 
Group III 
People who 
 left the 
cohort. 
(Did not die) 
Group IV 
People 
Who Died 
(Other 
causes, 
not 
dengue) 
Group V 
Total 
< 15 622 38 9 115   (14.7%) 0 784 
> 15 1745 140 21 544   (22.0%) 21 2471 
Sub-Total 2367 178 30 659   (20.2%) 21 3255 
Females 823 86 12 247   (20.9%) 13 1181 
Males 1544 92 18 412   (19.9%) 8 2074 
Sub-Total 2367 178 30 659   (20.2%) 21  
Total 2367 178  30 659 21 3255 
 
From these 710 people lost in the active surveillance, 21 died by causes different than 
dengue (13 in the first year and 8 in the second one). 30 left and came back to the study 
and 659 left definitely the study. 
According to the type of permanence of the people in the study, there were five 
groups: Type I, integrated by 2,367 (72.7%) people who never left the study. Type II, it 
had 178 (5.5%) people who only left the Bi-annual blood sample component to detect 
IgG specific antibody anti dengue virus but they did not leave the active surveillance 
component. Type III, formed by 30 (0.9%) people who left and returned to the study 
before it was over. Type IV, they were 659 (20.2%) people who left definitely the study 
in both components (active surveillance and biannual blood sample). Type V: 21 (0.7%) 
people who died during the period of the study. The Types I,II and III were always in the 
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active surveillance part of the study and only the Type I was in the bi-annual blood 
sample part of the study to detect IgG specific antibody anti dengue virus. (Table 5). 
  “23 de Enero” and “Piñonal” were the Barrios with the highest number of people lost 
in the study, 25.1%  and 23.3% respectively, and “Cana de Azúcar” and “La 
Cooperativa” had 19.6% and 16.4% of people lost, respectively. The proportion of death 
by no dengue cause was similar in the four barrios, being the fewer in “Piñonal” with 
0.5% and higher in “La Cooperativa” with 0.8%. 
  The percentage of people lost in the follow-up was small in young people (5 to 15) 
with 14.7% respect older people (>15%) with 22.9%.  The male sex, lost in the study, 
was little higher than female; 22.0% and 20.3% respectively.  All people who died were 
older than 15 (0.8%) and the proportion was higher in males than females (1.1% vs. 
0.4%). 
Table 5. 
   
Distribution of the people according to their type of permanency in the study. By 
neighborhoods, Maracay 2006-2008. 
 
Neighborhoods 
 
(Barrios) 
People 
who never 
left the 
Cohort 
Type I 
 
People 
who only 
left the Bi-
annual 
blood 
sample 
Type II 
People 
who Left 
and come 
back 
Type III 
 
People who 
left the 
cohort. 
(Did not die) 
Type IV 
 
People 
who Died 
Type V 
 
 
 
Total 
23deEnero 468 37 14 169   (24.4%) 5   (0.7%) 693 
Caña de 
Azucar 
984 55 5 247   (19.0%) 8   (0.6%) 1299 
Cooperativa 474 42 9 98   (15.6%) 5   (0.8%) 628 
Piñonal 441 44 2 145   (22.8%) 3   (0.5%) 635 
Total 2367 178 30 659  (20.2%) 21 (0.7%) 3255 
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Incidence Density 
The people in the study (3,255) contributed with 1,914,496 person-days (p/d) during 
the two years of follow-up. The period from Sep. 06, 2006 to Sep. 30, 2007 (2006-2007) 
had 808,339 p/d and the period from Oct. 01, 2007 to Dec. 08, 2008 (2007-2008) had 
1,106,157 p/d. Dividing the study period in nine trimesters, the first one had 132,396 p/d 
and the last one 177,453. Every other trimester had values among 218,000 p/d and 
239,000 p/d.   In this study period were also considered the number of person days by 
each month, with a total of 28 months. September 2006 had 528 p/d, October 2006 had 
18,388 p/d and November 2006 had 41,566 p/d. From December 2006 until November 
2008 all amounts of person-day were among values of 70,000 and 81,000. Finally, 
December 2008 had 20,592 p/d. 
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Figure 1 Incidence Density and Number of dengue cases by month, Maracay. 2006-2007  
 
According to the kind of permanence in the cohort, the people from the Type I, who 
never left the cohort, contributed with 1,634,162 p/d: 627,566 in the first year (2006-
2007) and 1,006,596 in the second one (2007-2008).  The people lost (Type IV) gave 
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117,594 p/d in the period 2006-2007 and 14,438 in the period 2007-2008. Dead and 
reincorporated people had a little impact in the number of person days. . (Table 7). 
Children, 5 to 15, contributed with 475,764 p/d and adults (>15) added 1,438,732 p/d 
in the study. Males and females between 5 and15 had similar number of person days, 
243,438 and 232,326 respectively.  However, adult females had 1,009,188 p/d versus 
429,544 p/d of adult males. (Table 8). 
Table 7. 
  
Number of person/days (p/d) by type of permanency in the study and by month in two 
years of follow-up. Maracay 2006-2008 
 
2006-2007 Oct-
06 
Nov-
06 
Dic- 
06 
Jan-  
07 
Feb- 
07 
Mar- 
07 
Abr-
07 
May-
07 
Jun-
07 
July 
07 
Ago-
07 
Sep-
07 
Type I* 334 13549 29997 50719 53754 48552 53754 52500 58720 64115 67921 67921 
Type II 23 817 2041 4390 4898 4424 4898 4762 5038 5133 5394 5394 
Type III 0 131 369 613 651 588 590 479 491 494 527 527 
Type IV 163 3784 8871 15675 16685 14753 14229 10621 8770 6011 6076 6076 
Type V 8 107 288 517 525 422 465 450 470 450 443 374 
Total 
Person/Days 
528 18388 41566 71914 76513 68739 73936 68812 73489 76203 80361 80292 
 
2007-2008 
 
Oct-
07 
 
Nov-
07 
 
Dic- 
07 
 
Jan- 
 08 
 
Feb- 
08 
 
Mar- 
08 
 
Abr-
08 
 
May-
08 
 
Jun-
08 
 
July 
08 
 
Ago-
08 
 
Sep-
08 
Type I 65730 67921 65730 69913 71610 66990 69300 71610 71666 70769 73377 73377 
Type II 5220 5394 5220 5463 5518 5162 5518 5340 5518 5340 5518 5518 
Type III 510 499 526 307 186 174 186 162 244 597 682 682 
Type IV 5880 5762 4639 1606 372 339 372 360 372 254 93 93 
Type V 258 222 195 134 124 116 124 93 93 85 62 47 
Total 
Person/Days 
77598 79798 76310 77423 77810 72781 75500 77565 77893 77045 79732 79717 
 
2007-2008 
 
Oct-
08 
 
Nov-
08 
 
Dic- 
08 
 
Total 
p/d 
        
Type I 71010 73377 18936 1634162         
Type II 5340 5518 1424 129563         
Type III 660 700 232 12587         
Type IV 90 78 0 132032         
Type V 30 31 0 6152         
Total 
Person/Days 
77130 79704 20592 1914496         
* Type I: People who never left the Cohort. Type II: People who only left the Bi-annual blood sample 
Type III: People who Left and come back to the study. Type IV: People who left the cohort. (Did not die). Type V: People who died. 
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The barrio “23 de Enero” had 381,295 p/d from 693 participants, “Cana de Azucar” 
contributed with 780,521 p/d from 1,299 people. “La Cooperativa” added 389,825 p/d 
with 628 people in the study and finally “Pinonal” had 362,855 p/d and 635 people in 
follow-up.  
Table 8. 
 
Number of person/days (p/d) by neighborhoods, age group and gender Maracay 2006-
2008. 
 
Neighborhoods 
          (Barrios) 
Children less than 
15 years old 
Adults equal and higher than 15 
years old 
Total 
 Females Males Subtotal Females Males Subtotal  
23deEnero 38733 54286 93019 209081 79195 288276 381295 
Caña de Azucar 91551 94697 186248 416868 177405 594273 780521 
La Cooperativa 61331 50747 112078 203811 73936 277747 389825 
Piñonal 40711 43708 84419 179428 99008 278436 362855 
Total 232326 243438 475764 1009188 429544 1438732 1914496 
   
The crude incidence density of the cohort during two years was 3.24 by 100,000 p/d 
(2.01 by 100,000 p/d adjusted by age group and gender of Maracay population): The first 
year (from Sep 2006 to Sep 2007) the ID was 5.69 p/d and 1.45 p/d in the second year 
(Oct. 2007 to Dec. 2008). The trimester with higher incidence density in both years of 
study was from July 2007 to September 2007 with 8.81 p/d. All trimesters in the first year 
had higher ID than second one. The months with higher ID were July 2007 (11.20 p/d) 
and August 2007 (11.21 p/d) (Figure 1).  
In two years of study (2006-2008), “Cana de Azucar” was the barrio with the highest 
Incidence Density: 4.23 p/d, followed by “La Cooperativa”: 3.59 p/d. However, in the 
2006-2007 period  “La Cooperativa” had 7.92 p/d of Incidence Density and “Cana de 
Azucar” had 6.67 p/d. In all Barrios, the ID was always higher in the first year of the 
study; 2006-2007. (Figure 2).  
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Table 9.  
 
Number of cases, person days (p/d) and Incidence density (ID) distributed by 
neighborhoods, gender and age groups, Maracay 2006-2008. 
 
Neighborhoods  Males 
<15 
Females 
<15 
Total   
<15 
Males 
>15 
Females 
>15 
Total 
>15 
Total 
23 de Enero Cases 2 4 6 1 3 4 10 
p/d 54286 38733 93019 79195 209081 288276 381295 
ID 3,68 10,33 6,45 1,26 1,43 1,39 2,62 
Cana  
de Azucar 
Cases 7 10 17 3 13 16 33 
p/d 94697 91551 186248 177405 416868 594273 780521 
ID 7,39 10,92 9,13 1,69 3,12 2,69 4,23 
Cooperativa Cases 8 2 10 2 2 4 14 
p/d 50747 61331 112078 73936 203811 277747 389825 
ID 15,76 3,26 8,92 2,71 0,98 1,80 3,59 
Pinonal Cases 1 1 2 0 3 3 5 
p/d 43708 40711 84419 99008 179428 278436 362855 
ID 2,29 2,46 2,37 0,00 1,67 1,08 1,38 
Total Cases 18 17 35 6 21 27 62 
p/d 243438 232326 475764 429544 1009188 1438732 1914496 
ID 7.39 7.31 7.36 1.40 2.08 1.88 3.24 
 
The incidence density during the two years study was higher in infants from 5 to 15 
years old with 7.36 p/d than adults equal and higher than 15 years old with 1.88 p/d. This 
difference was in both years of the study, but it was much evident in 2006-2007. (Table 
9).  In the period 2006-2007 and in the four barrios the incidence densities were always 
higher in infants but in 2008 in two barrios the Incidence density were a little higher in 
two of the four barrios. (Piñonal and La Cooperativa) (Figure 2). 
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Figure 2. Incidence Density of confirmed dengue cases by Neighborhoods, age group and 
year of follow-up. Maracay 2006-2008 
 
Relative Risk in Age Groups 
In the two of years study (2006-2008), the Relative risk (RR) in confirmed infant cases 
respect to adults was 3.92 (95% IC 2.38 – 6.48) being 4.77 (95% IC 2.66 – 8.54) in 2006-
2007 and 2.52 (95% IC 0.91 – 6.94) in 2007-2008. According to gender, in females 
between 5 to 15 the ID was 7.32 by 100,000 person-days and 2.08 in females higher than 
15.  RR 3.52 (95% IC 1.86 – 6.66)  In males 5 to 15 the ID was 7.39 by 100,000 person-
days and 1.40 by 100,000 person-days in males higher than 15. RR 5.28 (95% IC 2.10 – 
13.33). In the period 2006 to 2007 the Relative Risk in females was 5.13 by 100,000 
person-days; 15.01 by 100,000 p/d in females from 5 to 15 and 3.00 by 100,000 p/d in 
older female. In the same period, the ID in male 5 to 15 was 14.37 by 100,000 p/d and 
2.71 by 100,000 p/d in male older or equal than 15. In the period 2007-2008, the ID was 
reduced similarly in both sex and age: 2.16 by 100,000 p/d in young women and 1.39 by 
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100,000 p/d in the older ones and 2.74 by 100,000 p/d and 0.41 by 100,000 p/d in young 
and older men respectively (Table 10). 
Table 10  
 
Relative Risk ID of age group and gender by years of the study. 
 
  
2006-2008 
 
2006-2007 
 
2007-2008 
 RR IC RR IC RR IC 
Age Group 
(Children/Adults) 
3.92 2.38-6.48* 4.77 2.38-6.48* 2.52 0.92-6.94 
Female 3.52 1.86-6.66* 5.00 2.35-10.64* 1.55 0.41-5.86 
Male 5.29 2.10-13.3* 5.30 1.91-14.78* 6.72 0.75-60.11 
Gender (female/male) 0.86 0.51-143 0.76 0.42-1.37 1.20 0.42-3.46 
Children 0.99 0.51-1.92 1.04 0.50-2.19 0.79 0.18-3.52 
Adults 1.22 0.49-2.52 1.11 0.39-3.10 3.41 0.43-27.23 
* Significant Relative Risk. 
During the two years study, the Incidence Density in female was 3.06 by 100,000 
person-days and 3.56 by 100,000 persons-days in males: RR female/male: 0.86 (95% IC 
0.51 – 1.43).  In females <15 the ID was 7.32 by 100,000 person-days and 7.39 in males: 
RR 0.99 (95% IC 0.51 – 1.92).  In female >15 the ID was 2.08 versus 1.40 in women: RR 
1.22 (95% IC 0.49 – 2.52).  
Prevalence of antibody anti dengue virus and Incidence of infection by prospective sero-
prevalence of antibodies: IgM anti-antidengue antibody. 
The first biannual sample (at the beginning of the study) was made in all the 3,255 
participants in different times of the study, depending when they were included in the 
cohort. Out of them, 75 (2.3%) were IgM positive, 21 children and 54 adults. In the 
second biannual sample 2,622  people were tested and 86  were IgM positive (3.28%) 4 
of them had been detected with dengue infection by the Active Surveillance few weeks 
before (with a limit of 13 weeks), either by IgM or RT-PCR.  In the third biannual sample 
116 people were IgM positive and 11 were detected with dengue infection by active 
  
70 
surveillance in a period from zero to 13 weeks before the biannual sample. 2,402 people 
were participating in this third test so 105 (4.4%) were asymptomatic.  In the fourth 
biannual sample 69 people were IgM positive, only one of them had been detected by the 
active surveillance system.  It represented 3.24% of 2,129 people. The fifth and last 
biannual sample had 61 IgM positive and two of them were detected previously by the 
active surveillance system. 1,599 people were tested. 
Bi-annual samples, Plaque Reduction Neutralization Test. 
The Plaque Reduction Neutralization Test (PRNT) was applied in 2125 people; 65.3% 
from all people in the cohort. Four samples from 1,684 people who began the study 
cohort in 2006 and three samples from 441 people who began the study cohort in 2007.  
In the first sample (S1) in both years of the cohort, the PRNT detected at least one of the 
four anti DENV antibodies in 1,840 people (86.6%), it was negative in 283 (13.4%) 
people and 2 participants were not tested in their S1. All the anti DENV antibodies were 
detected either alone or in combination with other serotypes. Anti DENV-1 antibody was 
positive in 1,573 (74%) people but only in 157 (7.4%) this antibody was found alone. 
Anti DENV-1 and DENV-2 antibodies were positives simultaneously in 1,386 (65.2%) 
people. Three anti DENV serotypes were positive in 401 people and anti DENV 1, 
DENV-2 and DENV-3 antibodies were the most frequent combination, it occurred in 371 
(92.5 %) people. The four antibodies were present in 31 (1.5 %) people. (Table 11).  
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Table 11  
 
Results of Plaque Reduction Neutralization Test in the first sample of people studied; 
distributed by number of serotypes detected in each participant 
. 
Negatives and number of 
Serotypes detected 
in each individual. 
Frequency % of the 
subtotal 
% of the total 
           One Serotype 401 N/A 18.9 
                     DENV-1          157 39.2         7.4 
                     DENV-2          166 41.4         7.8 
                     DENV-3           70 17.4         3.3 
                     DENV-4             8 2.0         0.4 
    
          Two serotypes 1007 N/A 47.4 
                     DENV-1 DENV-2        955 94.8      44.9 
                     DENV-1 DENV-3         23 2.3        1.1 
                     DENV-2 DENV-3         16 1.6        0.8 
                     DENV-1 DENV-4           6 0.6        0.3 
                     DENV-2 DENV-4          2 0.2        0.1 
                     DENV-3 DENV-4          5 0.5        0.2 
    
          Three Serotypes 401 N/A 18.9 
                DENV-1 DENV-2 DENV-3       371 92.5      17.5 
                DENV-1 DENV-2 DENV-4       29 7.2        1.4 
                DENV-1 DENV-3 DENV-4        1 0.3        0.05 
    
          Four Serotypes 
    DENV-1 DENV-2 DENV-3 DENV-4 
31 N/A 1.5 
    
           Negatives 283 N/A 13.3 
           NR 2 N/A 0.1 
           Total  2125  100 
 
According to the age group, from 5 to 9 years old (y/o) interval had the less proportion 
of positive antibodies in S1 with 127 children (47.39%), in the next group from 10 to 14 
y/o, 202 children were positive (75.01%). The number of positives were increasing in 
correspondence with the groups of higher age:  89.34% in the group from 15 to 19;  
94.34% in the group from 20 to 24; in the group of 45 to 49, 99.12% were positive. 
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Separating into two age groups: less than 15 (children) and higher than or equal to15 
(adults), the proportion of negatives was significantly higher in children: 34.45 % versus 
4.72 % in adults.  This difference was consistent and significant (p value < 0.01) in the 
two years when the people started the study (cohorts of 2006 and 2007).  The proportion 
of antibodies against serotype 1 and 2 were higher in people > 15; 85.45 % and 87.34% 
versus 24.31% and 25.51 % in people < 15 respectively. On contrary, people <15 had 
lightly higher proportion of serotypes 3 and 4, but this difference was not significant. 
(Figure 3).     
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Figure 3 Percentage of people with antibodies according to serotype and negative results 
distributed by age groups and years when they started the study. Maracay 2006 - 2008. 
 
Figure 4 showed the most frequent results of the PRNT. DENV-1 and DENV-2 were 
in four of the five first more frequent results, representing 70.6%, in contrast DENV-4 
was in 3.95% of all possible results and DENV-3 in 24.45%.   
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 If we compare the prevalence of the three most frequent results in the PRNT, which 
included DENV-1 – DENV-2, DENV-1 – DENV-2 –DENV-3  and negatives according 
to age groups each 5 years, we can see how the proportions descend in negative results  
with the age groups and ascend with the serotype positive results. (Figure 5). 
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Figure 4 Plaque Reduction Neutralization Test in the first sample of 2,125 people sorted 
by most frequent results. Maracay 2006- 2008. 
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Figure 5 Percentage of the three most frequent results of PRNT in the first sample of 
people in the study by age group. Maracay 2006 – 2008. 
 
Thirty percent of the negative people in the first sample were positive either to one or 
more than one serotype six months later in the second sample (S2). In the third sample 
(S3), it was 29.6% of positives and 23.8 % in the last sample (S4). The sero conversion in 
people with previous detection of anti anti-dengue antibody serotype 2 was the highest 
percentage in the second sample with 58.1 %. In the third sample (S3) people with 
previous anti anti-dengue antibody serotype 4 was the highest with 50.0 % and finally 
anti anti-dengue antibody serotype 3 was the highest in the last sample with 34.1%. 
(Figure 6).  The same analysis but considering the people with negative results and the 
most frequent positive results (DENV-1 DENV-2, DENV-1 DENV-2 DENV-3, and 
DENV-1 DENV-2 DENV-4) showed the people with no antibody had the highest 
percentage of sero-conversion in the second sample (S2): 30.1%. In the third sample, the 
people with DENV-1 DENV-2 and DENV-1 DENV-2 DENV-4 combination in the 
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second sample had the highest percentage of sero-conversion with 36.7 and 35.7 
respectively. (Figure 7).      
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Figure 6 PRNT, percentage of sero conversion according to results of the previous PRNT 
in the second (S2), third (S3) and fourth (S4) samples. Maracay 2006 – 2008. 
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Figure 7 PRNT, percentage of sero conversion according to the most frequent results of 
the previous PRNT in the second (S2), third (S3) and fourth (S4) samples. Maracay 2006 
– 2008. 
 
When we compared the sero-conversion proportion of negative people with that 
proportion of people with previous monotypic antibody detection in the three samples 
  
76 
(S1, S2 and S3); the proportion of sero-conversion was always higher in the people with 
monotypic antibody. These differences were statistically significant. The people with 
multitypic antibodies detected had always less proportion of sero conversion respect to 
either people negative or people with monotypic antibody. (Table 12). 
Table 12  
 
PRNT, percentage of sero conversion according to results of the previous PRNT in the 
second (S2), third (S3) and fourth (S4) samples by monotypic and multitypic antibodies. 
Maracay 2006 – 2008. 
 
 Positives 
/ Number 
of people 
in 
Sample 2 
PRNT 
Sample 2  
% of Sero- 
Conversion  
Positives 
/ Number 
of people 
in 
sample 3 
PRNT 
Sample 3  
% of Sero- 
Conversion  
Positives 
/ Number 
of people 
in 
sample 4 
PRNT  
Sample 4  
% of Sero- 
Conversion  
DENV-1 * 47/157 29,9 45/133 33,8 20/86 23,3 
DENV-2 * 86/166 58,1 39/89 43,8 12/46 26,1 
DENV-3 * 28/70 40,0 10/46 21,8 15/29 34,1 
DENV-4 * 5/8 37,5 5/10 50,0 1/8 12,5 
 
DENV-1 ** 
DENV-2 
 
174/955 22,0 319/894 35,7 13/4818 43,6 
DENV-1 ** 
DENV-2 
DENV-3 
 
 
10/371 
 
3,8 
 
13/574 
 
2,3 
 
10/125 
 
1,4 
DENV-1  ** 
DENV-2 
DENV-4 
 
 
4/29 
 
13,8 
 
18/49 
 
36,7 
 
10/26 
 
38,5 
Monotypic  166/401 41,4 *** 99/278 35,6 *** 48/169 28,4 *** 
Multitypic 188/1355 13,9 *** 350/1517 23,1 *** 158/1232 12,8 *** 
Negatives 86/283 30.1 *** 58/156 29,6 *** 29/122 23,8 *** 
* Monotypic antibodies   ** Multitypic antibodies 
*** P value < 0.05 
 
The Logistical Regression model with the new infection of dengue in the sample 3, 
after the second six months of the study, as a dependent variable and previous infection in 
time cero (the first sample at the beginning of the study) and sample 1 (S1) at the first six 
months, age, sex, residence (neighborhoods), time of the beginning of the study (cohort 
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2006 or 2007),  number of serotypes in time cero and sample 1 and interaction variables 
between age and sex, residence and age, cohort and age and cohort and sex as a factors or 
independent variables showed a significant (P value less than 0.05)  relation with age, and 
number of serotypes in the sample 1 (sample previous to the new infection). The 
difference was significant between 2 and 3 serotype. In conclusion, younger people and 
two anti dengue antibodies in blood sample were the most important factors to predict a 
new infection of dengue by PRNT.   
Active Surveillance and Laboratory Diagnostic of dengue 
270 people with possible dengue infection were detected by the surveillance action in 
the prospective study; all of them had fever either equal or higher than 38º Celsius, at the 
moment of the evaluation.  The blood samples were taken the same day of the 
surveillance detection and that occurred between the first and the eighth day post onset of 
the symptoms. 137 (50.74 %) were less than 15 year old and 156 (57.78 %) were female.  
The neighborhood “Pinonal” had the highest percentage of people detected in the 
surveillance with 10.39% (66 from 635 people) and “La Cooperativa” had the lowest one 
with 5.25%. (Table 13). 
The highest proportion of blood samples were taken in the second and third day with 
37% and 28% respectively and 96.68 % of the samples were taken at the fifth day, or 
less, after the onset of the symptoms. (Table 14). 
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Table 13   
 
Number of possible cases of dengue detected in the active surveillance, distributed by 
Neighborhood and their population, age-group and gender. Maracay 2006 2008 
 
Neighborhoods 
(Barrios) and their 
population. 
Children less than 
15 years old 
Adults equal and higher 
than 15 years old 
Total 
 (% of 
population) F M Subtotal F M Subtotal 
23deEnero 
  693 
12 13 25 14 7 21 46  (6.64) 
Caña de Azucar 
 1,299 
25 31 56 49 18 67 123 (9.47) 
Cooperativa 
 628 
5 17 22 9 4 13 35 (5.25) 
Piñonal 
 635 
20 14 34 22 10 32 66 (10.39) 
Total Population 
3,255 
62 75 137 94 39 133 270 (8.29) 
 
Table14  
 
Number of cases, percentage and cumulative percentage by day of detection in active 
surveillance. Maracay, 2006 2008. 
 
Day of detection and 
blood sample 
Number of 
cases 
% Cumulative 
% 
1 18 6.67 6.67 
2 101 37.41 44.08 
3 77 28.52 72.60 
4 44 16.30 88.90 
5 21 7.78 96.68 
6 5 1.85 98.53 
7 2 0.74 99.27 
8 2 0.74 100.00 
 270 100.00  
 
The dengue infection was confirmed in 62 (22.96%) patients by RT-PCR. In 
addition, probable dengue cases were estimated by detection of anti anti-dengue IgM 
  
79 
antibody, with ELISA. For this test, two samples were taken: the first in the acute phase 
and the second one in the convalescence phase of the disease. 34 (54.84%) confirmed 
dengue cases were people less than 15 years old and 28 (45.16%) in older participants. 
The four serotypes were in both age groups. DENV-1 was more detected in <15 people 
and DENV-2 DENV-3 and DENV-4 in >15 people. (P value <0.01, Chi
2
 test).  DENV-1 
and DENV-2 were 67.74 % of the total confirmed dengue cases. (Table 15).     
 
 
Table 15  
 
Number and percentage of confirmed dengue cases by RT-PCR in the active  
surveillance at four neighborhoods of Maracay, distributed by age-group  
and serotype. Maracay, 2006 - 2008. 
 
Serotype Children less 
than 15 years 
 old (%) 
Adults equal and 
higher than 15 
years old   (%) 
Total 
DENV-1 17 
(50.00) 
4 
(14.29) 
21 
(33.87) 
DENV-2 10 
(29.41) 
11 
(39.29) 
21 
(33.87) 
DENV-3 3 
(8.82) 
4 
(14.29) 
7 
(11.29) 
DENV-4 4 
(11.76) 
9 
(32.14) 
13 
(20.97) 
Total 34 28 62 
 
Three of the four neighborhoods had all dengue serotypes; only “Pinonal” had only 
three dengue serotypes. There were not significant differences among the proportion of 
serotypes among neighborhoods. Figure 8. 
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Figure 8. Percentage and number of dengue cases by serotypes detected in each 
neighborhood. Maracay, 2006–2008 
 
73.48% of the confirmed cases by RT-PCR were detected in the first three days after 
onset of the symptoms and 24.19% in the days fourth and fifth. (Table 16). DENV-2 was 
the most detected serotype in the first two days after onset of the symptoms with 44.44% 
of 27 people with DENV detected in these two days.  DENV-1 was the most detected 
serotype in the third, fourth and fifth days with 42.42%. However, these differences were 
not statistically significant. (p value > 0.05, Chi
2 
test).  50 (18.5%) patients were negative 
the days fourth and fifth after onset of the symptoms. 
In the acute period (the first to seventh days after onset the symptoms) of the 270 
people, the IgM MAC ELISA test was positive in 29 patients and positive in 52 patients 
during the convalescence period (30 days after onset of the symptoms). In the acute 
period IgM was positive in 7 (12.5%) of the 62 Confirmed cases and positive in 23 (38.33 
%) of 60 confirmed cases in the convalescence period.  Six cases (10%) were positives in 
both periods (Table 17). 
  
81 
 
 
Table 16  
 
Number and percentage of cases detected by active surveillance according to DENV 
specific serotype identified by RT-PCR in each day after onset of the symptoms, Maracay 
2006 – 2008. 
 
Serotype Day of detection after onset of the symptoms. 
Number of people detected and percentage (%). 
1 2 3 4 5 6 7-8  
D1 1 
(4.76) 
6 
(28.57) 
7 
(33.33) 
4 
(19.05) 
3 
(14.29) 
0 
(0.00) 
0 
(0.00) 
21 
(100.00) 
D2 2 
(9.52) 
10 
(47.62) 
3 
(14.29) 
3 
(14.29) 
1 
(4.76) 
1 
(4.76) 
1 
(4.76) 
21 
(100.00) 
D3 0 
(0.00) 
1 
(14.29) 
4 
(57.14) 
0 
(0.00) 
2 
(28.57) 
0 
(0.00) 
0 
(0.00) 
7 
(100.00) 
D4 1 
(7.69) 
6 
(46.15) 
4 
(30.77) 
2 
(15.38) 
0 
(0.00) 
0 
(0.00) 
0 
(0.00) 
13 
(100.00) 
Total 
Positives 
4 
(6.45) 
23 
(38.00) 
18 
(29.03) 
9 
(14.52) 
6 
(9.67) 
1 
(1.61) 
1 
(1.61) 
62 
(100.00) 
Negatives 14 
(6.73 
78 
(37.50) 
59 
(28.37) 
35 
(16.83) 
15 
(7.21) 
4 
(1.92) 
3 
(1.44) 
208 
(100.00) 
Total 18 
(6.66) 
101 
(37.41) 
77 
(28.52 
44 
(16.30) 
21 
(7.77) 
5 
(1.85) 
4 
(1.48) 
270 
(100.00) 
 
Table 17  
 
Number and percentage of patient results of IgM MAC ELISA test according to day of 
detection by active surveillance. Maracay, 2006-2008. 
 
IgM Day of detection after onset of the symptoms 
Number of people detected and percentage (%). 
Total 
1 2 3 4 5 6 7 8 
IgM 
+ 
2 
(11.11) 
1 
(0.99) 
8 
(10.39) 
6 
(13.64) 
9 
(42.86) 
3 
(60.00) 
0 
(0.00) 
0 
(0.00) 
29 
(10.74) 
IgM  
- 
16 
(88.89) 
100 
(99.01) 
69 
(89.61) 
38 
(86.36) 
12 
(57.14) 
2 
(40.00) 
2 
(100.00) 
2 
(100.00) 
241 
(89.26) 
Total 18 
(100.00) 
101 
(100.00) 
77 
(100.00) 
44 
(100.00) 
21 
(100.00) 
5 
(100.00) 
2 
(100.00) 
2 
(100.00) 
270 
(100.00) 
P value  Chi 2 0.0001 
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The IgM MAC ELISA test was positive in 11 of 196 (5.61%) people who were tested 
in the first three days, and 18 of 70 (25.71%) were positives in those people who were 
tested between day 4 and day 6. In one hand, from 29 patients with IgM positive in the 
acute phase 7 (11.29%) were also RT-PCR positive. In the other hand, 23 of 50 (38.33
 
%) 
people were IgM positive in convalescence period. (p value 0.09, Chi
2 
test).  (Table 18). 
Table 18  
 
IgM MAC ELISA test in Acute and convalescence phase of the disease according to 
results of RT-PCR. Maracay, 2006-2008. 
 
 IgM+ 
in acute 
phase 
N % IgM + 
in acute 
phase 
IgM+ 
in conv. 
phase. 
N % IgM + 
in conv. 
Phase 
RT-PCR + 7 62 11.29 23 60 38.33 
RT-PCR - 22 208 10.58 27 162 16.67 
Total 29 270 10.74 50 222 22.52 
 
 Based in the positives RT-PCR of 62 people in active surveillance, we compared the 
dynamic of the virus infection by the specific serotype PRNT results, detecting those 
congruent and logical results between both tests. We look for: 1. temporal congruency 
between confirmed dengue case in active surveillance and new infection dengue case 
detected in the biannual sample to PRNT. 2. Specific serotype congruency between 
confirmed dengue case in active surveillance and PRNT results. From 62 confirmed cases 
by active surveillance: five were not tested by PRNT, four were detected by active 
surveillance after the last biannual sample was taken. Ten PRNT results were incongruent 
with confirmed dengue cases in active surveillance. 43 had temporal infection 
congruency between active surveillance and PRNT biannual test, and 35 out of them had 
also specific serotype congruency.  Five of ten cases without congruency between RT-
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PCR and PRNT were sero-negatives by neutralization, in three cases they were DENV-4 
and DENV-3 in two, it does not happen with DENV-1 and DENV-2.  Table 19. 
 
Table 19  
 
Congruency between confirmed dengue cases detected  in Active Surveillance  
and results of PRNT in biannual samples. Maracay, 2006-2008. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 AS: 
Active Surveillance 
 * 35 out of 43 confirmed cases were also congruent with the serotype reported by PRNT. 
 
 From the 35 confirmed dengue cases by active surveillance congruent with serotype 
specific PRNT, DENV-1 has the best congruency with 88 % (15/17), DENV-3 has 78 % 
(7/9), and DENV-2 69 % (11/16). DENV-4 has the lower proportion of congruency with 
17 % (2/12).     
 The relation between primary and secondary infection detected by PRNT was 
described with the IgM MAC ELISA test results of 62 confirmed dengue cases in active 
surveillance, looking for any association between them. From 62 confirmed cases by RT-
PCR, 23 had IgM antibody sero-conversion, 39 had not IgM antibody sero-conversion in 
either acute or convalescence phase of the disease. We compared the primary and 
secondary infection in the 62 people by PRNT with both kinds of IgM MAC ELISA 
 Number % 
Not tested by PRNT 5 8.1 
Detected by Act. Surveillance after 
last biannual sample. PRNT. 
4 6.5 
 
Neither temporal nor serotype infection 
congruency. 
 
10 
 
16.1 
 
Temporal Infection Congruency 
Between AS and PRNT. * 
 
43 
 
69.3 
Total Confirmed Dengue cases by AS  62 100.0 
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results. From 23 confirmed dengue cases who sero-converted, 61,1 % were primary 
infection according to PRNT and from 39 confirmed dengue cases who did not sero-
convert, 15,4 % were primary infection by PRNT.  This difference was statistically 
significant. Chi square p value < 0.0006.  
Active Surveillance and clinical manifestation. 
In the two years of study, 270 people were detected with fever and classified as 
probable dengue fever by active surveillance, 62 were confirmed by RT-PCR. Headache 
was the most frequent symptom, being referred by 94.9% of the people. Body pain, 
shiver, ocular pain and joint pain were also referred for more than 50% of the people. 
These percentages were affected significantly in the symptoms body pain, ocular pain, 
joint pain and abdominal pain depending on the age-group of the people. (Table 20). 
Table 20  
 
Number and percentage of people with symptoms of dengue detected in the active 
surveillance. Maracay, 2006-2008. 
 
 
Symptoms 
Number of 
people with 
symptoms. 
% 
N=270 
% in patients 
<15 
N=137 
% in patients 
>15 
N=133 
Chi
2
 
P value 
Headache 256 94.82 92.70 96.99 NS 
Body pain 206 76.30 65.69 87.22 S 
Shivers 196 72.59 68.61 76.69 NS 
Ocular pain 186 68.89 61.31 76.69 S 
Joint pain 159 58.89 45.99 72.18 S 
Nauseas – Vomits 128 47.41 46.72 48.12 NS 
Abdominal Pain 108 40.00 32.85 47.37 S 
Asthenia 93 34.44 35.04 33.84 NS 
Rash 66 24.44 25.55 23.31 NS 
Hyporeflexia 62 22.96 21.17 24.81 NS 
Tourniquet Test 21 7.78 8.03 7.52 NS 
Petechia 11 4.01 2.19 6.02 NS 
 
When we compared the frequency of symptoms according to the dengue disease 
confirmation by RT-PCR, headache was present in 96.9% of confirmed cases and 94.2 % 
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in no confirmed cases. It difference was not significant (NS) statistically with a 
probability value (p) higher than 0.05 (> 0.05).  Ocular pain was showed by 68.89% of 
the people; 79.03% in confirmed cases and 67.3% in no confirmed cases. It difference 
was significant (S). Rash also had a significant difference between confirmed and non 
confirmed cases with 37.10% and 20.67 % respectively.   Body pain was positive in 75% 
of the people but the difference between confirmed and no confirmed case was NS.  
Similarly, shiver was referred by 71% of the people and the difference, between of 
percentage of confirmed and no confirmed cases, was NS. In confirmed cases, joint pain, 
abdominal pain, asthenia and nauseas were positive in 54.84, 46.77%, 30.65% and 
53.23% respectively, without any significant difference with non confirmed cases.  The 
percentage of petechias and tourniquet test were always referred by less than 10 % of the 
patients and there are no significant differences between confirmed cases and no 
confirmed cases. (Table 21). 
Table 21  
 
Percentage of people with symptoms of dengue detected in the active surveillance by 
confirmed and non confirmed dengue cases. Maracay, 2006- 2008. 
 
 
 
 
Symptoms 
% of people 
with 
symptoms.  
Totals. 
% Confirmed 
Cases of 
dengue. 
N=62 
% Non Confirmed 
cases of dengue 
N=208 
 
 
Chi
2
. 
P value 
Headache 94.82 96.77 94.23 NS 
Body pain 76.30 72.58 77.40 NS 
Shivers 72.59 74.19 72.12 NS 
Ocular pain 68.89 79.03 65.87 S 
Joint pain 58.89 54.84 60.10 NS 
Nauseas  and vomits 47.41 53.23 45.67 NS 
Abdominal Pain 40.00 46.77 37.98 NS 
Asthenia 34.44 30.65 35.58 NS 
Rash 24.44 37.10 20.67 S 
Hyporeflexia 22.96 22.58 23.08 NS 
Tourniquet test 7.78 9.68 7.21 NS 
Petechia 4.01 8.02 2.89 NS 
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Table 22 shows the results of a Logistic regression to estimate which symptoms could 
be associated with dengue confirmed cases. It was adjusted by age-group, gender and 
residency. Rash and ocular pain were associated with confirmed dengue. 
 
Table 22  
 
Symptoms associated with confirmed dengue cases, applying Logistic Regression 
Maracay 2006 – 2008. 
 
Variables Odds 
Ratio 
95%   C.I. Z-
Statistic 
P-Value 
Age-group 0,6091 0,262 1,4159 -1,152 0,2493 
Gender 0,4507 0,0596 3,4084 -0,7721 0,4401 
Age-group * gender (M/F) 1,2688 0,3277 4,9124 0,3447 0,7303 
Neighborhood (2/1) 1,9177 0,801 4,5908 1,4619 0,1438 
Neighborhood (3/1) 2,9112 0,9992 8,4818 1,9585 0,0502 
Neighborhood (4/1) 0,2838 0,0787 1,0232 -1,9249 0,0542 
Asthenia 0,5765 0,2771 1,1993 -1,4736 0,1406 
Abdominal Pain 1,3865 0,6888 2,7907 0,9155 0,3599 
Joint Pain 0,8475 0,3657 1,9641 -0,3857 0,6997 
Headache 1,1204 0,206 6,0943 0,1316 0,8953 
Body Pain 0,5717 0,2257 1,4481 -1,1791 0,2383 
Hyporeflexia 1,0686 0,4727 2,4157 0,1595 0,8733 
Shiver 1,0694 0,5001 2,2867 0,1729 0,8627 
Nauseas Vomits 1,2743 0,6555 2,4772 0,7147 0,4748 
Tourniquet Test 1,7111 0,4105 7,1333 0,7374 0,4609 
Petechia 1,8569 0,3645 9,4607 0,745 0,4563 
Ocular Pain 2,2507 1,0035 5,0481 1,9684 0,049 * 
Rash 2,1038 1,0146 4,3623 1,9989 0,0456 * 
CONSTANT * * * -1,0243 0,3057 
Note:  * Significant p value. 
From the people detected in the active surveillance, a sub sample of patients was 
invited to participate in a special group of follow up. Several blood samples in the acute 
and one in convalescence phase of the disease were obtained to see the dynamic of some 
hematologic and serologic changes in those patients confirmed with dengue. From 270 
people only 50 accepted to participate and out of them 17 were RT-PCR positive. 
Hemoglobin, hematocrit, platelets, white blood cells, lymphocytes and neutrophils in the 
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first sample were compared in confirmed and non confirmed dengue cases (Table 23). In 
addition, only in the confirmed cases the hematologic and serologic indicators were 
repeated at least three times in the acute phase of the disease Platelets and white blood 
cells showed significant changes in that short period; both decrease in the second sample 
and increase in the third one. (Table 24). Platelets and white blood cells also had been 
less than values in non confirmed cases of dengue.  
Table 23  
 
Hematologic indicators of confirmed and non confirmed dengue cases at the moment of 
the detection by the active surveillance. Maracay 2006 2008. 
 
 
Hematologic 
Indicator 
Confirmed 
Cases N=17 
Means  
Non Confirmed 
Cases N=33 
Means  
 
T test
2
. 
P value 
Hemoglobin 13.28 13.03 NS 
Hematocrit 41.67 40.18 NS 
Platelets 179  (51.4) 188,8 (51.7) NS 
White blood cells 5.51 7.39 S 
Lymphocytes 39.8 40.93 NS 
Neutrophils 57.6 57.5 NS 
 
 
Table 24  
 
Hematologic indicators of 17 confirmed cases in three consecutives blood samples in 
different days of acute phase of dengue disease. Maracay 2006 2008. 
 
 
Hematologic 
Indicator 
 
 
Sample 1 
 
 
Sample 2 
 
 
Sample 3 
T  paired test 
between  S2-S1 
and S3-S2 
P value 
Hemoglobin 13.28 (1.59) 13.26 (1.30) 13.5(1.43) NS 
Hematocrit 41.67 (5,91) 41.26 (4.75) 41.34 (4.67) NS 
Platelets 176 (51.4) 165 (46.1) 188 (70.3) S 
White blood cells 5.51 (2.21) 4.73 (2.05) 5.00 (1.57) S 
Lymphocytes 39.81( 13.6) 49.6 (13.7) 55.29 (14.4) NS 
Neutrophils 57.6 (14.9) 46.4 (16.7) 41.8 (13.6) NS 
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IgM MAC ELISA test was positive in 3 of 17 patients at the moment of their detection 
by the active surveillance. The average of days after onset of the symptoms to take the 
blood sample was 2.65 in the first day, 3.29 in the second day,  and 3.88, 5.0, and 6.7  in 
the third, fourth and fifth day respectively.  All convalesce sample were obtained between 
31 and 47 days after the onset of the symptoms.   Four sero-conversions occurred in the 
third, fourth and fifth samples and one negative patient in the acute phase converted in 
positive in the convalescence sample. Finally, 8 (47%) patients never showed sero-
conversion in the period of acute and convalescence phase of the dengue disease and four 
out of them were RT-PCR positive to DENV-4. (Table 25). 
 
Comparing passive surveillance from regular system with  
active surveillance in this study. 
 For all 270 people in the two years of the study, 76 (28.1%) were confirmed with 
dengue disease by RT-PCR and IgM positive in sero-converted convalescence sample; 23 
(8.5%) probable dengue cases and 171 (63.3%) negative cases were also identified. 
Proportion of confirmed dengue cases was similar by age group, gender, days after the 
onset of the symptoms, and clinical presentation. Proportion of probable cases was higher 
in those people who were tested four or more days after onset of the symptoms (pvalue < 
0.001) Figure 9. 
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Table 25  
 
Serological conversion to IgM anti-dengue antibody in 17 confirmed dengue cases in the 
acute phase of the disease. Maracay 2006 2008. 
 
 
 
 
 
 
 
 
 
 
Note: DAOS: 
Days after 
onset of the symptoms.  
DV: Dengue Virus serotype. 
/ : No made  
 
Patient Age Sex DV First 
Sample 
DAOS 
IgM1 Second 
Sample 
DAOS 
IgM2 Third 
Sample 
DAOS  
IgM3 Fourth 
Sample 
DAOS  
IgM4 Fifth 
Sample 
DAOS  
IgM5 Sixth  
Sample 
DAOS  
IgM6 
1 20 F D1 2 - 3 - 4 - 5 - 8 - 44 + 
2 5 M D1 3 - / / 5 + / / 7 / 37 + 
3 16 F D1 3 - 4 - / / / / 6 - 35 - 
4 21 F D1 3 - 4 - 5 - 6 - 9 - 45 + 
5 22 F D2 1 - 2 - 3 - / / 5 - 33 - 
6 10 F D2 2 - 3 - 3 + / / 6 / 35 - 
7 15 M D2 2 - 3 - / / 5 - 8 - 45 - 
8 26 F D2 2 - 3 - 4 - 5 - 9 - 38 - 
9 32 F D2 3 + 4 / / / / / 6 / 31 + 
10 10 M D3 1 - 2 - 3 / 4 - 6 + 32 + 
11 15 M D3 5 + / / / / / / 7 / 39 + 
12 31 F D3 5 + / / / / / / 7 / 37 + 
13 11 M D4 2 - 3 - 4 - 5 + 7 / 38 - 
14 18 F D4 2 - 3 - / / / / 5 - 36 - 
15 19 M D4 2 - 3 - / / / / 5 - 46 - 
16 9 F D4 3 - 4 - / / / / 6 - 42 - 
17 15 M D4 4 - 5 - / / / / 7 - 47 - 
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0%
20%
40%
60%
80%
100%
Negatives 79 93 103 69 137 35 1 171 172
Probable 15 7 8 14 7 15 3 19 22
Confirmed 43 33 45 31 52 24 3 73 76
<15 >=15 Female Males <4 days >=4 days HDF DF
Age group Gender DAOS Clinical 
Manifestation
Total
 
Figure 9 Dengue case definitions by age group, gender, days after the onset of the 
symptoms and clinical presentation in the people detected in the active surveillance. 
Maracay, 2006-2008. 
 
2007 was a national dengue epidemic year, for that reason we compared this specific 
year with our data. We had 47 confirmed dengue cases in 2007 and the Cumulative 
Incidence was 1,873 per 100,000 populations. The months with highest CI were July, 
November and August. From January to May can see a reduction in the number of cases 
which is zero in May. Figure 10. 
Figure 11 shows the index of pluviosity by months in Venezuela compared with 
the cumulative incidence of dengue disease by months per 100,000 populations. The 
months with higher pluviosity are almost coincident with the months with where the 
cumulative incidence is greater.     
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Figure 10 Cumulative Incidence by months per 100,000 populations in the study cohort, 
during 2007. Maracay, 2006-2008. 
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Figure 11.  Cumulative incidences of dengue disease by months per 100,000 populations 
in the study cohort and pluviosity in centimeters during 2007 Maracay, 2006-2008. 
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The 2007 cumulative incidence of dengue disease in the cohort study (1,873 per 
100,000 populations) was higher than cumulative incidence in the state of Aragua (496 
per 100,000 populations) in the same year. Analyzing the cumulative incidence per 
months in 2007, except May in all months the cumulative incidence of dengue of the 
cohort study was higher than the state of Aragua. Figure 12.    
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Figure 12. Cumulative incidence of dengue disease by month. Ccomparison between 
study cohort and regular surveillance in the same barrios of the study and in the state of 
Aragua in 2007. Maracay 2006-2008 
 
Figure 13 shows the endemic levels of dengue in Venezuela and the cumulative 
incidence of dengue disease in 2005, 2006 and 2007.  The cumulative incidence of 
dengue in 2005 increased in the rainy months from June to September but this CI never 
passed the limit from endemic to epidemic (up to one standard deviation of the average) 
instead in 2006  the CI became epidemic in September and it was maintained in epidemic 
phase from October 2006 until December 2007.   
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Figure 13. Endemic levels of dengue in Venezuela and the cumulative incidence of 
dengue disease in Venezuela in 2005, 2006 and 2007. Maracay, 2006–2008. 
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CHAPTER FIVE: DISCUSSION 
 
In general terms the center of this study was to identify in a sample of one dengue 
disease endemic population those aspects that cannot be seen and understood in a regular 
public health surveillance system. The goal in a traditional passive surveillance is to 
detect a non expected number of cases in a specific period of time, assuming that any 
frequency of sick people can be correlated with the dynamic of the infection disease. 
Many times, the high number of detected disease cases cannot be equated to infectious 
disease intensity; the real strength of the infection could be masked if it is considered as a 
lineal relation. Silent or unapparent cases might not be important in other viral infections; 
on contrary; it could be a way to get immunity. However, dengue disease does not follow 
the same pattern. A previous benign infection could be a risk to get a secondary severe 
and sometimes fatal disease. In addition, people that are not recognized as sick patients, 
can be a source of potential transmission without a preventive action to reduce it. 
In this study design one of the main ideas was to know exactly how many people were 
clinically sick. Visiting their houses three times a week was the way to avoid the non-
registration of febrile people who could not have felt sick enough to go to the health 
service which is inserted in a traditional passive surveillance system. Additionally, this 
permanent contact with the people permitted us to know those healthy people who have 
had dengue antibody sero-conversion during the study; people whom neither active nor 
passive surveillance would have been able to detect as infected ones. 
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Even considering these previous aspects, it is important to discuss that active 
surveillance is designed not only to call or visit the place looking for cases, but also it 
could include special monitoring systems in specific samples from the population, of 
course, it always depends on the characteristics of the disease. Hypothetically in a Public 
Health Service, biannual sample to sero-prevalence test combined with active 
surveillance in a little sample of people could be a monitoring strategy to estimate, with a 
reasonable confidence level, the silent dynamic of the infection in the population.   
In one sense our results support the idea that new monitoring methods have to be 
implemented, beyond to the traditional and passive strategies to respond against dengue 
disease. With some exceptions most of the developing countries where dengue is a real 
problem, these new strategies are needed.  The focus of this discussion was oriented to 
relate analysis results with a hypothetic Public Health Surveillance System.  In another 
sense, our results can be discussed in particular terms, and each part of the study can add 
information to the knowledge of dengue disease. 
In this study the frequency of dengue disease and dengue infection were measured by 
two ways. On the one hand, the disease was directly estimated by the incidence of the 
dengue cases in the active surveillance and prospective design. Moreover, the infection 
was indirectly estimated by the sero-prevalence of the antibodies against dengue virus, 
which were obtained in fixed biannual blood samples. Two kinds of antibodies were 
tested: IgM and IgG. anti-dengue antibodies.  IgM MAC ELISA test detected antibodies 
which are circulating in blood around three months after dengue infection, consequently 
IgM could not have been detected in a half of the total people with IgM sero-conversion; 
however, it could be a good indicator of silent infection.  IgG anti dengue antibody was 
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measured by Plaque Reduction Neutralization Test. With this technique IgG anti dengue 
antibody can be detected 50 years after infection. However, PRNT is mainly a sensitive 
procedure to detect dengue primary infection been also a perfect test to identify 
serotypes.       
The present project is one of the few prospective dengue studies where the people were 
followed-up by door to door visits three times a week, asking for febrile cases. In the 
bibliographic review we checked 75 articles in PubMed of NCBI, using the key words: 
Dengue, prospective, incidence and prevalence to look for dengue prospective studies. 
We used the following descriptor: (Dengue and prospective) or (dengue and incidence) or 
(dengue and prevalence). The major numbers of prospective studies were made in 
community schools, being the children absence to class the alarm to investigate the cause. 
Other prospective studies were based in the use of health care services; when the people 
in the follow-up felt sick, they should have gone there. In another prospective adult 
studies, the workplace was the center of the follow-up. According to our review, none of 
the papers evaluated were made with a strategy of house visits. Our study, with three 
visits a week, gave us direct information about the patients and verified when exactly the 
onset of the symptoms occurred.  
In this study, the general incidence density in two years was 3.24 per 100,000 p/d. Few 
studies have reported Incidence Rate as incidence indicator; most of them have used 
Cumulative Incidence, being difficult to do a direct comparison with our results. Porter et 
al,. in 2005, have been one of the authors who reported Incidence Density. However, 
their study was made in adults and the ID was expressed in person/years (p/y). Eighteen 
cases per 1,000 p/y was the ID in 2,536 workers from two textile factories in Bandung, 
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Indonesia in two years study from 2000 to 2002.   Expressed in person/days, that means 
an ID of 4.9 per 100,000 person/days higher than 1.9 p/d adults ID in our study.  In 
dengue, this kind of difference could express two contrary situations. In one sense, if both 
places had the same structure of viral transmissibility with similar inter-epidemic periods, 
similar sero-prevalence of anti-dengue antibody by age groups, and similar number of 
serotypes circulating; probably, we could say that either for some unknown reason (like 
human genetic variation, or virulence, or environmental factors) or for specific risk in the 
work place (textile factory) the adults ID in Bandung is grater than adults ID in Maracay. 
In another sense, if each city has different endemic or hyperendemic history and the sero-
prevalence of antibodies by age groups are dissimilar, the situation analysis would be also 
different. Comparing the entire population cumulative incidence in similar periods in 
both countries where these cities exist; we can see that in Venezuela (where Maracay city 
is) historically has had four o five times more annual CI than Indonesia, (where Bandung 
city is): 143 and 26 per 100,000 populations respectively (six years average from 2000 to 
2005). The same conclusion can be made comparing cumulative incidence reported 
between Bandung and Maracay. From 1995 to 1998, Bandung had CI of 44, 54.7 and 
31.7 per 100,000 populations and Maracay, from 1996 to 1998, had CI of 73, 155 and 
157 per 100,000 populations, respectively.  According to these studies, in Maracay city 
respect to Bandung city, adults would have less susceptibility to dengue disease, being a 
place where the disease is probably, in terms of risk, a higher problem of public health. 
(Porter et al 2005), (Barrera et al 2002). 
Saddiqui et al in Karachi (Pakistan) reported an Incidence Rate of 0.5 cases per 
100,000 person/days in children in a 30 months study period. They obtained incidence 
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rate of 0.4 cases per 100,000 person/days in age group from 5 to 10 year old and 1.6 
cases per 100,000 person/days in age group from 11 to 15 year old. This values are low 
compared with the ID of 7.4 cases by 100,000 p/d found in our study in two years of 
study. This big difference could be explained because Pakistan has begun their dengue 
high epidemics in 1994 to 1996, and the second big epidemic occurred in 2006; 4 years 
after the study of Siddiqui et al was made. (Siddiqui et al 2009). In contrast, Venezuela 
has had several big epidemics from 1989 until 2008 when our study was completed. 
The difference between the study in Bandung and Karachi respect to our study is that 
children in endemic areas are always the target of dengue infection and dengue disease, 
making it easier to compare the Karachi city children study with our study. There are 
logical exceptions like Cuban dengue disease epidemic in 1997, where adults were 
almost exclusively affected, even though the dengue infection should have affected all 
population. (Guzman 2005). 
Prospective incidence and sero-prevalence studies should always consider children and 
adult people in their samples, to have a better perception about the viral dynamic in the 
people. In a monitoring surveillance of sample or sentinel population it would be 
indispensable.    
Although most of the prospective studies of dengue have reported cumulative 
incidence instead of incidence rate, when we assume that population is stable in the time 
(in size and age distribution) the person/time can be calculated multiplying the size of the 
disease free population by the actual duration of follow-up (Morgenstern, 1980), even 
considering that is difficult because of withdrawals from the study cohort. 
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Acording to the last paragraph, we estimated the differences and similarities between 
our results and the other worldwide incidence studies.  
Historically, two of the first prospective dengue studies were completed in Thailand in 
the 80’s, both based in the 1980 epidemic. One of them was done in Rayong city 
(Sangkawibha et al 1984) and the other in Bangkok city (Burke et al 1988). However, 
disease incidence was reported only in the Bangkok study; it was completed in an exact 
period of 7 months and based in the children school absenteeism.  Due to the finalization 
of the study by all the children, a close approximation to person time can be made. In 
seven months, the study reported 5.6 % of incidence, around 26 cases per 100,000 
person/days clearly higher to 7.4 cases per 100,000 p/d incidence density that we found in 
Maracay. The importance to compare our study with the Bangkok study, in Thailand, was 
because this city has reported dengue cases from 1958, and Thailand with Philippines 
were the first countries where DHF outbreaks occurred, sharing with Venezuela 
hyperendemicity, age population  structure,  weather conditions, similar dengue 
cumulative incidence, and incidence of DHF. In some aspects of dengue, Thailand is to 
South East Asia, as Venezuela is to Latin America.    
Eighteen years after Burke’s study, Endy et al. repeated a similar study in schools 
situated in a district close to Bangkok. This time, the incidence of the dengue disease was 
3.6% in 1998, approximately an Incidence Density of 9.9 cases per 100,000 p/d, 3.3% 
in1999, ID :9.0 cases per 100,000 p/d. and 0.8% in 2000, ID:2.2 cases per 100,000 p/d. 
The overall incidence in the three years study was 2.7% with an estimated ID of 7.4 cases 
per 100,000 p/d, the same values of our results of 7.4 cases per 100,000 p/d. This study 
was probably more accurate than Burke’s study 18 years before, the dengue disease and 
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dengue infection were better defined. Contrary to the other study of Bangkok, it was also 
designed to evaluate any children with one or more days of absence. One advantage in 
our study, in Maracay, was that we were usually able to make the medical evolution the 
first or second day after the onset of the symptom, and that day was exactly registered. 
We will get back to this point in the discussion of the clinical part of the study. (Endy et 
al, 2002).    
In the Americas few studies of incidence of dengue disease have been made, 
Balsameda et al in Nicaragua reported an annual incidence of 8.5 cases per 1,000 
schoolchildren in the first year of follow-up, and 8.3 per 1,000 schoolchildren in the 
second one; assuming the study did not have any lost, it means approximately 2.33 and 
2.27 cases per 100,000 p/d respectively. (Balmaseda et al. 2006)  
One limitation in many of the previous discussed studies is that they could not measure 
the incidence of the disease associated to age groups (children and adults), because those 
studies have been made either in children (usually in schools) or in adults. Working 
directly in the community permitted us to evaluate simultaneously the incidence in both 
groups and estimate the risk association. Its Relative Risk was 3.92 in children respect to 
adults, in the two years of the study; however, this risk was significant only the first year 
of follow-up, when the big Venezuelan dengue epidemic was occurring in 2007.  This RR 
was consistent in females and males, in the overall two years study. This result could 
indicate that in endemic period the risk between children and adults tends to be similar, 
being children clearly affected in epidemic periods. 
The incidence of dengue disease was close related with two external factors, the year 
of the study and the rainy months. The incidence density in the first year study (2007) 
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was affected by the second highest epidemic in Venezuela in the last twenty years. The 
Venezuelan cumulative incidence in 2007 was 304 per 100,000 populations; since 2002 
no annual CI in Venezuela was higher than 160 per 100,000 populations.  In Aragua 
state, where this study was made, the number of dengue cases and the cumulative 
incidence in 2007 has been the highest in the last twenty years.  The other factor 
associated with the incidence density was the rainy months.  The months with highest 
pluviosity: July, August and September were the months with the highest number of 
dengue cases. This pattern was similar to the 2007 national and regional reports of 
dengue cases. Even though, this result was less evident in 2008; dengue cases were 
reported in the first months of raining (May and June), without dengue cases reported in 
the months with less precipitations (January, February, March and April).This study with 
a cohort of 3,255 people in four neighborhoods of Maracay reflected the national and 
regional epidemic and how the rising of dengue cases are related with the rainy period 
and the vector activity.  
The incidence of the dengue disease has another advantage; it is the best way to 
identify specific serotypes in areas of hyperendemicity. Plaque Reduction Neutralization 
Test is the best test to estimate specific serotype in primary dengue infection, but it is not 
the same situation in secondary and tertiary ones.    
According to our results, we could not establish different spatial distribution of the 
serotypes among the four barrios in Maracay city. Even though, these neighborhoods are 
separated by at least one mile among them. Except “Pinonal” which had serotypes of 
DENV-1, DENV-2 and DENV-3, the other neighborhood had the four serotypes. Endy et 
al found specific serotypes as a focus of transmission in their prospective school based 
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study, giving to schools and community similar role in the dengue transmission. (Endy et 
al 2002). However, Mammen et al. studying spatial and temporal clustering virus 
transmission found that community was more important than schools as a source of the 
dengue infection transmissibility. (Mammen et al, 2008).       
The proportion of DENV-1 serotype, into all children confirmed dengue cases, was 
significantly higher than that proportion in adults. DENV-2 and DENV-3 proportions 
were similar in children and adults, DENV-4 proportion was higher in adults but this 
difference was not significant. Long history of exposure to endemic infection of dengue 
can explain in adults the low proportion of DENV-1 which has been reported in the last 
20 years in Venezuela. Similar proportion of DENV-3 in children and adults can be 
explained because this serotype was hardly introduced in Venezuela in 2001 and 
simultaneously many children and adults were infected. We could have expected with 
DENV-2 a similar behavior to DENV-1, due to long time adult exposition to that 
serotype.   
As well incidence of dengue disease is a good indicator of imminent public health 
problems like epidemics; incidence of dengue infection is the way to know how the 
dynamic of the virus is and probably the way to predict disease events in the close future.    
The sero-prevalence of IgM anti-dengue antibody in the first biannual sample was 
2.3%, it could be considered low, thinking in a hyperendemic population with high rate 
of infection. However, Gluber in 1998 reported that IgM titers in primary infection are 
significantly higher than in secondary infections (Gluber, 1998). Then, it is possible to 
deduce the less sensitivity of IgM CAPTURE ELISA detecting acute infections in 
population (like ours) with high prevalence of secondary and tertiary infections. Besides, 
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the lifetime of IgM antibody in people infected is around three months, and people 
infected before that time would not be detected.  2.3 % or little more percentage, even in 
a three months prevalence period, could indicate a high number of people who were 
silently infected. In this study, that was impossible to know in the first biannual sample 
but in a second biannual sample we were in capacity to know exactly which people had 
been symptomatic and who had not, because they have been identified in the active 
surveillance.  In this context, the IgM sero-prevalence in the second biannual sample was 
3.28%, 86 positive people in 2,622 populations tested.  Out of them, only 4 people were 
detected with fever in the active surveillance design, indicating that 84 (95 %) people 
were probably asymptomatic or lightly symptomatic dengue cases. In the third biannual 
sample, 116 people were IgM positive and 11 (9.5 %) out of them had been detected in 
the active surveillance, a higher amount of people. In the fourth and fifth biannual sample 
the percentage of possible asymptomatic people were 98 % and 97 % respectively out of 
all positives IgM.  
Sero-prevalence IgM test surveys in a sample population could be a quick and relative 
low cost way to estimate the proportion of unapparent dengue infection. However, 
reducing from 6 to 3 months period inter sero-prevalence samples would be a best way to 
adapt this strategy to the immunological dynamic of IgM antibodies.         
Any advantage that could have IgM MAC ELISA test will never have the accuracy of 
PRNT to detect dengue infection and dengue specific serotype. Even though this test is 
also affected by secondary infections reducing its capacity to identify specific dengue 
serotype in samples from infected people with multiple dengue serotypes, PRNT 
continues being the main test to detect dengue virus.    
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We tested 2,125 people with PRNT, 65.3 % of the complete cohort. It was a significant 
amount, thinking in this laborious and time consuming test. The overall sero-prevalence 
of anti-dengue IgG antibodies was 86% in the first biannual survey, 65.6 % in children 
less than 15 and 95.3% in adults. 66 % were positive to two or more dengue serotypes. 
Negatives results were found in 283 (13%) people where 34.5% were children and 4.7% 
adults. In Salvador city, Brazil, Texeira at al reported one of the few studies where they 
are considering sero-prevalence simultaneously in children and adults. They showed 
overall seroprevalence of 68.7%, 76.1% in adults and 57.4% in children. Similar to our 
study, Salvador is a complex city with poor areas and socio economic variations. 
However, its comparative lower seroprevalence could be explained because this study 
was made in 1998 – 1999 when Brazil was not yet in its worst period of epidemic after 
2001.(Texeira etal, 2002). Contrary to Texeira study but close to ours, Balsameda in 
Nicaragua has showed seroprevalence in children of 91% from 75% at age 4 to 100% at 
age 16. Historically, dengue epidemics in Nicaragua are similar to Venezuela and could 
explain the closer dynamic of the virus in both countries. (Balmaseda et al, 2006).  In 
Veracruz, Mexico 2003, Navarrete et al found IgG dengue antibody sero-prevalence of 
79.6% in 500 samples from all age, reporting an increase of prevalence from 17 % at 1 
year old to 94 % in people equal or higher than 65 years old.   Interestingly, sero-
prevalence in Texas Mexico-border, the authors reported prevalence of 40 % in 
Brownsville and 80 % in Matamoros, increasing the percentage according to age stratus.  
In the Maracay city, Comach et al in 2001 found a prevalence of 51 % in 
schoolchildren, even though this study was made in the same city to our study, this lower 
sero prevalence could be a main specific focus of dengue antibody prevalence and 
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transmission and not necessarily antibody prevalence in geographic communities. 
Mammen et al is recently showing difference between virus transmission in schools and 
communities. (Comach et al 2008), (Mammen et al, 2009). 
Asia, with more than 60 years of dengue epidemic history, had in Singapore an 
example were the dengue sero-prevalence is relatively low but the public health problem 
is yet important. Wilder in 2004 reported a sero-prevalence of 45 % in people from 18 to 
45 years old, in a country were paradoxically Goh et al in 1997 demonstrated high 
incidence of dengue cases with low density of mosquitoes. (Wilder et al 2004), (Goh et al 
1997).  At that age group our prevalence was over 90 %.  
In Vietnam, Thai et al reported sero-prevalence of 65.7 % in schoolchildren from 7 to 
14 years old. This age group and its dengue antibody prevalence were very similar to our 
results in a similar group of children. (Thai et al, 2006). Graham et al in Indonesia, doing 
one of the few dengue antibody sero-prevalence larger studies by PRNT, showed the 
results from 1,837 children between 4 to 9 years old. Interestingly, they, like in our study, 
focalized many of their results in the proportion of specific serotypes, at that age group 
DENV-1 (12%) and DENV-2 (16%) were the most frequent serotypes, being 3% in  
DENV-3 and 4 % in DENV-4. In contrast with our study, we were able to compare the 
PRNT with the RT-PCRT results obtained in the active surveillance; we will retake this 
point ahead in the discussion. Other difference with Graham’s study was that we 
described the specific serotypes combination in those people results with two or more 
serotypes.  DENV-1 and DENV-2 was the most frequent (45%) mixture in our study 
followed to DENV-1, DENV-2 and DENV-3 (17.5%) these combinations could show 
that DENV-1 and DENV-2 are the viruses which have had not only more contact with 
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Maracay population but also many people in Maracay would have less probability to get 
sick with dangerous virus infection sequences seen in HDF. It could be an incomplete 
herd immunity but enough to avoid many of the possible HDF. However, the same data 
shows that an important proportion (18.9%) of the study population, and probably in the 
total population of Maracay, is at risk to get HDF.  
In advantage to have prospective sero-prevalence surveys through the biannual 
samples, we have been able to obtain indirectly, cumulative incidence of dengue infection 
from the sero-conversion detected inter each sample. In that sense, people with 
monotypic sero-prevalence had the highest six month period incidence of dengue 
infection. This position was repeated in the three inter biannual period of samples. 
Understandably, people with multitypic sero-prevalence had less incidence of dengue 
infection. For some systematic reason, people tested negative had less propensity to a 
new dengue infection than people with one serotype. The people in this study shared 
similar social conditions, water supply and houses characteristics so it was not our 
interest to identify social aspect associated to dengue disease. However, probably 
particular and personal habits could be related with this result. It is a good question to 
investigate in the future. Is it an action of the age stratification? Or, do those people have 
less personal risky conditions to be negative and to be less prospectively infected than 
monotipyc people?  
The six month incidence around 30 % was found exactly in a period of national dengue 
epidemic, it could explain these huge values. The reduction to 23 % in the third   inter 
biannual sample is also coincident with the end of the national epidemic. Low values of 
incidence of infection has been reported by Balmaseda et al in Nicaragua, with similar 
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values between primary and secondary infection, probably because they did not 
discriminate between people with monotypic and multitypic sero-prevalence. (Balmaseda 
et al, 2006).   
It has been reported the limitation that PRNT has to identify specific anti dengue 
antibody serotypes when there are multiple serotypes in the sera because of cross 
reactivity among them.  In order to determine the precision of PRNT results in 
hyperendemic population, we compared the results of confirmed dengue cases in active 
surveillance by RT-PCR with the results of PRNT of each patient in the next biannual 
sample. We found that PRNT has a good sensitivity to detect DENV-1 (88%), DENV-3 
(78%0 and DENV-2 (69%). However, it had poor capacity to detect DENV-4 (17%).  
Additionally, in other part of this study when we compare the day of IgM sero-
conversion in patients early confirmed by RT-PCR, it is not occurred neither in three 
samples of acute phase nor convalescence phase in four from five DENV-4 infected 
patients, even though it could not happen exclusively with DENV-4. New studies could 
be necessary to ratify this result or to look new ways to improve the detection of DENV-
4. 
The fact of being almost permanently close to the house of the studied people and 
visiting them three or more times a week permitted us to have more than 70% of blood 
samples from sick people taken before or at the third day after the onset of the symptoms, 
and 97% at the fifth day. We did not find any study made in communities with those 
statistics.  With this information, we were able to see the proportion of confirmed dengue 
cases by RT-PCR by day of sample. It did not change in the first five days, being it 
around 25%. However, according to many opinions, the specificity is good until the third 
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day; after that many false negative could be registered. Some surveillance systems use 
RT-PCR as diagnostic method until the fifth day after the onset of the symptoms. We 
found that 20% of the sample on sixth and seventh days can be positive by RT-PCR, and 
it agrees with the initial authors who describe this technique. The question is: could be 
RT-PCR used in routinely recommended to days six and seven. This question makes a 
connection with other of our results. In conditions of low endemicity, a good combination 
between RT-PCR from the first to fifth day and IgM MAC ELISA test after the fifth day 
would be enough. However, we suspected and now confirmed that IgM test could reduce 
its sensitivity in hyperendemic conditions and it could be so important in surveillance of 
inter-epidemic periods. In our results some confirmed dengue cases never sero-converted 
through the IgM MAC ELISA test, being more important in adult people. We suspected 
that when the proportion of secondary infection (respect to primary infection) was higher 
in IgM negative people having positive RT-PCR test than in IgM positive people in equal 
condition. Supporting our assumption, several of the 17 confirmed dengue cases with 
four samples tested in acute and convalescence phase of the disease never had IgM sero-
conversion. 
Describe the clinical and hematological results considering the days in which the 
symptoms and hematological changes occurred is also, in our criteria, a small 
contribution of this study. Why? In the literature we can see different and sometimes 
contrary results when they are reporting symptoms. In our opinion it could be caused 
because those studies were made evaluating people in different moments of the disease. 
Any of the reviewed papers discriminate in this single aspect. We can say that our results 
are based in people who were asked about their symptoms the first days after they 
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became sick.  Many studies were made in people who went to the health services, and the 
main symptoms in that moment could have been different to initial symptoms of the 
disease. Similar cases can occur in retrospective studies, describing those main 
symptoms, in terms of patient perception or medical interest, instead either the initial, or 
more frequent or more specific symptoms.  
Although, it is not specific, headache is a sensitive symptom in confirmed people in 
initial days. Ocular pain and rash were symptoms statistically associated with dengue 
disease and probably more specific than any other in the first days of the disease.  We 
were not in capacity to describe the clinic days after of the dengue disease evolution in 
the studied people when probably other type of symptoms appeared but we can say with 
security that these were the most important symptoms at the beginning of the dengue 
disease. Health workers in a surveillance of dengue have to be in capacity to recognize 
these differences.   
In a sub sample of 50 voluntary people who were previously detected in the active 
surveillance, we were able to expand the number of hematologic indicators. However, 
after that, only 17 of them, those who were confirmed with dengue disease, were 
followed with repeated blood samples in the short period of the disease.  
Hematologic results only showed a significant reduction in the white blood cells in 
confirmed people (17) compared with non confirmed people (33). We have to insist that 
these samples were taken in the first days of the disease although they were enough to 
illustrate that some hematologic parameters can be similar to non confirmed dengue cases 
in early stages of the disease.  The repeated samples in the 17 confirmed cases showed 
the dynamic of the parameters although only changes in platelets and white blood cells 
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were statistically significant. Interestingly, the proportion of neutrophils in relation to 
lymphocytes was not reasonably higher in the sample number 1, and according to that we 
could think in a bacterial infection.  Nevertheless, immediately (1 or 2 days) this 
proportion can change in the logical sense of a viral disease. Sometimes in stressful 
situation a physician, influenced by these small clinic aspects, could change a medical 
diagnostic. For that reason each small detail should be discussed in a surveillance 
program.   
The last part of this discussion is related with the real surveillance of the state and 
country where this design was applied. In the Aragua state and similarly in Venezuela the 
surveillance system is structured by the classical three level of attention: Primary, 
secondary and tertiary levels. Primary level is the first step where the people have to go 
when they are sick. When physicians detect possible dengue cases they report the case to 
the state central health service, called CORPOSALUD in the Aragua state and 
simultaneously send either the patients or their blood sample and a card with the patient 
clinical and epidemiological information to LARDIDEV which is the state center to viral 
diagnosis. According to the laboratory results, based mainly in IgM MAC ELISA test and 
secondarily in RT-PCR and viral isolation made to a partial number of cases, 
LARDIDEV classifies the patients as confirmed, probably, negative and undetermined 
dengue cases.  This information is reported to the epidemiological services at state and 
national level. The national level of health ministry makes a public report through the 
Weekly Epidemiological Bulletin. The goal of the state and national health level is to 
analyze weekly the dynamic of the dengue cases, comparing the number of week cases 
with an average of week cases in the last seven years. With the average and its standard 
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deviation (SD) is built the endemic channel or endemic levels to establish zone of 
security (between average and – 1 SD), zone of alarm (between average and + 1 SD) and 
zone of epidemic (up to the 1 + SD). The expected cases in the Venezuelan endemic 
channel are always higher in the rainy months (June, July, August, September, October 
and November). For that reason, it is always a question if the initial increase of cases in 
May and June is either the beginning of the seasonal period or the beginning of one 
epidemic.   
In order to compare our data with the state surveillance in this part of the study, we 
defined a confirmed case as that case either with positive result of RT-PCR or viral 
isolation or with sero-converted IgM dengue antibody in the period between the acute 
and convalescence phase of the dengue disease. 
We did not have cumulative incidence from previous years in the neighborhoods 
included in the study so we decided to compare with the state and national CI in 2007. 
We selected 2007 to do the comparison because it was an epidemic year, perhaps the 
second huge epidemic in Venezuela in the last twenty years. In our study population, the 
CI was at least 1,873 cases per 100,000 populations (47 cases in 2509 people); we said at 
least 1,873 cases because we included the people who left the cohort. In other words, the 
CI could be higher in our results but not less because people who left the study could 
have had dengue after they were gone in the same 2007.  In 2007 the Aragua state CI was 
496 cases per 100,000 populations and 293 per 100,000 populations in Venezuela.  
The question is if this epidemic could have been predicted. Puerto Rico has been 
considered with high capacity to do it. (Gubler ) (Perez-Rigau), reporting a sensitivity of 
66 % (two predictions in three epidemics) and they have been able to do the prediction 
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from 4 to 8 weeks before the epidemic is installed. Puerto Rican system based this 
analysis in the proportion of cases detected by virus isolation in May because they 
consider May as a key month in the prediction system, being this month the beginning of 
the rainy season. In Venezuela and the Aragua state, the epidemic had really begun in 
October 2006 but comparing CI tendencies between 2005 and 2006 in September, it was 
practically impossible to know why in 2005 the CI decreased and in 2006 increased 
becoming an epidemic.  
Even though our study had much more detected cases and CI in 2006 and 2007, it had 
also high sample error. For instance: The study did not detect cases in May 2007. Based 
in our data, we could have thought the 2007 epidemic was ending.  
We thought that a prediction 8 weeks before the epidemic is good enough to activate 
health service mechanisms but not to avoid it. Current active surveillance in Puerto Rico 
and most of the countries with passive surveillance system are structured to predict 
(Puerto Rican situation) or identify epidemics but any of these surveillance system has 
been thought to understand the virus transmission, different levels of people at risk, and 
which could be the impact of a new epidemic in a specific population. Consequently, it is 
also important to make surveillance of factors and interventions in endemic populations. 
Since epidemics in Singapore has been related with low densities of vector, other studies 
have found evidence that partial successful programs of mosquito control could have 
unexpected and contrary effects, increasing the incidence of severe forms of dengue 
disease.   Partially, it explains the complex mechanism of the virus transmission which 
should be also followed-up by surveillance programs.   In addition, the Basic 
Reproductive Number (BRN) has been considered an essential element to be applied in 
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disease control and evaluation of vaccination programs. However, it is uncertain what the 
role of unapparent infeccion people could have to establish the BRN.  To respond the 
question could be very important in a new dengue vaccine era. How many or what 
percentage of individuals should be vaccinated to obtain successful dengue herd 
immunity?     
                                 Summarizing the Defense 
One of the aspects more discussed in the defense of the dissertation was that in a high 
proportion of confirmed dengue cases the sero-conversion of IgM anti dengue antibody 
never was reached.  This result was supported either by the active surveillance or by the 
biannual sample. The importance of this point is because the IgM is considered the 
angular stone in the surveillance of dengue epidemic in a population. In addition, it has 
clinical implication due to the probable low specificity of this test. Its result could be 
explained by the huge proportion of secondary infection of dengue in the study 
population where the IgG anti dengue antibody could veiled the IgM response. For any 
explanation this outcome suggests the necessity of early detection of dengue cases using 
RT-PCR especially in interepidemic periods where the confirmation of the cases is very 
important. 
Other significant issue discussed in the defense was the coincidence between the 
surveillance in the study design with the real surveillance in the city of Maracay in the 
same period of time. The real dengue epidemic in Maracay city in 2007 was reflected 
similarly in the study in the four sample population of the “Barrios”.  In 2007 the peak of 
cases and incidence of dengue occurred in the months of higher rain (July and August) 
similarly to the historic increase of cases in Aragua state from 2005 to 2007. However, 
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either in the study or in the regular surveillance it is difficult to predict when the increase 
of the case will be caused by the epidemic or by the rain effect. 
One question was related about the people lost in the study, around 22 % in the two 
years of the study, being this lost higher in adults with 22 % than children with 14 %. 
This study was made in poor neighborhoods where there is a high mobility of the adults 
looking for better economic incomes. 
Other question in the defense was why DENV-1 was more present in adults and why 
DENV-3 was similar in adults and children. Since 1989, when the first big epidemic of 
Dengue Hemorrhagic Fever was described in Venezuela, DENV-1 always has been 
present; therefore, many adults have actually antibodies against this serotype and children 
have been less exposed to DENV-1. In the other hand, epidemic of DENV-3 had not been 
described in Venezuela until 2001 when a huge epidemic occurred, as a result children 
and adults were exposed similarly and it is the probable reason that DENV-3 has similar 
proportion of infection in both age groups.         
How the results of this study could impact the surveillance system in the state of 
Aragua?  
The passive surveillance is the current system in Aragua state and it is useful only to 
detect the initial growth of the epidemic and prepare the health services to reduce its 
impact. This study, made in small areas of population and communities, could be a model 
of sentinel surveillance to detect the real impact of the virus circulation, detecting the real 
number of asymptomatic people.  This people could be an important factor in the 
transmission of the disease. In terms of control, the surveillance of the vector along with 
the human surveillance is a necessary strategy to improve the impact of the disease. The 
  
115 
only reduction of the vector index is not enough to reduce the risk of DHF because 
simultaneously it could increase the number of susceptible people. The control of the 
vector has to be almost one hundred percent effective, permanent and integrated with the 
active surveillance if we really want to avoid worst situations of dengue epidemic in the 
future.  
 This sentinel groups from specific endemic areas could also identify people with 
different number of antibodies anti dengue and people without antibodies anti dengue to 
determine where the risk of DHF is higher.   
.   
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CHAPTER SIX: CONCLUSIONS 
 
This was the first follow-up study of dengue disease made in Venezuela since it re-
emerged in 1989.  There have been other prospective dengue studies in this country but 
based in repeated surveys of seroprevalence. Similarly, few studies in the Americas have 
been designed to establish dengue incidence, identifying and following previously the 
healthy people at risk.  It is also the first time in Venezuela and probably in Latin 
America that the Incidence Density is established in a high risk population of dengue. 
Other studies from the Americas and Asia have described the frequency of unapparent 
dengue infection, estimating the disease incidence based in cases reported from schools, 
workplaces or health service centers but very few of them have obtained the people 
information directly from their houses and communities. It permitted us to reduce the 
time when the sick people was recognized and registered. For example to know exactly if 
a person was really asymptomatic when he or she was infected by the dengue virus. 
This study analyzed three particular aspects of dengue disease: epidemiology, 
diagnosis, and clinical of the people in the follow-up. All of them were considered in the 
framework of the public health surveillance.        
 From the epidemiological point of view we described the dengue disease according to 
temporal variable, determining the disease frequency in years and months. Personal 
factors were studied through the age groups, gender and immunological history of 
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infection variables. Finally, the space variable was described through the four 
hyperendemic neighborhoods in the endemic city of Maracay. 
 Laboratory diagnosis was analyzed according to: the dynamic of the surveillance, type 
of test, the day of the diagnosis and its interrelation with personal factors, mainly age 
groups and immunological status. In the same way, some clinical aspects were analyzed 
trying to link them with the surveillance strategy. 
We obtained the first ID values of dengue disease in sample population from a 
hyperendemic city in Venezuela. 5.69 per 100,000 p/d in the first year of study (Sep. 
2006 to Sep. 2007), being this years coincident with a national dengue epidemic, and 1.45 
per 100,000 p/d in the second year (Sept 2007 Sep. 2008) when the epidemic 
disappeared. In addition, for the first time we obtained a direct and significant higher 
Relative Risk in children. In the first year the RR was 4.77 and 2.52 in the second one. 
All these results were valuables for us because we had an important validity aspect in the 
study; we were able to demonstrate when the people were really symptomatic; even 
though sample error had to be present in our results. Comparing with the state massive 
and passive surveillance system, in this study the advantage that we lost in precision was 
probably earned in validity.         
Cumulative Incidence and Incidence Density are different measures and have different 
goals. However, thinking how to visualize the ID values found in this study, we showed 
this example: 274 people followed-up by 365 days (one year) represents around 100,000 
person days of follow-up. Then, if all 274 finished a supposed study period, we could 
obtain ID and CI independently. In one year, 2 cases of any disease will correspond not 
only with a CI of 730 per 100,000 populations but also with an ID of 2 cases per 100,000 
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p/d.  In our study we did not have fixed population but this example permitted us to have 
an idea in terms of magnitude about what an ID of 1 or 2 or 15 means.  
 We had two important limitations in this part of the study. The first one, we did not 
include children less than 5 years old. Future studies have to include this special age 
group of risk, by no published reports we know that a high proportion of children was 
born with mother IgG dengue antibody and it should be affecting the crude incidence of 
the disease. The second limitation was that we studied only hyperendemic communities; 
we should have had comparative non hyperendemic communities to see how different the 
incidence among them could be. 
   In our opinion, public health surveillance, in a big city as Maracay, should have at least 
two samples of population (with high and low incidence), like sentinel surveillance. It 
could detect new changes in the virus transmission, changes in the expected incidence 
and validate information obtained in massive and passive surveillance system. 
 We were able to demonstrate that either IgM sero-prevalence or PRNT sero-prevalence 
evidenced high proportion of asymptomatic infection of dengue. Thereby, systematic 
surveys of IgM sero-prevalence in supposed healthy people, in a complementary 
surveillance strategy, could be a less time consuming and cheaper way to track and 
estimate the virus dynamic in the entire population. Smaller sub samples tested by PRNT 
would be used to validate this information.       
 Even supposing IgM seroprevalence could be a good indicator of unapparent infection, 
we also demonstrated that IgM was not able to detect an important number of infected 
people by dengue virus when they were secondarily infected. Considering hyperendemic 
population in a surveillance system with high proportion of secondary infection, precise 
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laboratory strategies should be implemented. We propose to investigate a little expansion 
in the days to test RT-PCR; it could improve the surveillance sensitivity by confirmed 
dengue cases.            
 The analysis of serotype infection by age groups permits us to conclude that DENV-1 
and DNEV-2 have been the two specific causes of dengue infection in the last 20 or 30 
years in the sample studied and probably a good estimation of the hyperendemic 
neighborhoods of Maracay city. As a result, children have shown to be less protected 
against those serotypes and then higher proportions of those dengue serotypes cases were 
detected in them. In a surveillance system historical registrations of these proportions and 
values could be appreciated to detect changes by the action of new serotypes and 
potential new genotypes.  We cannot demonstrate a spatial distribution of specific 
serotypes, and again our study limitation having only high endemic areas kept the 
question if there would be different distribution of serotypes depending on the incidence 
level of the community. 
 Another remarkable conclusion is that 86% of studied people have been infected by 
dengue virus and 68% have been infected by two or more serotypes, finally, 63% of the 
total study population was infected by DENV-1 and DENV-2.   
 Our sample size was big enough to estimate the DF cases but it was relatively small to 
have a significant number of HDF cases.  Unfortunately we cannot look for association 
between number and serotypes sequences of previous dengue infection and clinic 
severity. On the other hand, fortunately enough percentage of multitypic infection could 
have protected the people against severe forms of dengue.   
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 By two different results, we found similar inconsistency whit DENV-4 serotype 
identification. Contrary with the others serotypes, PRNT results detecting DENV-4 were 
incongruent with the RT-PCR made in active surveillance to detect disease incidence. 
Additionally, four from five RT-PCR DENV-4 positive cases did not sero-converted in 
three acute samples and one convalescence sample tested by IgM MAC ELISA. These 
preliminary results could be a sufficient argument to investigate the DENV-4 
immunological behavior. 
 Reasonably, a person with one serotype should have less probability (3 from 4 
serotypes) to get a new dengue infection than those people with negative results to anti-
dengue antibodies at risk to get 4 from 4 serotypes. However, consistently, our results 
showed that people with one serotype were more frequent infected by a second dengue 
serotype than people that have never been in contact with the virus. This is a conclusion 
but is also a question to be answered in a next investigation.   
 Our results, according to clinical symptoms associated with dengue confirmed cases, 
have to be understood in the framework of the short period in which the cases were 
detected and confirmed. That means that 72 % of our cases were detected by active 
surveillance in the third day or before after the onset of the symptoms, and 96 % equal or 
before to the fifth day after the onset of the symptoms. Therefore, we made emphasis to 
describe those early symptoms of dengue disease. Those symptoms which should appear 
in the late acute phase of the disease were not described in this study.  
On one hand headache was the most sensitive symptom present in more than 94 % of 
the confirmed cases. On the other hand, ocular pain and rash were independently 
associated with dengue confirmed cases.  
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In the surveillance system health workers should be ready to differentiate the 
symptoms when the patients are coming in early or in late acute phase of the dengue 
disease. 
The incidence of dengue cases detected by this study in the last trimester of 2006 and 
2007 was higher than the incidence of 2008. This incidence dynamic was similar to the 
national incidence and Aragua state incidence which identified the epidemic in 2006 and 
2007 hence we were also able to identify the 2006-2007 epidemic in our study 
population. However, the study sample was probably affected by the sample error and we 
could not see cases in May 2007 so it could have been understood like the epidemic was 
ending.  In conclusion a sample size around 3,000 people could not be enough to have a 
monthly number of dengue cases to detect changes in an epidemic dynamic. Passive 
surveillance in the country or state is working with the total population therefore the 
sample error is practically zero and good indicator of the incidence dynamic. We believe 
the use of small sample size like sentinel group of surveillance can help but is not the 
fundamental point in the system to identify or predict epidemics. Smaller groups of 
sentinel active surveillance may help in those aspects where massive procedure cannot 
identify clue elements of the analysis.    
 A parallel discussion is the capacity to predict or identify epidemics. We thought that 
passive surveillance system can only identify but not predict epidemic. Therefore, it is in 
these cases of prediction and prevention where close active and sentinel surveillance of 
key and usually hidden aspects would be necessary. 
Unfortunately, the dengue surveillance systems in Latin America and probably in other 
developing countries in the world are not structured to either prevent dengue epidemic or 
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improve endemic situations. Basically their function and goals are to detect epidemics in 
the initial stage to prepare hospitals, health workers and communities in response to that 
situation. However, real advantages of new surveillance strategies are not being well-
spent to improve the control and prevention of dengue disease.   
In a near future we have to include new procedures in the surveillance of dengue and 
this study was oriented to help in that sense. 
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APENDIX A:   Map of Venezuela, Aragua State and their Municipalities. 
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Municipalities: Bolivar (1), Camatagua (2), Girardot (3), J.F. Rivas (4), L. Alcántara (5), Lamas (6), 
Libertador (7), M.B. Iaragorry (8), Mariño (9), Revenga (10), San Casimiro (11), S. Michelena (12), S. 
Sebastián (13), Sucre (14), Tovar (15), Urdaneta (16) y Zamora (17).
South America
Venezuela
Aragua State
The two municipalities in the study.
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APENDIX B:  Maracay city and the Four Barrios: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
“La Cooperativa” 
“Piñonal” 
      
“23 de Enero” 
“Caña de Azucar” 
Population: 16,996 
      Sample:      635  
Population: 12,722 
      Sample:      628  
Population: 58,522 
      Sample:   1,299  
Population: 15,718 
      Sample:      693  
Total Population in the four 
“Barrios”:  103,958 
Total sample:  3,225 
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APENDIX C: Maracay monthly mean total precipitation (mm) 
 
 
 
 
Venezuela  
 
Venezuela Air Force Weather Service  
 
 
Weather Information for  
Maracay 
  
  
 
 
  
Climatological Information 
Month 
Mean Temperature oC 
Mean Total 
Precipitation (mm)  
Mean Number of 
Precipitation Days  
Daily 
Minimum 
Daily 
Maximum 
Jan 15.5 34.0 3.5 2 
Feb 16.3 35.0 4.5 1 
Mar 17.0 36.0 7.0 2 
Apr 19.0 35.5 45.2 6 
May 20.4 33.7 105.5 13 
Jun 19.5 32.9 133.3 16 
Jul 19.0 31.6 129.1 17 
Aug 19.2 32.3 172.4 18 
Sep 19.3 32.1 135.2 16 
Oct 19.0 32.5 99.0 14 
Nov 18.6 32.8 51.5 10 
Dec 15.4 32.9 15.3 4 
 
>> Click here for temperatures in oF 
 
 
Remarks: 
* Climatological information is based on monthly averages for the 30-year period 1961-
1990.  
* Mean number of precipitation days = Mean number of days with at least 1 mm of 
precipitation.  
* Precipitation includes both rain and snow. 
* Attention: Please note that the averaging period for climatological information and the 
definition of "Mean Number of Precipitation/Rain Days" quoted in this web site may be 
different for different countries. Hence, care should be taken when city climatologies 
are compared. 
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APPENDIX D:  Clinic epidemiologic card of febrile syndrome. 
 
Interview date   ___/___/___ Epidemiological week  ______________
(  ) ACUTE SAMPLE (complete the questionaire-collect convalescent sample two/three weeks after onset of symptoms)
(  ) CONVALESCENT SAMPLE: Total duration of symptoms _____ still symptomatic (  ) if it is convalescent, APPLY CODE ON ACUTE SAMPLE:______
Demographic Data
 1st Eval.       2nd Eval.  1º Eval.        2º Eval.  1º Eval.       2º Eval. 
Last name  Temperature (  )___ºC (  )___ºC  Abdominal pain  (Yes)     (NO)  (Yes)     (NO)  Dysuria    (Yes)     (NO) (Yes)     (NO)
 Shivers  (Yes)     (NO)  (Yes)     (NO)  Diarrhea                           (Yes)     (NO)  (Yes)     (NO)  Oliguria   (Yes)     (NO) (Yes)     (NO)
First name  General Malaise  (Yes)     (NO)  (Yes)     (NO)  Nausea                        (Yes)     (NO)  (Yes)     (NO)  Polyuria                (Yes)     (NO) (Yes)     (NO)
 Date:                    Age:          Sex:  Hiporrhexia                      (Yes)     (NO)  (Yes)     (NO)  Vomiting                         (Yes)     (NO)  (Yes)     (NO)  Constipation                 (Yes)     (NO) (Yes)     (NO)
 ___/___/___                              1M(   ) 2F(   )  Asthenia                         (Yes)     (NO)  (Yes)     (NO)  Melena                          (Yes)     (NO)  (Yes)     (NO)  Urinary urgency  (Yes)     (NO) (Yes)     (NO)
Health center  Prostracion                     (Yes)     (NO)  (Yes)     (NO)  Hematochezia  (Yes)     (NO)  (Yes)     (NO)  PPL                             (Yes)     (NO) (Yes)     (NO)
 Weight loss   (Yes)     (NO)  (Yes)     (NO)  Ascites                           (Yes)     (NO)  (Yes)     (NO) Cervix tender to 
Actual address  Palor  (Yes)     (NO)  (Yes)     (NO)  Abdominal  distention   (Yes)     (NO)  (Yes)     (NO) movement  (Yes)     (NO) (Yes)     (NO)
 Conjuntival Injection  (Yes)     (NO)  (Yes)     (NO)  Hepatomegaly               (Yes)     (NO)  (Yes)     (NO)  Leukorrhea  (Yes)     (NO) (Yes)     (NO)
 District             Province           Department.  Epistaxis                       (Yes)     (NO)  (Yes)     (NO)  Splenomegaly           (Yes)     (NO)  (Yes)     (NO)  Pelvic pain  (Yes)     (NO) (Yes)     (NO)
 Gingivorragia               (Yes)     (NO)  (Yes)     (NO)  Icterus                          (Yes)     (NO)  (Yes)     (NO)  Concrete mass  (Yes)     (NO) (Yes)     (NO)
Phone number  Ecchymosis  (Yes)     (NO)  (Yes)     (NO) Hepatojugular
PAST HISTORY  Petequiae                      (Yes)     (NO)  (Yes)     (NO) Reflux  (Yes)     (NO)  (Yes)     (NO) Conciousness 
 Purpura                         (Yes)     (NO)  (Yes)     (NO) disorder  (Yes)     (NO) (Yes)     (NO)
 Ocupation _______________________  Vaginal bleeding  (Yes)     (NO)  (Yes)     (NO) Headache  (Yes)     (NO) (Yes)     (NO)
 Maculopapular  Rash  (Yes)     (NO)  (Yes)     (NO)  Congestiva Pharynx  (Yes)     (NO)  (Yes)     (NO) Seizures  (Yes)     (NO) (Yes)     (NO)
 Vaccines received:  Facial Erythema  (Yes)     (NO)  (Yes)     (NO)  Rhinorrhea  (Yes)     (NO)  (Yes)     (NO)  Neck stiffness         (Yes)     (NO) (Yes)     (NO)
 Yellow Fever:                  Hepatitis:  Central Rash  (Yes)     (NO)  (Yes)     (NO)  Coughing                             (Yes)     (NO)  (Yes)     (NO) Focalizing signs  (Yes)     (NO) (Yes)     (NO)
 NO (   )  YES (   )            NO (   )  YES (   )  Distal Rash  (Yes)     (NO)  (Yes)     (NO)  Expectoration               (Yes)     (NO)  (Yes)     (NO)
 Date  ___/___/___       Date ___/___/___  Vesicles  (Yes)     (NO)  (Yes)     (NO)  Polipnea                        (Yes)     (NO)  (Yes)     (NO)
 Place of residence for the last 60 days: Subcutaneous  Dyspnea                            (Yes)     (NO)  (Yes)     (NO)  Retroocular pain  (Yes)     (NO) (Yes)     (NO)
 Locality: ________________________ nodules  (Yes)     (NO)  (Yes)     (NO)  Wheezing  (Yes)     (NO)  (Yes)     (NO)  Otorrhea                         (Yes)     (NO) (Yes)     (NO)
 District: __________________________ Facial edema  (Yes)     (NO)  (Yes)     (NO)  Cyanosis                        (Yes)     (NO)  (Yes)     (NO)  Ear pain  (Yes)     (NO) (Yes)     (NO)
 Trips in the last 30 days: Lower limbs edema  (Yes)     (NO)  (Yes)     (NO)  Roncors                     (Yes)     (NO)  (Yes)     (NO)
 Locality: __________________________ Soft tisues  Crepitus                      (Yes)     (NO)  (Yes)     (NO)
 District: ___________________________ edema  (Yes)     (NO)  (Yes)     (NO)  Pulmonar murmur  (Yes)     (NO)  (Yes)     (NO) CURED
CLINICAL DATA Joint inflamation  (Yes)     (NO)  (Yes)     (NO)  Pulmonary murmur  (Yes)     (NO)  (Yes)     (NO) RECOVERED
 Arthralgias               (Yes)     (NO)  (Yes)     (NO)  Cardiac murmur  (Yes)     (NO)  (Yes)     (NO)
 Clinical History Number _______________  Myalgias        (Yes)     (NO)  (Yes)     (NO)  Jugular regurgitation  (Yes)     (NO)  (Yes)     (NO) Possible diagnosis
Bone pain  (Yes)     (NO)  (Yes)     (NO)  Gallop  (Yes)     (NO)  (Yes)     (NO)
 Date of symptom onset:  ___/___/___ Joint function  Arritmia  (Yes)     (NO)  (Yes)     (NO)  Name of health provider:
incapacity  (Yes)     (NO)  (Yes)     (NO)
 Date of second evaluation:  ___/___/___  Adenopathy  (Yes)     (NO)  (Yes)     (NO)
 DEAD (Date)   ___/___/___
  ______________________________
Nervous system
Cardio-Respiratory System
Others
OUTCOME
                      EPIDEMIOLOGICAL CLINICAL INVESTIGATION OF FEBRILE SYNDROME
ANSWER YES OR NOT ON EACH CASE Digestive System/Abdomen Urogenital System 
 APPENDIX E: Inform Consent Adult 
 
ADULT CONSENT FORM  
Longitudinal Serology Survey 
CONSENT FORM 
Laboratorio Regional de Diagnostico e Investigacion del Dengue y otras Enfermedades  
Virales y el Centro de Investigaciones Biomedicas de la Universidad de Carabobo, 
Maracay, Venezuela (LARDIDEV/BIOMED-UC) 
Naval Medical Research Center Detachment, Lima, Peru (NMRCD) 
Walter Reed Army Institute of Research, USA (WRAIR) 
Persons of 18 years or older  
Consent to Participate in a Research Study 
Project Title: Active Dengue Surveillance and Predictors of Disease Severity in Maracay, Venezuela. 
 
Project House Code: _____________ Participant ID No. __________    
 
1. PURPOSE: LARDIDEV/BIOMED-UC, NMRCD and theWRAIR are carrying out a research study called  “Active 
Dengue Surveillance and Predictors of Disease Severity in Maracay, Venezuela.”   The purpose of this study is to 
determine what type of dengue virus is transmitted in Maracay and how severe is the disease presentation with that 
virus type.   We would like to ask you to volunteer to take part in this research project, which will include about 3500 
people and it will last about 3 years.  
 
2. PROCEDURES: If you decide to participate in the study, there are two possible levels of participation from which 
you may choose.  The first option is that we will ask you for a small sample of blood every six months for the next 3 
years and allow us to visit to your house 3 times a week to ask if anyone in the house has a fever or other illness.  The 
second option is to simply allow us to visit to your house 3 times a week to ask if anyone in the house has a fever or 
other illness.       
 
An experienced laboratory technician or a study physician will take the blood samples.  The six-month blood samples 
will be 5 ml (1.25 teaspoons).  The first sample will be used to determine if you have had dengue in the past and if you 
have had dengue which type of virus it was.  The subsequent samples will be used to determine if you have had dengue 
(and if so what type of virus) during the last sampling period.   
 
Study personnel will visit your house 3 times each week to ask if anyone in the house has a fever or other illness. If 
anyone with fever or history of fever is found, you/they will be invited to participate in an additional study where a 
blood sample (5 ml, 1.25 teaspoons) will be taken from your/their arm (venipuncture), and a physician free of charge 
will examine you/them.  A study worker will visit your house daily until you/they are well. During the daily visits a 
study worker will take your/their temperature, vital signs, ask some questions about how you/they feel, and carry out a 
tourniquet test. The tourniquet test is used to look for signs of serious illness and applies pressure to the upper arm 
using a blood pressure cuff.  A final sample of blood will be requested 10 to 21 days later.  Your/their blood will be 
used to attempt to isolate virus from the first sample and to identify dengue antibodies from both the first and last 
specimens. 
 
3. RISK TO PARTICIPANT:  Blood will be drawn from your arm with a needle by an experienced laboratory 
technician or physician. The risk that you may be injured during collection of blood is minimal, but it is possible that 
there may be some pain and discomfort when the blood is removed from your arm; afterwards there may be some 
bruising or swelling and a very small possibility of infection at the site where the blood was collected. You may feel 
faint when the sample is taken but this is uncommon and the feeling will pass quickly.  The dengue tourniquet test can 
cause arm pain in some people while the blood pressure cuff is inflated.  This pain goes away when the cuff is deflated.  
While the cuff is inflated the skin on your arm and hand below the cuff may appear discolored (red, blue, purple).  This 
discoloration will clear up after the cuff is deflated.  You may develop a rash on your forearm appearing as many small 
red dots.  This rash will disappear after a few days. 
 
4. POTENTIAL BENEFITS: The possible benefits to you from taking part in this study include:  the blood samples 
you give will tell you if you have had dengue (but will not prevent the disease directly) and the wellness visits to your 
home by a study physician at the time of illness may provide you with timely referral for medical care.  
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APPENDIX E: Continued 
 
5. COST AND COMPENSATION:  There is no cost to you to participate in the study.  
 
6. MEDICAL CARE FOR RESEARCH RELATED INJURY: If you are injured as a direct result of taking part in this 
research project, you will be given medical care for that injury.  This will be given to you at no cost to you. You will 
not receive any injury compensation, only medical care.  You should discuss this issue thoroughly with the study 
personnel before you enroll in this study. Signing this document does not limit your rights to seek legal remedies 
through the Venezuelan legal system. 
 
7. SUBJECT CONFIDENTIALITY:  All the information related to this project will be confidential.  The documents of 
this research study will be kept at the LARDIDEV/BIOMED-UC office in Maracay and at the NMRCD office in Lima. 
The data may be reviewed by the Institutional Review Board of the Naval Medical Research Center, Silver Spring, 
Maryland, USA and by the BIOMED-UC Investigation Ethics Committee.  We will keep them private to the extent 
legally possible. 
 
8. VOLUNTARY PARTICIPATION: You can decide not to take part in this study or you can leave this study at 
anytime without any negative consequences.   
 
9. POINTS OF CONTACT:  If you want to talk to someone about this study or if you have been injured from taking 
part in this study, please contact:  Dr. Guillermo Comach at LARDIDEV/BIOMED-UC at 0-416-543-2116. If you have 
any questions about your rights as a participant, contact Dr. Silvia Montano, of NMRCD-Peru, at 011-511-561-2733. 
 
10. ADULT CONSENT:  Signing below indicates that the study has been explained to you and that you agree to take 
part at no cost to you or your family, or others living in the house. Additionally, your signature indicates that you have 
had the chance to ask questions.  You should know that any questions that you may have in the future will be answered 
by one of the study investigators, and that you have informed all adult members of the household about the study.  You 
will be given a copy of the consent form so that you have this information.  
 
I agree to have blood samples taken  _______.   I prefer not to give blood samples _______. 
                                                            Initials                       Initials 
It is possible that after we have completed the laboratory tests on your blood samples that there will be some leftover.  
What do you what us to do with your leftover blood samples?  Initial only one option. 
________ After the study is completed destroy all remaining specimens. 
Initials 
________ After the study is complete the remaining specimens can be used for any scientific purpose 
Initials      provided that the scientific purpose is approved by an Institutional Review Board and that my 
                 specimen will not be identified by my name but only by a number.   I also understand that there will be  
                 no compensation for the future use of my specimen(s).  
 
If you change your mind, at any time, and would like your leftover blood samples destroyed contact Dr. Guillermo 
Comach at 0-416-543-2116. 
 
11. ADULT HEAD OF HOUSEHOLD CONSENT:  Signing below indicates that the study has been explained to you 
and that you agree to take part at no cost to you or your family, or others living in the house. Additionally, your 
signature indicates that you have had the chance to ask questions.  You should know that any questions that you may 
have in the future will be answered by one of the study investigators, and that you have informed all adult members of 
the household about the study. You will be given a copy of the consent form so that you have this information.  
 
I agree that my household will participate in the project   ___________. 
                             Initials 
Name of Participant: _____________________________________  Age__________ 
 
Signature of Participant: _________________________________   Date __________ 
If the Participant is illiterate an adult must witness the consent process. 
 
Name of Witness: _______________________________________  Age___________ 
Signature of Witness ____________________________________  Date ____________ 
Name of Investigator: _____________________________________   
Signature of Investigator _________________________________  Date ____________ 
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APPENDIX F: Inform Consent Children 
 
PARENTAL CONSENT FORM (Longitudinal Serology Survey) 
CONSENT FORM 
Laboratorio Regional de Diagnostico e Investigacion del Dengue y otras Enfermedades  
Virales y el Centro de Investigaciones Biomedicas de la Universidad de Carabobo, 
Maracay, Venezuela (LARDIDEV/BIOMED-UC) 
Naval Medical Research Center Detachment, Lima, Peru (NMRCD) 
Walter Reed Army Institute of Research, USA (WRAIR) 
Parental Consent for children 5-17 years of age 
Consent to Participate in a Research Study 
Project Title: Active Dengue Surveillance and Predictors of Disease Severity in Maracay, Venezuela. 
 
Project House Code: _____________ Participant ID No. __________    
 
1. PURPOSE: LARDIDEV/BIOMED-UC, NMRCD and the WRAIR are carrying out a research study called  “Active 
Dengue Surveillance and Predictors of Disease Severity in Maracay, Venezuela.”   The purpose of this study is to 
determine what type of dengue virus is transmitted in Maracay and how severe is the disease presentation with that 
virus type.   We would like to ask your child/children to volunteer to take part in this research project, which will 
include about 3500 people and it will last about 3 years.  
 
2. PROCEDURES:  If you agree to your child’s/children’s participating in this study, we will ask your child/children 
for a small sample of blood every six months for the next 3 years and allow us to visit to your house 3 times a week to 
ask if anyone in the house has a fever or other illness.    
 
An experienced laboratory technician or a study physician will take the blood samples.  The six-month blood samples 
will be 3 ml (0.6 teaspoons).  The first sample will be used to determine if your child/children has/have had dengue in 
the past and if your child/children has/have had dengue which type of virus it was.  The subsequent samples will be 
used to determine if your child/children has/have had dengue (and if so what type of virus) during the last sampling 
period.   
 
Study personnel will visit your house 3 times each week to ask if anyone in the house has a fever or other illness. If 
your child/children is with fever or history of fever is found, your child/children will be invited to participate in an 
additional study where a blood sample (3 ml, 0.6 teaspoons) will be taken from their arm (venipuncture), and a 
physician will examine them free of charge.  A study worker will visit your house daily until they are well. During the 
daily visits a study worker will take their temperature, vital signs, ask some questions about how they feel, and carry 
out a tourniquet test. The tourniquet test is used to look for signs of serious illness and applies pressure to the upper arm 
using a blood pressure cuff.  A final sample of blood will be requested 10 to 21 days later.  Their blood will be used to 
attempt to isolate virus from the first sample and to identify dengue antibodies from both the first and last specimens. 
 
3. RISK TO PARTICIPANT:  Blood will be drawn from your child’s/children’s arm with a needle by an experienced 
laboratory technician or a physician. The risk that they may be injured during collection of blood is minimal, but it is 
possible that there may be some pain and discomfort when the blood is removed from their arm; afterwards there may 
be some bruising or swelling and a very small possibility of infection at the site where the blood was collected. They 
may feel faint when the sample is taken but this is uncommon and the feeling will pass quickly.  The dengue tourniquet 
test can cause arm pain in some people while the blood pressure cuff is inflated.  This pain goes away when the cuff is 
deflated.  While the cuff is inflated the skin on their arm and hand below the cuff may appear discolored (red, blue, 
purple).  This discoloration will clear up after the cuff is deflated.  They may develop a rash on their forearm appearing 
as many small red dots.  This rash will disappear after a few days. 
 
4. POTENTIAL BENEFITS: The possible benefits to your child/children from taking part in this study include:  the 
blood samples they give will tell them if they have had dengue (but will not prevent the disease directly) and the 
wellness visits to your home by a study physician at the time of illness may provide you with timely referral of your 
child/children for medical care.  
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APPENDIX F: Continued 
5. COST AND COMPENSATION:  There is no cost to you or to your child/children to participate in the study.  
 
6. MEDICAL CARE FOR RESEARCH RELATED INJURY: If your child/children is/are injured as a direct result of 
taking part in this research project, they will be given medical care for that injury.  This will be given to them at no cost 
to you. They will not receive any injury compensation, only medical care.  You should discuss this issue thoroughly 
with the study personnel before you enroll your child/children in this study. Signing this document does not limit 
your/their rights to seek legal remedies through the Venezuelan legal system. 
 
7. SUBJECT CONFIDENTIALITY:  All the information related to this project will be confidential.  The documents of 
this research study will be kept at the LARDIDEV/BIOMED-UC office in Maracay and at the NMRCD office in Lima. 
The data may be reviewed by the Institutional Review Board of the Naval Medical Research Center, Silver Spring, 
Maryland, USA and by the BIOMED-UC Investigation Ethics Committee.  We will keep them private to the extent 
legally possible. 
 
8. VOLUNTARY PARTICIPATION: Your child/children can decide not to take part in this study or they can leave 
this study at anytime without any negative consequences.   
 
9. POINTS OF CONTACT:  If you want to talk to someone about this study or if your child/children has been injured 
from taking part in this study, please contact:  Dr. Guillermo Comach at LARDIDEV/BIOMED-UC at 0-416-543-
2116. If you have any questions about your rights as a participant, contact Dr. Silvia Montano, of NMRCD-Peru, at 
011-511-561-2733. 
 
10. CONSENT: THE PROJECT HAS BEEN EXPLAINED TO YOUR CHILD/CHILDREN IN YOUR PRESENCE 
IN A LANGUAGE AND LEVEL HE/SHE/THEY CAN UNDERSTAND. HE/SHE/THEY HAS/HAVE BEEN 
ENCOURAGED TO ASK QUESTIONS ABOUT THE RESEARCH STUDY. YOUR SIGNATURE BELOW WILL 
SHOW THAT YOU HAVE CONSENTED TO LET YOUR CHILD/CHILDREN VOLUNTEER TO TAKE PART IN 
THIS STUDY.  
 
1 ______________________________________________________________________________________ 
     Name of child               Age of Child                             Signature of Parent or Guardian 
 
2 ______________________________________________________________________________________ 
     Name of child               Age of Child                             Signature of Parent or Guardian 
 
3 _____________________________________________________________________________________ 
     Name of child               Age of Child                             Signature of Parent or Guardian 
 
4 _____________________________________________________________________________________ 
     Name of child               Age of Child                             Signature of Parent or Guardian 
 
 
It is possible that after we have completed the laboratory tests on your child’s/children’s blood samples that there will 
be some leftover.  What do you want us to do with their leftover blood samples?  Initial only one option. 
 
________  After the study is completed destroy all remaining specimens. 
Initials 
 
________  After the study is complete the remaining specimens can be used for any scientific purpose 
Initials       provided that the scientific purpose is approved by an Institutional Review Board and that my 
                  child’s/children’s specimen will not be identified by their name but only by a number.    
                  I also understand that there will be no compensation for the future use of their specimen(s).  
 
If you change your mind, at any time, and would like their leftover blood samples destroyed contact Dr. Guillermo 
Comach at 0-416-543-2116. 
 
If the parent or guardian is illiterate an adult must witness the consent process. 
Name of Witness: _______________________________________  Age___________ 
Signature of Witness ____________________________________  Date ____________ 
Name of Investigator: _____________________________________   
Signature of Investigator _________________________________  Date ____________
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